




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 237/16, 237/20, 281/06, 311/08, 311/21, C07D 207/08, 217/06, 241/08, 333/20, A61K 31/16, 31/33		A1	(11) International Publication Number: WO 98/03473 (43) International Publication Date: 29 January 1998 (29.01.98)
<p>(21) International Application Number: PCT/DK97/00314</p> <p>(22) International Filing Date: 17 July 1997 (17.07.97)</p> <p>(30) Priority Data: 0803/96 22 July 1996 (22.07.96) DK</p> <p>(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): PESCHKE, Bernd [DE/DK]; Eskebjerggård 58, DK-2760 Måløv (DK). ANKERSEN, Michael [DK/DK]; Dalgas Have 34, DK-2000 Frederiksberg (DK). HANSEN, Thomas, Kruse [DK/DK]; Tibbevangen 78, DK-2730 Herlev (DK). THØGERSEN, Henning [DK/DK]; Gregersmindevej 8, DK-3520 Farum (DK).</p> <p>(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	

(54) Title: COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES

(57) Abstract

The present invention relates to novel compounds of general formula (I), pharmaceutical compositions containing them, a method of stimulating the release of growth hormone from the pituitary, a method for increasing the rate and extent of growth of animals to increase their milk and wool production, or for the treatment of ailments, and to use of the compounds for the preparation of medicaments.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES

FIELD OF INVENTION

5 The present invention relates to novel compounds, pharmaceutical compositions containing them, a method of stimulating the release of growth hormone from the pituitary, a method for increasing the rate and extent of growth of animals to increase their milk and wool production, or for the treatment of ailments, and to use of the compounds for the preparation of medicaments.

10

BACKGROUND OF THE INVENTION

Growth hormone is a hormone which stimulates growth of all tissues capable of growing. In addition, growth hormone is known to have a number of effects on metabolic processes, e.g.,

15 stimulation of protein synthesis and free fatty acid mobilization and to cause a switch in energy metabolism from carbohydrate to fatty acid metabolism. Deficiency in growth hormone can result in a number of severe medical disorders, e.g., dwarfism.

20 Growth hormone is released from the pituitary. The release is under tight control of a number of hormones and neurotransmitters either directly or indirectly. Growth hormone release can be stimulated by growth hormone releasing hormone (GHRH) and inhibited by somatostatin. In both cases the hormones are released from the hypothalamus but their action is mediated primarily via specific receptors located in the pituitary. Other compounds which stimulate the release of growth hormone from the pituitary have also been described. For example arginine,

25 L-3,4-dihydroxyphenylalanine (L-Dopa), glucagon, vasopressin, PACAP (pituitary adenylyl cyclase activating peptide), muscarinic receptor agonists and a synthetic hexapeptide, GHRP (growth hormone releasing peptide) release endogenous growth hormone either by a direct effect on the pituitary or by affecting the release of GHRH and/or somatostatin from the hypothalamus.

30

In disorders or conditions where increased levels of growth hormone is desired, the protein nature of growth hormone makes anything but parenteral administration non-viable. Furthermore, other directly acting natural secretagogues, e.g., GHRH and PACAP, are longer polypeptides for which reason oral administration of them is not viable.

The use of certain compounds for increasing the levels of growth hormone in mammals has previously been proposed, e.g. in EP 18 072, EP 83 864, WO 89/07110, WO 89/01711, WO 89/10933, WO 88/9780, WO 83/02272, WO 91/18016, WO 92/01711, WO 93/04081, WO 5 95/17422, WO 95/17423, WO 95/14666, WO 96/15148 and WO 96/10040.


The composition of growth hormone releasing compounds is important for their growth hormone releasing potency as well as their bioavailability. It is therefore an object of the present invention to provide novel compounds with growth hormone releasing properties.

10

SUMMARY OF INVENTION

Accordingly, the present invention relates to a compound of the general formula I

15




formula I

20 wherein

A is A¹ or A²;

G is G¹ or G²;


D is hydrogen, -O-(CH₂)_k-R^{5a},




wherein R^5 , R^6 , R^7 , R^8 , and R^9 independently are hydrogen, halogen, aryl, C_{1-6} -alkyl or C_{1-6} -alkoxy;

5 R^{5a} is hydrogen, aryl optionally substituted with halogen or C_{1-6} -alkyl, or C_{1-6} -alkyl optionally substituted with halogen or C_{1-6} -alkyl,
 k is 0, 1, 2, or 3;

E is hydrogen, $-O-(CH_2)_rR^{10a}$,



10 wherein R^{10} , R^{11} , R^{12} , R^{13} and R^{14} independently are hydrogen, halogen, aryl, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-CONR^{15}R^{16}$, $-(CH_2)_v-NR^{15}SO_2R^{17}$, $-(CH_2)_v-NR^{15}COR^{16}$, $-(CH_2)_v-OR^{17}$, $-(CH_2)_v-OCOR^{16}$, $-CH(R^{15})R^{16}$, $-(CH_2)_v-NR^{15}-CS-NR^{16}R^{18}$, $-(CH_2)_v-NR^{15}-CO-NR^{16}R^{18}$,



15 wherein

X^1 is $-N(R^{19})-$, $-O-$ or $-S-$,

X^2 is $-C(R^{20})=$ or $-N=$,

X^3 is $-C(R^{21})=$ or $-N=$,

20 X^4 is $-C(R^{22})=$ or $-N=$;

R^2 and R^{10} may be taken together to form $-CH_2-$ or $-CH_2-CH_2-$,


R^{19} is hydrogen or C_{1-6} -alkyl optionally substituted with aryl,

25 R^{20} , R^{21} and R^{22} independently are hydrogen, $-COOR^{23}$, $-CONR^{24}R^{25}$, $-(CH_2)_wNR^{24}R^{25}$, $-(CH_2)_wOR^{23}$, $-(CH_2)_wR^{23}$ or halogen;

R^{15} , R^{16} , R^{23} , R^{24} and R^{25} independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, $-N(R^{26})R^{27}$, hydroxyl, C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkyl- carbonyloxy or aryl,

or R^{16} is

5



wherein

Q^1 is $-CH<$ or $-N<$,

T^1 and J^1 are independently $-CH_2-$, $-CO-$, $-O-$, $-S-$, $-NR^{28}-$ or a valence bond,

10 where R^{28} is hydrogen or linear or branched C_{1-6} -alkyl;

t and u are independently 0, 1, 2, 3 or 4;

R^{17} is C_{1-6} alkyl or phenyl optionally substituted with hydroxyl or aryl;

R^{18} is C_{1-6} alkyl;

R^{26} and R^{27} are independently hydrogen or C_{1-6} -alkyl;


15 v and w are independently 0, 1, 2 or 3;

R^{10a} is hydrogen, aryl optionally substituted with halogen or C_{1-6} -alkyl, or C_{1-6} -alkyl optionally substituted with halogen or C_{1-6} -alkyl,

l is 0, 1, 2, or 3;


20

A^1 is



wherein R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} , R^{35} and R^{36} are independently hydrogen or C_{1-6} -alkyl
 5 optionally substituted with halogen, amino, hydroxyl or aryl;
 R^{33} and R^{34} , R^{33} and R^{35} , or R^{34} and R^{35} may optionally form $-(CH_2)_i-Z-(CH_2)_j-$, wherein i and j
 independently are 1 or 2 and Z is $-O-$, $-S-$ or a valence bond;
 n , m and q are independently 0, 1, 2, or 3;
 o and p are independently 0 or 1;
 10 M is $-CR^{37}=CR^{38}-$, $-O-$, $-S-$, or a valence bond;
 R^{37} and R^{38} are independently hydrogen, or C_{1-6} -alkyl optionally substituted with aryl;


A^2 is



wherein R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} , R^{35} and R^{36} are independently hydrogen or C_{1-6} -alkyl

5 optionally substituted with halogen, amino, hydroxyl or aryl;
 R^{33} and R^{34} , R^{33} and R^{35} or R^{34} and R^{35} may optionally form $-(CH_2)_i\text{-}Z\text{-}(CH_2)_j-$, wherein i and j independently are 1 or 2 and Z is $-\text{O}\text{-}$, $-\text{S}\text{-}$ or a valence bond;
 n, m and q are independently 0, 1, 2, or 3;
 o and p are independently 0 or 1;
 10 M is $-\text{CR}^{37}=\text{CR}^{38}\text{-}$, $-\text{O}\text{-}$, or $-\text{S}\text{-}$;
 R^{37} and R^{38} are independently hydrogen, or C_{1-6} -alkyl optionally substituted with aryl;

G^1 is hydrogen, halogen, aryl, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-\text{CONR}^{39}R^{40}$, $-(CH_2)_e\text{-NR}^{39}\text{SO}_2R^{41}$, $-(CH_2)_e\text{-NR}^{39}\text{COR}^{40}$, $-(CH_2)_e\text{-OR}^{41}$, $-(CH_2)_e\text{-OCOR}^{40}$, $-\text{CH}(R^{39})R^{40}$, $-\text{CON}^{39}\text{-NR}^{40}R^{42}$, $-(CH_2)_e\text{-NR}^{39}\text{-CS-NR}^{40}R^{42}$,
 15 $-(CH_2)_e\text{-NR}^{39}\text{-CO-NR}^{40}R^{42}$,



wherein


X^5 is $-\text{N}(R^{43})\text{-}$, $-\text{O}\text{-}$ or $-\text{S}\text{-}$,
 20 X^6 is $-\text{C}(R^{44})=$ or $-\text{N}=$,
 X^7 is $-\text{C}(R^{45})=$ or $-\text{N}=$,
 X^8 is $-\text{C}(R^{46})=$ or $-\text{N}=$,

R^{43} is hydrogen or C_{1-6} -alkyl optionally substituted with aryl;

R^{44} , R^{45} and R^{46} independently are hydrogen, $-COOR^{47}$, $-CONR^{48}R^{49}$, $-(CH_2)_fNR^{48}R^{49}$, $-(CH_2)_fOR^{47}$, $-(CH_2)_fR^{47}$ or halogen;

5 R^{39} , R^{40} , R^{47} , R^{48} and R^{49} independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, $-N(R^{50})R^{51}$, hydroxyl, C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkylcarbonyloxy or aryl;

10 or R^{40} is



wherein

Q^2 is $-CH<$ or $-N<$,

15 J^2 and T^2 are independently $-CH_2-$, $-CO-$, $-O-$, $-S-$, $-NR^{52}-$ or a valence bond, where R^{52} is hydrogen or C_{1-6} -alkyl;

x and y are independently 0, 1, 2, 3 or 4;

R^{41} is C_{1-6} alkyl substituted with aryl;

R^{42} is C_{1-6} alkyl;

20 R^{50} and R^{51} are independently hydrogen or C_{1-6} -alkyl;


e and f are independently 0, 1, 2 or 3;

G^2 is hydrogen or C_{1-6} -alkyl;

25 R^1 is hydrogen or C_{1-6} -alkyl;

R^2 is hydrogen, $-C(=O)-R^{54}$ or C_{1-6} -alkyl;

R^1 and R^2 may be taken together to form a bridge of type



wherein R⁵⁵ and R⁵⁶ independently of each other are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl, C₁₋₆-alkoxyl or aryl;

5 R⁵⁵ and R⁵⁶ may be taken together to form =O or =S;

c and d are independently 0, 1, or 2;

c + d is 0, 1, or 2;

R⁵⁴ is hydrogen or C₁₋₆-alkyl,

R³ and R⁴ are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl, C₁₋₆-alkoxyl, halogen, or

10 aryl;

R³ and R⁴ may be taken together to form =S, =O;

L¹ is CR⁵⁷ or N;

L² is CR⁵⁸ or N;

R⁵⁷ and R⁵⁸ independently are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl,


15 halogen, C₁₋₆-alkoxy, or aryl;

a and b independently are 0, 1, 2, or 3;

with the proviso that

20 when G is G² and L¹ is CR⁵⁵ and L² is CR⁵⁶, then A is A²;

when G is G¹ and L¹ is CR⁵⁵ and L² is CR⁵⁶, then A is A¹ and R² is -C(=O)-R⁵⁴ or R¹ and R² are taken together to form a bridge of the type



when either of L¹ or L² is N, then G is G¹ and A is A¹;

25

or a pharmaceutically acceptable salt thereof.

In one embodiment of the compound of formula I A is

30 R³³-NH-(CR³⁴R³⁵)_p-(CH₂)_m-M-(CHR³⁶)_o-(CH₂)_n-

wherein R^{33} is hydrogen or C_{1-6} alkyl optionally substituted with hydroxyl, preferably hydrogen, methyl or hydroxypropyl, e.g. (2R)-2-hydroxypropyl,


R^{34} and R^{35} are independently of each other C_{1-6} alkyl, preferably methyl, R^{36} is hydrogen,

5 M is $-CR^{37}=CR^{38}-$ or $-O-$, wherein R^{37} and R^{38} are hydrogen or C_{1-6} alkyl, preferably $-CH=CH-$ or O,

p is 1, m is 1, o is 0 or 1 and n is 0 or 1.

In another embodiment of the compound of formula I A is

10




wherein M is $-O-$ or $-S-$, preferably $-O-$,

o is 0 or 1, preferably 1,

q is 0, 1 or 2, preferably 1, and

15 $m + n$ is 3 or 4, preferably 3.

In a further embodiment of the compound of formula I A is



wherein R^{33} is hydrogen or C_{1-6} alkyl, preferably, hydrogen,

20 R^{34} and R^{35} independently of each other are hydrogen or C_{1-6} alkyl, preferably hydrogen or methyl,


m is 0 or 1, n is 0 or 1, preferably 0 and p is 0 or 1. In particular the phenylen moiety is meta-substituted, however it might be ortho- or para-substituted as well and the invention is by no means limited hereto.

25

In the above compound of formula I A is preferably (1E)-4-amino-4-methylbut-1-enyl, (1E)-4-amino-4-methylpent-1-enyl (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylpent-1-enyl, (1E)-4-methyl-4-methylaminopent-1-enyl,

5 3-(1-aminoethyl)phenyl or 3-(aminomethyl)phenyl. In one embodiment hereof A is (1E)-4-amino-4-methylbut-1-enyl, (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl or (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl.


In one embodiment of the compound of formula I D is



10

wherein R⁵, R⁶, R⁷, R⁸ and R⁹ independently of each other are hydrogen or aryl, preferably hydrogen or phenyl. More preferred R⁵, R⁶, R⁸ and R⁹ are hydrogen and R⁷ is phenyl.

In a further embodiment of the compound of formula I D is




15

wherein R⁵ and R⁶ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In the above compound of formula I D is preferably (2-naphthyl), benzyloxy, or biphenyl-4-yl. More preferred (2-naphthyl) or biphenyl-4-yl.

20


In one embodiment of the compound of formula I E is



wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

25

In a further embodiment of the compound of formula I E is



wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, preferably 0, R¹⁵ is

hydrogen or C₁₋₆ alkyl, preferably hydrogen, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted

5 with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with amino, R¹⁷ is C₁₋₆ alkyl or phenyl optionally substituted with hydroxyl or phenyl, preferably methyl, C₁₋₆ alkyl substituted with hydroxyl, e.g. -CH₂CH₂OH or -CH₂CH₂CH₂OH, or phenyl. In particular the phenylen moiety is ortho-substituted, however it may also be meta- or para-substituted and the invention is by no means limited hereto. In one embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵SO₂R¹⁷, v is 0, R¹⁵ is

10 hydrogen, and R¹⁷ is C₁₋₆ alkyl or phenyl, preferably methyl or phenyl. In a second embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵COR¹⁶, v is 0, R¹⁵ is hydrogen and R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with -NH₂, preferably aminomethyl. In a third embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-OR¹⁷, v is 0, and R¹⁷ is C₁₋₆ alkyl substituted with hydroxyl, preferably -CH₂CH₂OH or -

15 CH₂CH₂CH₂OH.

In the above compound of formula I E is preferably phenyl, 2-thienyl, 2-(2-hydroxyethoxy)phenyl, 2-(3-hydroxypropoxy)phenyl, biphenyl-4-yl, 2-(aminoacetylamino)phenyl, 2-(phenylsulfonylamino)phenyl or 2-(methylsulfonylamino)phenyl.

20 In one embodiment hereof E is phenyl, 2-thienyl or 2-(methylsulfonylamino)phenyl.

In one embodiment of the compound of formula I G is hydrogen or -CONR³⁹R⁴⁰, wherein R³⁹ and R⁴⁰ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen, methyl or ethyl.

25 In the above compound of formula I G is preferably hydrogen, methyl, methylcarbamoyl, or ethylcarbamoyl.

In one embodiment of the compound of formula I R¹ is hydrogen or C₁₋₆ alkyl, preferably hydrogen or C₁₋₄ alkyl.


In the above compound of formula I R¹ is preferably hydrogen or methyl.

In one embodiment of the compound of formula I R² is hydrogen, -C(=O)-R⁵⁴ or C₁₋₆ alkyl, wherein R⁵⁴ is C₁₋₆ alkyl, preferably hydrogen, C₁₋₆ alkyl or -C(=O)-CH₃.

5

In the above compound of formula I R² is preferably methyl, hydrogen, or acetyl.

In the above compound of formula I R¹ and R² may be taken together to form a bridge of type



10

wherein R⁵⁵ and R⁵⁶ are hydrogen, or

R⁵⁵ and R⁵⁶ may be taken together to form =O or =S, preferably =O;

c and d are independently 0, 1, or 2, preferably 0 or 1;

c + d is 0, 1, or 2, preferably 1.

15

In the above compound of formula I R¹ and R² may be taken together to form a bridge of type -CH₂-C(=O)- or -CH₂-CH₂-.

20

In the above compound of formula I R² and R¹⁰ may be taken together to form -(CH₂)_r-, wherein r is 1, 2 or 3, preferably 1 or 2, more preferred 1. In a preferred embodiment E is phenyl, wherein R¹¹ to R¹⁴ is hydrogen and R¹⁰ is taken together with R² to form -(CH₂)_r-.

In one embodiment of the compound of formula I R³ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

25

In one embodiment of the compound of formula I R⁴ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In the above compound of formula I R³ and R⁴ may be taken together to form =O.

30


In the above compound of formula I a is preferably 1.

In the above compound of formula I b is preferably 0 or 1.

In the above compound of formula I L¹ is preferably -CH-.

5 In the above compound of formula I L² is preferably -CH- or >N-.

One embodiment of the compound of formula I relates to a compound of the general formula II



10 formula II

wherein

L¹ is CR⁵⁷ or N;

L² is CR⁵⁸ or N;

R⁵⁷ and R⁵⁸ independently are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl,


15 halogen, C₁₋₆-alkoxy, or aryl;

with the proviso that either L¹ or L² is N; and

A¹, R¹, R², R³, R⁴, G¹, D, E, a, and b are defined above;

or a pharmaceutically acceptable salt thereof.

20 In one embodiment of the compound of formula II A¹ is



wherein R³³ is hydrogen or C₁₋₆ alkyl optionally substituted with hydroxyl, preferably hydrogen, methyl or hydroxypropyl, e.g. (2R)-2-hydroxypropyl,


25 R³⁴ and R³⁵ are independently of each other C₁₋₆ alkyl, preferably methyl,

R³⁶ is hydrogen,

M is -CR³⁷=CR³⁸- or -O-, wherein R³⁷ and R³⁸ are hydrogen or C₁₋₆ alkyl, preferably -CH=CH- or O,


p is 1, m is 1, o is 0 or 1 and n is 0 or 1.

In another embodiment of the compound of formula II A¹ is



5 wherein M is -O- or -S-, preferably -O-,
 o is 0 or 1, preferably 1,
 q is 0, 1 or 2, preferably 1, and
 m + n is 3 or 4, preferably 3.

10 In a further embodiment of the compound of formula II A¹ is



wherein R³³ is hydrogen or C₁₋₆ alkyl, preferably, hydrogen,


R^{34} and R^{35} independently of each other are hydrogen or C_{1-6} alkyl, preferably hydrogen or methyl,

15 m is 0 or 1, n is 0 or 1, preferably 0 and p is 0 or 1. In particular the phenylen moiety is meta-substituted, however it might be ortho- or para-substituted as well and the invention is by no means limited hereto.

In the above compound of formula II A' is preferably (1E)-4-amino-4-methylbut-1-enyl, (1E)-4-amino-4-methylpent-1-enyl (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylpent-1-enyl, (1E)-4-methyl-4-methylaminopent-1-enyl, 3-(1-aminoethyl)phenyl or 3-(aminomethyl)phenyl. In one embodiment hereof A' is (1E)-4-amino-4-methylbut-1-enyl, (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, or (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl. In


another embodiment hereof A¹ is (1E)-4-amino-4-methylpent-1-enyl, (2-amino-2-methylpropoxy)methyl or ((2S)-pyrrolidin-2-yl)methoxymethyl.

5 In one embodiment of the compound of formula II D is



wherein R⁵, R⁶, R⁷, R⁸ and R⁹ independently of each other are hydrogen or aryl, preferably hydrogen or phenyl. More preferred R⁵, R⁶, R⁸ and R⁹ are hydrogen and R⁷ is phenyl.


10 In a further embodiment of the compound of formula II D is



wherein R⁵ and R⁶ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R⁵ and R⁶ are both hydrogen.


15 In the above compound of formula II D is preferably (2-naphthyl), benzyloxy, or biphenyl-4-yl. More preferred (2-naphthyl) or biphenyl-4-yl. In one embodiment 2-naphthyl.

In one embodiment of the compound of formula II E is



20 wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In another embodiment of the compound of formula II E is



wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, preferably 0, R¹⁵ is 5 hydrogen or C₁₋₆ alkyl, preferably hydrogen, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with amino, R¹⁷ is C₁₋₆ alkyl or phenyl optionally substituted with hydroxyl or phenyl, preferably methyl, C₁₋₆ alkyl substituted with hydroxyl, e.g. -CH₂CH₂OH or -CH₂CH₂CH₂OH, or phenyl. In particular the phenylen moiety is ortho-substituted, however it may also be meta- or para-substituted and the invention is by no 10 means limited hereto. In one embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵SO₂R¹⁷, v is 0, R¹⁵ is hydrogen, and R¹⁷ is C₁₋₆ alkyl or phenyl, preferably methyl or phenyl. In a second embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵COR¹⁶, v is 0, R¹⁵ is hydrogen and R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with -NH₂, preferably aminomethyl. In a third embodiment, when R¹⁰ or R¹⁴ is - 15 (CH₂)_v-OR¹⁷, v is 0, and R¹⁷ is C₁₋₆ alkyl substituted with hydroxyl, preferably -CH₂CH₂OH or -CH₂CH₂CH₂OH.

In the above compound of formula II E is preferably phenyl, 2-thienyl, 2-(2-hydroxyethoxy)phenyl, 2-(3-hydroxypropoxy)phenyl, biphenyl-4-yl, 2-(aminoacetylarnino)phenyl, 2-(phenylsulfonylarnino)phenyl or 2-(methylsulfonylarnino)phenyl. 20 In one embodiment hereof E is phenyl, 2-thienyl or 2-(methylsulfonylarnino)phenyl, preferably phenyl, or 2-thienyl, more preferred phenyl.

In one embodiment of the compound of formula II G¹ is hydrogen or -CONR³⁹R⁴⁰, wherein R³⁹ and R⁴⁰ independently of each other are hydrogen or C₁₋₆ alkyl, preferably one of R³⁹ or R⁴⁰ is 25 hydrogen and the other is methyl or ethyl.

In the above compound of formula II G¹ is preferably hydrogen, methylcarbamoyl, or ethylcarbamoyl.

In one embodiment of the compound of formula II R¹ is C₁₋₆ alkyl, preferably hydrogen or C₁₋₄ alkyl.


In the above compound of formula II R¹ is preferably methyl.

5 In one embodiment of the compound of formula II R² is hydrogen, -C(=O)-R⁵⁴ or C₁₋₆ alkyl, wherein R⁵⁴ is C₁₋₆ alkyl, preferably hydrogen, C₁₋₆ alkyl or -C(=O)-CH₃.

In the above compound of formula II R² is preferably methyl, hydrogen, or acetyl, more preferred methyl or hydrogen, most preferred hydrogen.

10

In the above compound of formula II R¹ and R² may be taken together to form a bridge of type



wherein R⁵⁵ and R⁵⁶ are hydrogen, or

15 R⁵⁵ and R⁵⁶ may be taken together to form =O or =S, preferably =O;
 c and d are independently 0, 1, or 2, preferably 0 or 1;
 c + d is 0, 1, or 2, preferably 1.

20 In one embodiment of the above compound of formula II R¹ and R² may be taken together to form a bridge of type -CH₂-C(=O)-. In another embodiment of the above compound of formula II R¹ and R² may be taken together to form a bridge of the type -CH₂-CH₂-.

In one embodiment of the compound of formula II R³ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

25

In one embodiment of the compound of formula II R⁴ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In the above compound of formula II R³ and R⁴ may be taken together to form =O.

30


In the above compound of formula II a is preferably 1.

In the above compound of formula II b is preferably 1.

In the above compound of formula II L¹ is preferably -CH-.

5 In the above compound of formula II L² is preferably -CH- or >N-.

A further embodiment of the compound of formula I relates to a compound of the general formula III



10


formula III

wherein

A¹, D, E, G¹, R³, R⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, a, b, c, and d are defined above;


15 or a pharmaceutically acceptable salt thereof.

In one embodiment of the compound of formula III A¹ is



20 wherein R³³ is hydrogen or C₁₋₆ alkyl optionally substituted with hydroxyl, preferably hydrogen, methyl or hydroxypropyl, more preferred hydrogen,
 R³⁴ and R³⁵ are independently of each other C₁₋₆ alkyl, preferably methyl,
 R³⁶ is hydrogen,
 M is -CR³⁷=CR³⁸- or -O-, wherein R³⁷ and R³⁸ are hydrogen or C₁₋₆ alkyl, preferably -CH=CH-,
 25 p is 1, m is 1, o is 0 or 1, preferably 0 and n is 0 or 1, preferably 0.

In another embodiment of the compound of formula III A¹ is




wherein M is -O- or -S-, preferably -O-,

ϕ is 0 or 1, preferably 1,

q is 0, 1 or 2, preferably 1, and

5 m + n is 3 or 4, preferably 3.

In a further embodiment of the compound of formula III A¹ is



wherein R³³ is hydrogen or C₁₋₈ alkyl, preferably, hydrogen,

10 R^{34} and R^{35} independently of each other are hydrogen or C_{1-6} alkyl, preferably hydrogen or methyl,

m is 0 or 1, n is 0 or 1, preferably 0 and p is 0 or 1. In particular the phenylen moiety is meta-substituted, however it might be ortho- or para-substituted as well and the invention is by no means limited hereto.


15

In the above compound of formula III A¹ is preferably (1E)-4-amino-4-methylbut-1-enyl, (1E)-4-amino-4-methylpent-1-enyl (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-

yl)methoxymethyl, 4-piperidinyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylpent-1-enyl, (1E)-4-methyl-4-methylaminopent-1-enyl,


20 3-(1-aminoethyl)phenyl or 3-(aminomethyl)phenyl. In one embodiment hereof A¹ is (1E)-4-amino-4-methylbut-1-enyl, (2-amino-2-methylpropoxy)methyl or ((2S)-pyrrolidin-2-yl)methoxymethyl. In another embodiment hereof A¹ is (1E)-4-amino-4-methylpent-1-enyl.

In one embodiment of the compound of formula III D is



wherein R⁵, R⁶, R⁷, R⁸ and R⁹ independently of each other are hydrogen or aryl, preferably hydrogen or phenyl. More preferred R⁵, R⁶, R⁸ and R⁹ are hydrogen and R⁷ is phenyl.


5 In a further embodiment of the compound of formula III D is



wherein R⁵ and R⁶ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R⁵ and R⁶ are both hydrogen.


10 In the above compound of formula III D is preferably (2-naphthyl), benzyloxy, or biphenyl-4-yl. More preferred (2-naphthyl).

In one embodiment of the compound of formula III E is



15 wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In a further embodiment of the compound of formula III E is



20 wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, preferably 0, R¹⁵ is hydrogen or C₁₋₆ alkyl, preferably hydrogen, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl,

preferably R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with amino, R¹⁷ is C₁₋₆ alkyl or phenyl optionally substituted with hydroxyl or phenyl, preferably methyl, C₁₋₆ alkyl substituted with hydroxyl, e.g. -CH₂CH₂OH or -CH₂CH₂CH₂OH, or phenyl. In particular the phenyl moiety is ortho-substituted, however it may also be meta- or para-substituted and the invention is by no means limited hereto. In one embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵SO₂R¹⁷, v is 0, R¹⁵ is hydrogen, and R¹⁷ is C₁₋₆ alkyl or phenyl, preferably methyl or phenyl. In a second embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵COR¹⁶, v is 0, R¹⁵ is hydrogen and R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with -NH₂, preferably aminomethyl. In a third embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-OR¹⁷, v is 0, and R¹⁷ is C₁₋₆ alkyl substituted with hydroxyl, preferably -CH₂CH₂OH or -CH₂CH₂CH₂OH.

In the above compound of formula I E is preferably phenyl, 2-thienyl, 2-(2-hydroxyethoxy)phenyl, 2-(3-hydroxypropoxy)phenyl, biphenyl-4-yl, 2-(aminoacetylamino)phenyl, 2-(phenylsulfonylamino)phenyl or 2-(methylsulfonylamino)phenyl.

15 In one embodiment hereof E is phenyl, 2-thienyl or 2-(methylsulfonylamino)phenyl, preferably phenyl.

In one embodiment of the compound of formula III G¹ is hydrogen or -CONR³⁹R⁴⁰, wherein R³⁹ and R⁴⁰ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen or methyl.

20 In the above compound of formula III G¹ is preferably hydrogen or methylcarbamoyl.

In one embodiment of the compound of formula III R³ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

25 In one embodiment of the compound of formula III R⁴ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In the above compound of formula III R³ and R⁴ may be taken together to form =O.

30 In the above compound of formula III a is preferably 1.


In the above compound of formula III b is preferably 1.

In the above compound of formula III R⁵⁵ and R⁵⁶ are hydrogen, or R⁵⁵ and R⁵⁶ may be taken together to form =O; c and d are independently 0, 1, or 2, preferably 0 or 1; c + d is 0, 1, or 2, preferably 1.

5

In the above compound of formula III R⁵⁷ and R⁵⁸ are independently hydrogen or C₁₋₆-alkyl, preferably hydrogen.

A still further embodiment of the compound of formula I relates to a compound of the general
10 formula IV




formula IV

15 wherein


A¹, D, E, and G¹ are defined above;
or a pharmaceutically acceptable salt thereof.

In one embodiment of the compound of formula IV A¹ is
20



wherein R³³ is hydrogen or C₁₋₆ alkyl optionally substituted with hydroxyl, preferably hydrogen, R³⁴ and R³⁵ are independently of each other C₁₋₈ alkyl, preferably methyl, M is -CR³⁷=CR³⁸- or -O-, wherein R³⁷ and R³⁸ are hydrogen or C₁₋₆ alkyl, preferably -CH=CH-, p is 1, m is 1, o is 0 and n is 0.

In another embodiment of the compound of formula IV A¹ is




wherein M is -O- or -S-, preferably -O-,

o is 0 or 1, preferably 1,

q is 0, 1 or 2, preferably 1, and

5 m + n is 3 or 4, preferably 3.

In a further embodiment of the compound of formula IV A¹ is



wherein R³³ is hydrogen or C₁₋₆ alkyl, preferably, hydrogen,

10 R³⁴ and R³⁵ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen or methyl,


m is 0 or 1, n is 0 or 1, preferably 0 and p is 0 or 1. In particular the phenyl moiety is meta-substituted, however it might be ortho- or para-substituted as well and the invention is by no means limited hereto.

15

In the above compound of formula IV A¹ is preferably (1E)-4-amino-4-methylbut-1-enyl, (1E)-4-amino-4-methylpent-1-enyl (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylpent-1-enyl, (1E)-4-methyl-4-methylaminopent-1-enyl,


20 3-(1-aminoethyl)phenyl or 3-(aminomethyl)phenyl. In one embodiment hereof A¹ is (1E)-4-amino-4-methylbut-1-enyl, (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, or (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl. In another embodiment hereof A¹ is (1E)-4-amino-4-methylpent-1-enyl.

25 In one embodiment of the compound of formula IV D is



wherein R⁵, R⁶, R⁷, R⁸ and R⁹ independently of each other are hydrogen or aryl, preferably hydrogen or phenyl. More preferred R⁵, R⁶, R⁸ and R⁹ are hydrogen and R⁷ is phenyl.


5 In a further embodiment of the compound of formula IV D is



wherein R⁵ and R⁶ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R⁵ and R⁶ are both hydrogen.


10 In the above compound of formula IV D is preferably (2-naphthyl), benzyloxy, or biphenyl-4-yl. More preferred (2-naphthyl).

In one embodiment of the compound of formula IV E is



15 wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In a further embodiment of the compound of formula IV E is




20 wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, preferably 0, R¹⁵ is hydrogen or C₁₋₆ alkyl, preferably hydrogen, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl,

preferably R^{16} is hydrogen or C_{1-6} alkyl substituted with amino, R^{17} is C_{1-6} alkyl or phenyl optionally substituted with hydroxyl or phenyl, preferably methyl, C_{1-6} alkyl substituted with hydroxyl, e.g. $-CH_2CH_2OH$ or $-CH_2CH_2CH_2OH$, or phenyl. In particular the phenylen moiety is ortho-substituted, however it may also be meta- or para-substituted and the invention is by no means limited hereto. In one embodiment, when R^{10} or R^{14} is $-(CH_2)_v-NR^{15}SO_2R^{17}$, v is 0, R^{15} is hydrogen, and R^{17} is C_{1-6} alkyl or phenyl, preferably methyl or phenyl. In a second embodiment, when R^{10} or R^{14} is $-(CH_2)_v-NR^{15}COR^{16}$, v is 0, R^{15} is hydrogen and R^{16} is hydrogen or C_{1-6} alkyl substituted with $-NH_2$, preferably aminomethyl. In a third embodiment, when R^{10} or R^{14} is $-(CH_2)_v-OR^{17}$, v is 0, and R^{17} is C_{1-6} alkyl substituted with hydroxyl, preferably $-CH_2CH_2OH$ or $-CH_2CH_2CH_2OH$.

In the above compound of formula IV E is preferably phenyl, 2-thienyl, 2-(2-hydroxyethoxy)phenyl, 2-(3-hydroxypropoxy)phenyl, biphenyl-4-yl, 2-(aminoacetylamo)phenyl, 2-(phenylsulfonylamino)phenyl or 2-(methylsulfonylamino)phenyl. In one embodiment hereof E is phenyl, 2-thienyl or 2-(methylsulfonylamino)phenyl, preferably phenyl.

In one embodiment of the compound of formula IV G¹ is hydrogen or $-CONR^{39}R^{40}$, wherein R^{39} and R^{40} independently of each other are hydrogen or C_{1-6} alkyl, preferably hydrogen or methyl. In the above compound of formula IV G¹ is preferably hydrogen or methylcarbamoyl, preferably methylcarbamoyl.

A further embodiment of the compound of formula I relates to a compound of the general formula V




formula V

wherein R^2 is $-C(=O)-R^{54}$ wherein R^{54} is hydrogen or C_{1-6} -alkyl; and

A¹, D, E, G¹, R¹, R³, and R⁴ are defined above;
or a pharmaceutically acceptable salt thereof.

In one embodiment of the compound of formula II A¹ is

5



wherein R³³ is hydrogen or C₁₋₆ alkyl optionally substituted with hydroxyl, preferably hydrogen, methyl or hydroxypropyl, e.g. (2R)-2-hydroxypropyl,


R³⁴ and R³⁵ are independently of each other C₁₋₆ alkyl, preferably methyl,

10 R³⁶ is hydrogen,

M is -CR³⁷=CR³⁸- or -O-, wherein R³⁷ and R³⁸ are hydrogen or C₁₋₆ alkyl, preferably -CH=CH- or O,

p is 1, m is 1, o is 0 or 1 and n is 0 or 1.

15 In another embodiment of the compound of formula II A¹ is




wherein M is -O- or -S-, preferably -O-,

o is 0 or 1, preferably 1,

20 q is 0, 1 or 2, preferably 1, and

m + n is 3 or 4, preferably 3.

In a further embodiment of the compound of formula V A¹ is



25 wherein R³³ is hydrogen or C₁₋₆ alkyl, preferably, hydrogen,


R^{34} and R^{35} independently of each other are hydrogen or C_{1-6} alkyl, preferably hydrogen or methyl,

m is 0 or 1, n is 0 or 1, preferably 0 and p is 0 or 1. In particular the phenylen moiety is meta-substituted, however it might be ortho- or para-substituted as well and the invention is by no

5 means limited hereto.


In the above compound of formula $V A^1$ is preferably (1E)-4-amino-4-methylbut-1-enyl, (1E)-4-amino-4-methylpent-1-enyl (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl, (1E)-10 4-((2R)-2-hydroxypropylamino)-4-methylpent-1-enyl, (1E)-4-methyl-4-methylaminopent-1-enyl, 3-(1-aminoethyl)phenyl or 3-(aminomethyl)phenyl. In one embodiment hereof A^1 is preferably (1E)-4-amino-4-methylbut-1-enyl, (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, or (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl.

15 In one embodiment of the compound of formula $V D$ is



wherein R^5 , R^6 , R^7 , R^8 and R^9 independently of each other are hydrogen or aryl, preferably hydrogen or phenyl. More preferred R^5 , R^6 , R^8 and R^9 are hydrogen and R^7 is phenyl.

20 In a further embodiment of the compound of formula $V D$ is




wherein R^5 and R^6 independently of each other are hydrogen or C_{1-6} alkyl, preferably hydrogen.

In the above compound of formula $V D$ is preferably (2-naphthyl), benzyloxy, or biphenyl-4-yl.


25 More preferred (2-naphthyl) or biphenyl-4-yl.

In one embodiment of the compound of formula $V E$ is



wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

5 In a further embodiment of the compound of formula V E is



wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, preferably 0, R¹⁵ is hydrogen or C₁₋₆ alkyl, preferably hydrogen, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with amino, R¹⁷ is C₁₋₆ alkyl or phenyl optionally substituted with hydroxyl or phenyl, preferably methyl, C₁₋₆ alkyl substituted with hydroxyl, e.g. -CH₂CH₂OH or -CH₂CH₂CH₂OH, or phenyl. In particular the phenylen moiety is ortho-substituted, however it may also be meta- or para-substituted and the invention is by no means limited hereto. In one embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵SO₂R¹⁷, v is 0, R¹⁵ is hydrogen, and R¹⁷ is C₁₋₆ alkyl or phenyl, preferably methyl or phenyl. In a second embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵COR¹⁶, v is 0, R¹⁵ is hydrogen and R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with -NH₂, preferably aminomethyl. In a third embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-OR¹⁷, v is 0, and R¹⁷ is C₁₋₆ alkyl substituted with hydroxyl, preferably -CH₂CH₂OH or -CH₂CH₂CH₂OH.

In the above compound of formula II E is preferably phenyl, 2-thienyl, 2-(2-hydroxyethoxy)phenyl, 2-(3-hydroxypropoxy)phenyl, biphenyl-4-yl, 2-(aminoacetylamino)phenyl, 2-(phenylsulfonylamino)phenyl or 2-(methylsulfonylamino)phenyl.

25 In one embodiment hereof E is phenyl, 2-thienyl or 2-(methylsulfonylamino)phenyl, preferably phenyl, or 2-thienyl.

In one embodiment of the compound of formula V G¹ is hydrogen or -CONR³⁹R⁴⁰, wherein R³⁹ and R⁴⁰ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen, methyl or ethyl.

5 In the above compound of formula V G¹ is preferably hydrogen, methyl, methylicarbamoyl, or ethylicarbamoyl.

In one embodiment of the compound of formula V R¹ is C₁₋₆ alkyl, preferably hydrogen or C₁₋₄ alkyl.

10 In the above compound of formula V R¹ is preferably hydrogen or methyl, most preferred hydrogen.

In one embodiment of the compound of formula V R² is -C(=O)-R⁵⁴, wherein R⁵⁴ is C₁₋₄ alkyl, preferably -C(=O)-CH₃.


15

In one embodiment of the compound of formula V R³ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

20

In one embodiment of the compound of formula V R⁴ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

A still further embodiment of the compound of formula I relates to a compound of the general formula VI




formula VI

wherein A², D, E, G², R¹, R², R³, R⁴, and b are defined above;
or a pharmaceutically acceptable salt thereof.

30

In one embodiment of the compound of formula VI A² is



wherein R³³ is hydrogen or C₁₋₆ alkyl optionally substituted with hydroxyl, preferably hydrogen,


5 methyl or hydroxypropyl, e.g. (2R)-2-hydroxypropyl,

R³⁴ and R³⁵ are independently of each other C₁₋₆ alkyl, preferably methyl,

M is -CR³⁷=CR³⁸- or -O-, wherein R³⁷ and R³⁸ are hydrogen or C₁₋₆ alkyl, preferably -CH=CH-,

p is 1, m is 1, o is 0 and n is 0 or 1, preferably 0.

10 In another embodiment of the compound of formula VI A² is




wherein M is -O- or -S-, preferably -O-,

o is 0 or 1, preferably 1,

15 q is 0, 1 or 2, preferably 1, and

m + n is 3 or 4, preferably 3.

In a further embodiment of the compound of formula VI A² is



20 wherein R³³ is hydrogen or C₁₋₆ alkyl, preferably, hydrogen,


R³⁴ and R³⁵ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen or methyl,

m is 0 or 1, n is 0 or 1, preferably 0 and p is 0 or 1. In particular the phenylen moiety is meta-substituted, however it might be ortho- or para-substituted as well and the invention is by no

25 means limited hereto.


In the above compound of formula VI A² is preferably (1E)-4-amino-4-methylbut-1-enyl, (1E)-4-amino-4-methylpent-1-enyl (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylpent-1-enyl, (1E)-4-methyl-4-methylaminopent-1-enyl, 3-(1-aminoethyl)phenyl or 3-(aminomethyl)phenyl. In one embodiment hereof A² is (1E)-4-amino-4-methylbut-1-enyl, (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-yl)methoxymethyl, 4-piperidinyl or (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl. In another embodiment hereof A² is (1E)-4-amino-4-methylpent-1-enyl, 4-piperidinyl or (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl.

10 In one embodiment of the compound of formula VI D is



wherein R⁵, R⁶, R⁷, R⁸ and R⁹ independently of each other are hydrogen or aryl, preferably hydrogen or phenyl. More preferred R⁵, R⁶, R⁸ and R⁹ are hydrogen and R⁷ is phenyl.


15 In a further embodiment of the compound of formula VI D is



wherein R⁵ and R⁶ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R⁵ and R⁶ are both hydrogen.


20 In the above compound of formula VI D is preferably (2-naphthyl), benzyloxy, or biphenyl-4-yl. More preferred (2-naphthyl) or biphenyl-4-yl, most preferred 2-naphthyl.

25 In one embodiment of the compound of formula VI E is



wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In a further embodiment of the compound of formula VI E is



5 wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, preferably 0, R¹⁵ is hydrogen or C₁₋₆ alkyl, preferably hydrogen, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with amino, R¹⁷ is C₁₋₆ alkyl or phenyl 10 optionally substituted with hydroxyl or phenyl, preferably methyl, C₁₋₆ alkyl substituted with hydroxyl, e.g. -CH₂CH₂OH or -CH₂CH₂CH₂OH, or phenyl. In particular the phenylen moiety is ortho-substituted, however it may also be meta- or para-substituted and the invention is by no means limited hereto. In one embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵SO₂R¹⁷, v is 0, R¹⁵ is 15 hydrogen, and R¹⁷ is C₁₋₆ alkyl or phenyl, preferably methyl or phenyl. In a second embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-NR¹⁵COR¹⁶, v is 0, R¹⁵ is hydrogen and R¹⁶ is hydrogen or C₁₋₆ alkyl substituted with -NH₂, preferably aminomethyl. In a third embodiment, when R¹⁰ or R¹⁴ is -(CH₂)_v-OR¹⁷, v is 0, and R¹⁷ is C₁₋₆ alkyl substituted with hydroxyl, preferably -CH₂CH₂OH or -CH₂CH₂CH₂OH.

20 In the above compound of formula I E is preferably phenyl, 2-thienyl, 2-(2-hydroxyethoxy)phenyl, 2-(3-hydroxypropoxy)phenyl, biphenyl-4-yl, 2-(aminoacetylarnino)phenyl, 2-(phenylsulfonylarnino)phenyl or 2-(methylsulfonylarnino)phenyl. In one embodiment hereof E is phenyl, 2-thienyl or 2-(methylsulfonylarnino)phenyl.

25 In one embodiment of the compound of formula VI G² is hydrogen or C₁₋₄ alkyl, preferably hydrogen, methyl or ethyl. In the above compound of formula VI G² is preferably hydrogen or methyl.

In one embodiment of the compound of formula VI R¹ is hydrogen or C₁₋₆ alkyl, preferably hydrogen or C₁₋₄ alkyl.

In the above compound of formula VI R¹ is preferably methyl.

5

In one embodiment of the compound of formula VI R² is hydrogen, -C(=O)-R⁵⁴ or C₁₋₆ alkyl, wherein R⁵⁴ is C₁₋₆ alkyl, preferably hydrogen, C₁₋₆ alkyl or -C(=O)-CH₃.

In the above compound of formula VI R² is preferably methyl, hydrogen, or acetyl, most preferred methyl.

10

In one embodiment of the compound of formula VI R³ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.

15 In one embodiment of the compound of formula VI R⁴ is hydrogen or C₁₋₆ alkyl, preferably hydrogen.


In the above compound of formula VI R³ and R⁴ may be taken together to form =O.

20

In the above compound of formula VI b is preferably 0 or 1, most preferred 1.

A further embodiment of the compound of formula I relates to a compound of the general formula VII


25



formula VII

wherein

30 E is hydrogen, -O-(CH₂)_{1-10a},



wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently are hydrogen, halogen, aryl, C₁₋₆-alkyl, C₁₋₆-alkoxy;


R^{10a} is hydrogen, aryl optionally substituted with halogen or C₁₋₆-alkyl, or C₁₋₆-alkyl optionally substituted with halogen or C₁₋₆-alkyl, and

I is 0, 1, 2, or 3;

and A¹, D, G¹, R¹, R², a, and b are defined above;

or a pharmaceutically acceptable salt thereof.

In one embodiment of the compound of formula VII A¹ is



wherein R³³ is hydrogen or C₁₋₆ alkyl optionally substituted with hydroxyl, preferably hydrogen or methyl, most preferred hydrogen,


R³⁴ and R³⁵ are independently of each other C₁₋₆ alkyl, preferably methyl,

R³⁶ is hydrogen,

M is -CR³⁷=CR³⁸- or -O-, wherein R³⁷ and R³⁸ are hydrogen or C₁₋₆ alkyl, preferably -CH=CH- or O,

p is 1, m is 1, o is 0 or 1 and n is 0 or 1.


In another embodiment of the compound of formula VII A¹ is



wherein M is -O- or -S-, preferably -O-,
 o is 0 or 1, preferably 1,
 q is 0, 1 or 2, preferably 1, and
 m + n is 3 or 4, preferably 3.

5


In a further embodiment of the compound of formula VII A¹ is



wherein R³³ is hydrogen or C₁₋₆ alkyl, preferably, hydrogen,
 R³⁴ and R³⁵ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen or
 10 methyl,
 m is 0 or 1, n is 0 or 1, preferably 0 and p is 0 or 1. In particular the phenyl moiety is meta-
 substituted, however it might be ortho- or para-substituted as well and the invention is by no
 means limited hereto.


15 In the above compound of formula VII A¹ is preferably (1E)-4-amino-4-methylbut-1-enyl, (1E)-
 4-amino-4-methylpent-1-enyl (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-
 yl)methoxymethyl, 4-piperidinyl, (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl, (1E)-
 4-((2R)-2-hydroxypropylamino)-4-methylpent-1-enyl, (1E)-4-methyl-4-methylaminopent-1-enyl,
 3-(1-aminoethyl)phenyl or 3-(aminomethyl)phenyl. In one embodiment hereof A¹ is (1E)-4-
 20 amino-4-methylbut-1-enyl, (2-amino-2-methylpropoxy)methyl, ((2S)-pyrrolidin-2-
 yl)methoxymethyl, 4-piperidinyl, or (1E)-4-((2R)-2-hydroxypropylamino)-4-methylbut-1-enyl. In
 another embodiment hereof A¹ is (1E)-4-amino-4-methylpent-1-enyl, (2-amino-2-
 methylpropoxy)methyl or ((2S)-pyrrolidin-2-yl)methoxymethyl.

25 In one embodiment of the compound of formula VII D is



wherein R⁵, R⁶, R⁷, R⁸ and R⁹ independently of each other are hydrogen or aryl, preferably hydrogen or phenyl. More preferred R⁵, R⁶, R⁸ and R⁹ are hydrogen and R⁷ is phenyl.


5 In a further embodiment of the compound of formula VII D is



wherein R⁵ and R⁶ independently of each other are hydrogen or C₁₋₆ alkyl, preferably R⁵ and R⁶ are both hydrogen.


10 In the above compound of formula VII D is preferably (2-naphthyl), benzyloxy, or biphenyl-4-yl. More preferred (2-naphthyl) or biphenyl-4-yl, most preferred 2-naphthyl.

In one embodiment of the compound of formula VII E is



15 wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl, preferably hydrogen.

In a further embodiment of the compound of formula VII E is



20 wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, preferably 0, R¹⁵ is hydrogen or C₁₋₆ alkyl, preferably hydrogen, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl.

preferably R^{16} is hydrogen or C_{1-6} alkyl substituted with amino, R^{17} is C_{1-6} alkyl or phenyl optionally substituted with hydroxyl or phenyl, preferably methyl, C_{1-6} alkyl substituted with hydroxyl, e.g. $-CH_2CH_2OH$ or $-CH_2CH_2CH_2OH$, or phenyl. In particular the phenyl moiety is ortho-substituted, however it may also be meta- or para-substituted and the invention is by no means limited hereto. In one embodiment, when R^{10} or R^{14} is $-(CH_2)_v-NR^{15}SO_2R^{17}$, v is 0, R^{15} is hydrogen, and R^{17} is C_{1-6} alkyl or phenyl, preferably methyl or phenyl. In a second embodiment, when R^{10} or R^{14} is $-(CH_2)_v-NR^{15}COR^{16}$, v is 0, R^{15} is hydrogen and R^{16} is hydrogen or C_{1-6} alkyl substituted with $-NH_2$, preferably aminomethyl. In a third embodiment, when R^{10} or R^{14} is $-(CH_2)_v-OR^{17}$, v is 0, and R^{17} is C_{1-6} alkyl substituted with hydroxyl, preferably $-CH_2CH_2OH$ or $-CH_2CH_2CH_2OH$.

In the above compound of formula VII E is preferably phenyl, 2-thienyl, 2-(2-hydroxyethoxy)phenyl, 2-(3-hydroxypropoxy)phenyl, biphenyl-4-yl, 2-(aminoacetylamo)phenyl, 2-(phenylsulfonylamino)phenyl or 2-(methylsulfonylamino)phenyl.

15 In one embodiment hereof E is preferably phenyl, or 2-thienyl, most preferred phenyl.

In one embodiment of the compound of formula VII G¹ is hydrogen or $-CONR^{39}R^{40}$, wherein R^{39} and R^{40} independently of each other are hydrogen or C_{1-6} alkyl, preferably hydrogen, methyl or ethyl.

20 In the above compound of formula VII G¹ is preferably methylcarbamoyl or ethylcarbamoyl, most preferred ethylcarbamoyl.

25 In one embodiment of the compound of formula VII R¹ is C_{1-6} alkyl, preferably hydrogen or C_{1-4} alkyl.

In the above compound of formula VII R¹ is preferably methyl.

In one embodiment of the compound of formula VII R² is hydrogen, $-C(=O)-R^{54}$ or C_{1-6} alkyl, wherein R^{54} is C_{1-6} alkyl, preferably hydrogen, C_{1-6} alkyl or $-C(=O)-CH_3$.

30 In the above compound of formula VII R² is preferably methyl, hydrogen, or acetyl, more preferred methyl or hydrogen, most preferred hydrogen.


In the above compound of formula VII a is preferably 1.

In the above compound of formula VII b is preferably 1.


5 The compounds of formulas I-VII comprise any optical isomers thereof, in the form of
separated, pure or partially purified optical isomers or racemic mixtures thereof.

Preferred compounds of the invention are:


10 1-((2R)-2-(N-((2E)-5-amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-2-
benzyl-4-ethylsemicarbazide:



15 (2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionic acid N-
methyl-N-phenethylamide:




1-((2R)-2-(N-(2-((2S)-pyrrolidin-2yl)methoxy)acetyl)-N-methylamino)-3-(2-naphthyl)propionyl)-2-benzyl-4-ethylsemicarbazide:



5


1-((2R)-2-(N-((2-amino-2-methylpropoxy)acetyl)-N-methylamino)-3-(2-naphthyl)propionyl)-2-benzyl-4-ethylsemicarbazide:



10


(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-(2-(methylsulfonylamino)phenyl)ethyl)amide:

40



5


(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-(2-(2-thienyl)ethyl)amide:




10

(2R)-2-((5R)-4-((2E)-5-Amino-5-methylhex-2-enoyl)-5-(2-naphthyl)methyl-2-oxopiperazin-1-yl)-N-methyl-3-phenylpropionamide:

15




(2R)-2-(N-((2E)-5-((2R)-2-hydroxypropylamino)-5-methylhex-2-enoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-phenethylpropionamide:




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(N-acetyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)amino)-1-((2-naphthyl)methyl)ethyl)amide:


10




(2E)-5-Amino-5-methyl-N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide




15 (2E)-5-Methyl-5-(methylamino)-N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)amide




5 (2R)-2-(N-(3-(1-Aminoethyl)benzoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-1-(2-naphthyl)methyl)-2-oxoethyl)-N-methylamide




10 (2E)-5-Methyl-N-methyl-5-(methylamino)-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide




(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enyl)-N-methylamino)-N-(2-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methyl-3-(2-naphthyl)propionamide




5 (2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-(2-(2-methylsulfonylaminophenyl)ethyl)propionamide




(2E)-5-Amino-N-((1R)-2-(biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-5-methyl-N-methylhex-2-enamide




(2E)-N-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methyl-5-methyl-5-(methylamino)hex-2-enamide




5 3-Aminomethyl-N-[(1R)-1-(N-{2-[2-hydroxyethoxy]phenyl}ethyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl]benzamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)amide




10 (2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[2-(2-benzenesulfonylamino)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide




2-Amino-N-(2-(2-(N-((2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-N-methylamino)ethyl)phenyl)acetamide




5 (2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-N-(2-(3-hydroxypropoxy)phenyl)ethyl)-N-methyl-3-(2-naphthyl)propionamide



10 3-Aminomethyl-N-[(1R)-1-(N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]benzamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide



5

(3R)-4-((2E)-5-Amino-5-methylhex-2-enoyl)-3-((2-naphthyl)methyl)-1-phenethylpiperazin-2-one



10

Throughout the present specification compounds of formula I are also intended to comprise compounds of formula II, III, IV, V, VI, and VII, and thus, a reference to formula I is also a reference to any one of formula II, III, IV, V, VI, and VII.

It is believed that compounds of formula I exhibit an improved resistance to proteolytic degradation by enzymes compared to that of the peptides suggested in the prior literature, due to the lack of natural peptide bonds. The increased resistance to proteolytic degradation combined with the reduced size of the compounds of the invention in comparison with known 5 growth hormone releasing peptides is expected to improve their bioavailability compared to that of the peptides suggested in the prior literature.

In the above structural formulas and throughout the present specification, the following terms have the indicated meanings:

10 The C_{1-6} -alkyl groups specified above are intended to include those alkyl groups of the designated length in either a linear or branched or cyclic configuration. Examples of linear alkyl are methyl, ethyl, propyl, butyl, pentyl, and hexyl. Examples of branched alkyl are isopropyl, sec-butyl, tert-butyl, isopentyl, and isohexyl. Examples of cyclic alkyl are C_{3-6} -cycloalkyl such as 15 cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

20 The C_{1-6} -alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a linear or branched or cyclic configuration. Examples of linear alkoxy are methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexoxy. Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, and isohexoxy. Examples of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.

25 In the present context, the term "aryl" is intended to include aromatic rings, such as carbocyclic and heterocyclic aromatic rings selected from the group consisting of phenyl, naphthyl, pyridyl, 1-H-tetrazol-5-yl, thiazolyl, imidazolyl, indolyl, pyrimidinyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, quinolinyl, pyrazinyl, or isothiazolyl, optionally substituted by one or more C_{1-6} -alkyl, C_{1-6} -alkoxy, halogen, amino or aryl. Aryl is preferably phenyl, thienyl, imidazolyl, oxadiazolyl, pyridyl, indolyl, quinolinyl or naphthyl optionally substituted with 30 halogen, amino, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy.

30 The term "halogen" is intended to include Cl, F, Br and I.

The compounds of the present invention may have one or more asymmetric centres and it is intended that stereoisomers, as separated, pure or partially purified stereoisomers or racemic mixtures thereof are included in the scope of the invention.

The compounds of the present invention may optionally be in a pharmaceutically acceptable

5 salt form such as the pharmaceutically acceptable acid addition salts of compounds of formula I which include those prepared by reacting the compound of formula I with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, acetic, phosphoric, lactic, maleic, phthalic, citric, glutaric, gluconic, methanesulfonic, salicylic, succinic, tartaric, toluenesulfonic, trifluoracetic, sulfamic or fumaric acid.

10

The compounds of formula I may be administered in pharmaceutically acceptable acid addition salt form or, where appropriate, as an alkali metal or alkaline earth metal or lower alkylammonium salt. Such salt forms are believed to exhibit approximately the same order of activity as the free base forms.

15

In another aspect, the present invention relates to a pharmaceutical composition comprising, as an active ingredient, a compound of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

20

Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.

25

The pharmaceutical carrier or diluent employed may be a conventional solid or liquid carrier. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water.

30

Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

A typical tablet which may be prepared by conventional tabletting techniques may contain:

10 Core:

Active compound (as free compound or salt thereof)	100mg
Colloidal silicon dioxide (Aerosil)	1.5mg
Cellulose, microcryst. (Avicel)	70mg
Modified cellulose gum (Ac-Di-Sol)	7.5mg

15 Magnesium stearate

Coating:

HPMC approx.	9mg
*Mywacett 9-40 T approx.	0.9mg

20

*Acylated monoglyceride used as plasticizer for film coating.

For nasal administration, the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The 25 carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.

Generally, the compounds of the present invention are dispensed in unit dosage form 30 comprising 50-200 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.

The dosage of the compounds according to this invention is suitably 0.1-500 mg/day, e.g. from about 5 to about 50 mg, such as about 10 mg per dose, when administered to patients, e.g. humans, as a drug.

- 5 It has been demonstrated that compounds of the general formula I possess the ability to release endogenous growth hormone *in vivo*. The compounds may therefore be used in the treatment of conditions which require increased plasma growth hormone levels such as in growth hormone deficient humans or in elderly patients or livestock.
- 10 Thus, in a particular aspect, the present invention relates to a pharmaceutical composition for stimulating the release of growth hormone from the pituitary, the composition comprising, as an active ingredient, a compound of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- 15 In a further aspect, the present invention relates to a method of stimulating the release of growth hormone from the pituitary, the method comprising administering to a subject in need thereof an effective amount of a compound of the general formula I or a pharmaceutically acceptable salt thereof.
- 20 In a still further aspect, the present invention relates to the use of a compound of the general formula I or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulating the release of growth hormone from the pituitary.

To those skilled in the art, it is well known that the current and potential uses of growth hormone in humans are varied and multitudinous. Thus, compounds of formula I can be administered for purposes stimulating release of growth hormone from the pituitary and would then have similar effects or uses as growth hormone itself. The uses of growth hormone may be summarized as follows: stimulation of growth hormone release in the elderly; prevention of catabolic side effects of glucocorticoids, prevention and treatment of osteoporosis, treatment of NIDDM, stimulation of the immune system, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating renal failure or insufficiency resulting from growth retardation, treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic illness, treatment of obesity and growth retardation associated with obesity, treatment of anorexia, treating growth retardation

associated with the Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients; treatment of intrauterine growth retardation, skeletal dysplasia, hypercortisolism and Cushing's syndrome; induction of pulsatile growth hormone release; replacement of growth hormone in stressed patients, treatment of 5 osteochondrodysplasias, Noonan's syndrome, schizophrenia, depressions, Alzheimer's disease, delayed wound healing and psychosocial deprivation, treatment of pulmonary dysfunction and ventilator dependency, attenuation of protein catabolic responses after major surgery, reducing cachexia and protein loss due to chronic illness such as cancer or AIDS; treatment of hyperinsulinemia including nesidioblastosis, adjuvant treatment for ovulation 10 induction; to stimulate thymic development and prevent the age-related decline of thymic function, treatment of immunosuppressed patients, improvement in muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis, renal homeostasis in the frail elderly, stimulation of osteoblasts, bone remodelling and cartilage growth, stimulation of the immune system in companion animals and treatment of disorder of aging in companion animals, growth 15 promoter in livestock and stimulation of wool growth in sheep.

For the above indications the dosage will vary depending on the compound of formula I employed, on the mode of administration and on the therapy desired. However, generally dosage levels between 0.0001 and 100 mg/kg body weight daily are administered to patients 20 and animals to obtain effective release of endogenous growth hormone. Usually, dosage forms suitable for oral, nasal, pulmonary or transdermal administration comprise from about 0.0001 mg to about 100 mg, preferably from about 0.001 mg to about 50 mg of the compounds of formula I admixed with a pharmaceutically acceptable carrier or diluent.

25 Optionally, the pharmaceutical composition of the invention may comprise a compound of formula I combined with one or more compounds exhibiting a different activity, e.g., an antibiotic or other pharmacologically active material.

The route of administration may be any route which effectively transports the active compound 30 to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal or parenteral, the oral route being preferred.

Apart from the pharmaceutical use of the compounds of formula I, they may be useful in vitro tools for investigating the regulation of growth hormone release.

Compounds of formula I may also be useful in vivo tools for evaluating the growth hormone releasing capability of the pituitary. For example, serum samples taken before and after administration of these compounds to humans can be assayed for growth hormone.

5 Comparison of the growth hormone in each serum sample would directly determine the ability of the patients pituitary to release growth hormone.

Compounds of formula I may be administered to commercially important animals, such as cows, sheeps, pigs, goats, etc. to increase their rate and extent of growth, and to increase milk 10 production.

A further use of growth hormone secretagogue compounds of formula I is in combination with other secretagogues such as GHRP (2 or 6), GHRH and its analogues, growth hormone and its analogues or somatomedins including IGF-1 and IGF-2.

15

Pharmacological Methods

Compounds of formula I may be evaluated in vitro for their efficacy and potency to release growth hormone in rat pituitary primary cultures.

20 The isolation of rat pituitary cells is a modification of O. Sartor et al., *Endocrinology* 116, 1985, pp. 952-957. Male albino Sprague-Dawley rats (250 +/- 25 grams) were purchased from Møllegaard, Lille Skensved, Denmark. The rats were housed in group cages (four animals/cage) and placed in rooms with 12 hour light cycle. The room temperature varied from 19-24°C and the humidity from 30 - 60%.

25

The rats were decapitated and the pituitaries dissected. The neurointermediate lobes were removed and the remaining tissue was immediately placed in icecold isolation buffer (Gey's medium (Gibco 041-04030) supplemented with 0.25% D-glucose, 2% non-essential amino acids (Gibco 043-01140) and 1% bovine serum albumine (BSA) (Sigma A-4503)). The tissue 30 was cut into small pieces and transferred to isolation buffer supplemented with 3.8 mg/ml of trypsin (Worthington #3707 TRL-3) and 330 mg/ml of DNase (Sigma D-4527). This mixture was incubated at 70 rotations/min for 35 min at 37°C in a 95/5% atmosphere of O₂/CO₂. The tissue was then washed three times in the above buffer. Using a standard pasteur pipette, the tissue was then aspirated into single cells. After dispersion, cells were filtered through a nylon

filter (160 mm) to remove undigested tissue. The cell suspension was washed 3 times with isolation buffer supplemented with trypsin inhibitor (0.75 mg/ml, Worthington #2829) and finally resuspended in culture medium; DMEM (Gibco 041-01965) supplemented with 25 mM HEPES (Sigma H-3375), 4 mM glutamine (Gibco 043-05030H), 0.075% sodium bicarbonate (Sigma S-8875), 0.1% non-essential amino acid, 2.5% fetal calf serum (FCS, Gibco 011-06290), 3% horse serum (Gibco 034-06050), 10% fresh rat serum, 1 nM T₃ (Sigma T-2752) and 40 mg/L dexamethasone (Sigma D-4902) pH 7.3, to a density of 2 x 10⁵ cells/ml. The cells were seeded into microtiter plates (Nunc, Denmark), 200 ml/well, and cultured for 3 days at 37°C and 8% CO₂.

10

Compound testing

After culturing, the cells were washed twice with stimulation buffer (Hanks Balanced Salt Solution (Gibco 041-04020) supplemented with 1% BSA (Sigma A-4503), 0.25% D-glucose (Sigma G-5250) and 25 mM HEPES (Sigma H-3375) pH 7.3) and preincubated for 1 hour at 37°C. The buffer was exchanged with 90 ml stimulation buffer (37°C). Ten ml test compound solution was added and the plates were incubated for 15 min at 37°C and 5% CO₂. The medium was decanted and analyzed for GH content in an rGH SPA test system.

20 All compounds were tested in doses ranging from 10 pM to 100 mM. A dose-response relation was constructed using the Hill equation (Fig P, Biosoft). The efficacy (maximal GH released, E_{max}) was expressed in % of the E_{max} of GHRP-6. The potency (EC₅₀) was determined as the concentration inducing half maximal stimulation of the GH release.

25 Compounds of formula I may be evaluated for their metabolic stability.

Compounds were dissolved at a concentration of 1 mg/ml in water. 25 ml of this solution is added to 175 ml of the respective enzyme-solution (resulting in an enzyme:substrate ratio (w/w) of approximately 1:5). The solution is left at 37°C overnight. 10 ml of the various 30 degradation solutions is analyzed against a corresponding zero-sample using flow injection electrospray mass spectrometry (ESMS) with selected ion monitoring of the molecular ion. If the signal has decreased more than 20% compared to the zero-sample, the remainder of the solution is analyzed by HPLC and mass spectrometry in order to identify the extent and site(s) of degradation precisely.

Several standard peptides (ACTH 4-10, Angiotensin 1-14 and Glucagon) have been included in the stability tests in order to verify the ability of the various solutions to degrade peptides.

5 Standard peptides (angiotensin 1-14, ACTH 4-10 and glucagon) were purchased from Sigma, MO, USA)

Enzymes (trypsin, chymotrypsin, elastase aminopeptidase M and carboxypeptidase Y and B) were all purchased from Boehringer Mannheim GmbH (Mannheim, Germany)

10 Pancreatic enzyme mix: trypsin, chymotrypsin and elastase in 100 mM ammoniumbicarbonate pH 8.0 (all concentrations 0.025 mg/ml).

15 Carboxypeptidase mix: carboxypeptidase Y and B in 50 mM ammoniumacetate pH 4.5 (all concentrations 0.025 mg/ml).

Aminopeptidase M solution: aminopeptidase M (0.025 mg/ml) in 100 mM ammoniumbicarbonate pH 8.0

20 Mass spectrometric analysis was performed using two different mass spectrometers. A Sciex API III triple quadrupole LC-MS instrument (Sciex instruments, Thornhill, Ontario) equipped with an electrospray ion-source and a Bio-Ion 20 time-of-flight Plasma Desorption instrument (Bio-Ion Nordic AB, Uppsala, Sweden).

25 Quantification of the compounds (before and after degradation) was done on the API III instrument using single ion monitoring of the molecular ion in question with flow injection of the analyte. The liquid flow (MeOH:water 1:1) of 100 ml/min was controlled by an ABI 140B HPLC unit (Perkin-Elmer Applied Biosystems Divisions, Foster City, CA). The instrument parameters were set to standard operation conditions, and SIM monitoring was performed using the most 30 intense molecular ion (in most cases this corresponded to the doubly charged molecular ion).

Identification of degradation products furthermore involved the use of plasma desorption mass spectrometry (PDMS) with sample application on nitrocellulose coated targets and standard

instrumental settings. The accuracy of the hereby determined masses is generally better than 0.1%.

Separation and isolation of degradation products was done using a HY-TACH C-18 reverse phase 4.6x105 mm HPLC column (Hewlett-Packard Company, Palo Alto, CA) with a standard acetonitrile: TFA separation gradient. The HPLC system used was HP1090M (Hewlett-Packard Company, Palo Alto, CA).

Peptide derivative	MW/SIM ion (amu)	Carboxy-peptidase mix	Pan. enzyme mix
Standards			
ACTH 4-10	1124.5/562.8	+	-
Glucagon	3483/871.8	-	-
Insulin (B23-29)	859.1/430.6		
Angiotensin 1-14	1760.1/881.0	-	-
GHRP-2	817.4/409.6	-	-
GHRP-6	872.6/437.4	-	-

10

+: Stable (less than 20% decrease in SIM signal after 24 h in degradation solution)

-: Unstable (more than 20% decrease in SIM signal after 24 h in degradation solution)

Any novel feature or combination of features described herein is considered essential to this
15 invention.

EXAMPLES

The process for preparing compounds of formula I and preparations containing them is further illustrated in the following examples, which however, are not to be construed as

5 limiting.

The structures of the compounds are confirmed by either elemental analysis (MA) nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR shifts (δ) are given in parts per million (ppm) and only selected peaks are given. mp is melting point and is given in °C.

10 Column chromatography was carried out using the technique described by W.C. Still et al, J. Org. Chem. 1978, 43, 2923-2925 on Merck silica gel 60 (Art 9385). Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se.

15 Abbreviations:

TLC: thin layer chromatography

DMSO: dimethylsulfoxide

min: minutes

h: hours

20

HPLC-Analysis:

Method A1.


The RP-analysis was performed using UV detections at 214, 254, 276, and 301 nm on a

25 218TP54 4.6 mm x 250 mm 5m C-18 silica column (The Separations Group, Hesperia), which was eluted at 1 mL/min at 42°C. The column was equilibrated with 5% acetonitrile in a buffer consisting of 0.1 M ammonium sulfate, which was adjusted to pH 2.5 with 4M sulfuric acid. after injection the sample was eluted by a gradient of 5% to 60% acetonitrile in the same buffer during 50 min.

30

Example 1


(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionic acid
N-methyl-N-phenethylamide



5

N-Methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamic acid

10 **tert-butylester**



15


(2R)-2-(N-tert-Butoxycarbonyl-N-methylamino)-3-(2-naphthyl)propionic acid (1.40 g, 4.3 mmol) was dissolved in N,N-dimethylformamide (5 ml) and dichloromethane (5 mL). Hydroxy-7-azabenzotriazole (0.59 g, 4.3 mmol) was added as a solid. The solution was cooled to 0 °C. N-20 (3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.99 g, 5.2 mmol) was added. The solution was stirred for 20 min at 0 °C. N-Methyl-N-phenethylamine (0.86 ml, 6.0 mmol) was added. The solution was stirred for 16 h, while it was warming up to room temperature. It was diluted with water (300 ml) and ethyl acetate (150 ml). 10% sodium hydrogen sulfate solution (80 ml) was added. The phases were separated. The aqueous phase was extracted

with ethyl acetate (4 x 50 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (200 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (90 g), using ethyl acetate/heptane 1:1 as eluent to give 1.89 g of N-methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butylester.

10 ¹H-NMR (CDCl₃): δ 1.01, 1.09, 1.25, and 1.30 (all s, together 9 H); 2.60 - 3.85 (m, 12 H); 4.75, 5.03, 5.31, and 5.37 (all dd, together 1 H); 7.00 - 7.85 (m, 12 H).

(2R)-2-(Methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-phenethylamide

15




20 N-Methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butylester (1.84 g, 4.12 mmol) was dissolved in dichloromethane (6 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (6 ml) was added. The solution was stirred for 10 min at 0 °C. The solvent was removed in vacuo at 20 °C. The residue was dissolved in dichloromethane (100 ml) and the solvent was removed in vacuo. This latter procedure was repeated two times. The crude product was purified by flash chromatography on silica (70 g), using

25 dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 350 mg of (2R)-2-(methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-phenethylamide.

¹H-NMR (CDCl₃): δ 1.72 (br, 1 H); 2.12, 2.30, 2.44, and 2.87 (all s, together 6 H); 2.58, 2.76, 2.91, 2.98, 3.09, 3.25, 3.50, 3.61, and 3.73 (all m, together 7 H); 6.90 - 7.85 (m, 12 H).

5 (3E)-1,1-Dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enylcarbamic acid tert-butylester



10 (2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-3-enoic acid (303 mg, 1.04 mmol) was dissolved in N,N-dimethylformamide (2 ml) and dichloromethane (2 ml). Hydroxy-7-azabenzotriazole (170 mg, 1.25 mmol) was added as a solid. The solution was cooled to 0 °C. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (299 mg, 1.56 mmol) was added. The solution was stirred for 10 min at 0 °C. (2R)-2-(Methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-phenethylamide (360 mg, 1.04 mmol) was dissolved in 15 dichloromethane (2 ml) and added to the reaction mixture. Ethyldiisopropylamine (0.18 ml, 1.04 mmol) was added. The reaction mixture was stirred for 16 h, while it was warming to room temperature. The solution was diluted with water (200 ml) and ethyl acetate (150 ml). 10% aqueous sodium hydrogen sulfate solution (50 ml) was added. The phases were separated, and the aqueous phase was extracted with ethyl acetate (4 x 50 ml). The combined organic 20 layers were washed with saturated sodium hydrogen carbonate solution (200 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (110 g), using ethyl acetate/heptane 1:1 as eluent, to give 546 mg of (3E)-1,1-dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enylcarbamic acid tert-butylester.

25

¹H-NMR (CDCl₃): δ 1.14, 1.17, 1.23, and 1.26 (all s, together 6 H); 1.38 and 1.41 (both s, together 9H); 2.40 - 3.10, 3.30 - 3.60, and 3.92 (all m, together 8 H); 2.78, 2.89, and 3.03 (all s, together 6 H); 4.28 and 4.40 (both br, together 1 H); 5.78 and 5.85 (both dd, together 1 H);

6.15 and 6.23 (both d, together 1 H); 6.70 and 6.80 (both m, together 1 H); 7.00 - 7.85 (m, 12 H).

(3E)-1,1-dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enylcarbamic acid tert-butylester (528 mg, 0.85 mmol) was dissolved in dichloromethane (2 ml). Trifluoroacetic acid (2 ml) was added. The solution was stirred at room temperature for 10 min. The solvent was removed in vacuo at 20 °C. The residue was dissolved in dichloroemethane (50 ml), and the solvent was removed in vacuo. This latter procedure was repeated two times. The crude product was purified by flash chromatography on silcia, using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 320 mg of the title compound as free base. 100 mg of this was dissolved in ethyl acetate (3 ml). 3 M hydrogen chloride in ethyl acetate (0.7 ml) was added. The solvent was removed in vacuo. The residue was purified by two HPLC-chromatographies on a 25 mm x 250 mm 10m C18 silica column at 40 °C with a gradient of 30 to 43% acetonitrile in a 0.1M ammonium sulfate buffer, which was adjusted to pH 2.5 with 4M sulfuric acid. The peptide containing fractions were collected, diluted with 3 volumes of water and applied to a Sep-Pak® C18 cartridge (Waters part. #: 51910) which was equilibrated with 0.1% trifluoroacetic acid. The peptide was eluted from the Sep-Pak® cartridge with 70% acetonitrile in a 0.1% trifluoroacetic acid solution in water. The product was liophilized to give 10 mg of the title compound as trifluoroacetate.

HPLC (A1): R_t 34.27 min.

25


NMR (CDCl₃, selected values, free base): d 1.04, 1.05, 1.11, and 1.12 (all s, together 6 H); 5.78 and 5.87 (both dd, together 1 H); 6.14 and 6.23 (both d, together 1 H); 6.78 and 6.87 (both dt, together 1 H).

30 MS: 472.1 [M+H]⁺.

Example 2

(2R)-2-(N-((2E)-5-((2R)-2-hydroxypropylamino)-5-methylhex-2-enyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-phenethylpropionamide


5



10

(2R)-2-(N-((2E)-5-((2R)-2-(tert-Butoxydimethylsilyloxy)propylamino)-5-methylhex-2-enyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-phenethylpropionamide

15



(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enyl)-N-methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-phenethylamide (179 mg, 0.38 mmol) was dissolved in methanol (10 ml). Glacial acetic acid (0.30 ml, 5.30 mmol) and mol sieves (3 Å, 5.0 g) were added successively. (2R)-2-(tert-Butyldimethylsilyloxy)propanal (500 mg, 2.66 mmol) was dissolved in methanol (3 ml) and

added to the reaction mixture. Sodium cyanoborohydride (95 mg, 1.51 mmol) was added as a solid. The reaction mixture was stirred for 3 h at room temperature. Another portion of sodium cyanoborohydride (95 mg, 1.51 mmol) was added. The reaction mixture was stirred 16 h at room temperature. The mol sieves was filtered off through a plug of celite, which was washed 5 with methanol (30 ml). The solvent was removed in vacuo. The residue was dissolved in water/1N sodium hydroxide solution (50 ml/50 ml). The solution was extracted with diethyl ether (3 x 50 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on 10 silica (60 g) using ethyl acetate/heptane/triethylamine (10:10:1) as eluent to give 160 mg of (2R)-2-(N-((2E)-5-((2R)-2-(tert-butoxydimethylsilyloxy)-propylamino)-5- methylhex-2-enoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-phenethylpropionamide.

¹H-NMR (CDCl₃, selected values): δ = 5.80 and 5.86 (t and dd, together 1 H); 6.14 and 6.23 (both d, together 1 H); 6.85 (m, 1 H).

15 (2R)-2-(N-((2E)-5-((2R)-2-(tert-Butoxydimethylsilyloxy)-propylamino)-5- methylhex-2-enoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-phenethylpropionamide (135 mg, 0.21 mmol) was dissolved in THF (2 ml). An 1.1 M solution of tertbutylammonium fluoride (0.42 ml, 0.46 mmol) was added. The reaction mixture was stirred for 1 h at room temperature. 20 The solution was diluted with ethyl acetate (50 ml). It was extracted with saturated sodium hydrogen carbonate solution (3 x 20 ml). The combined organic layers were dried over magnesium sulfate. The solvents were removed in vacuo. The residue was purified on silica (20 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 24 mg of the crude product. The residue was purified by HPLC-chromatography on a 25 mm x 25 mm 10m C18 silica column at 40 °C with a gradient of 30.0 to 43.5% acetonitrile in a 0.1M ammonium sulfate buffer, which was adjusted to pH 2.5 with 4M sulfuric acid. The peptide containing fractions were collected, diluted with 3 volumes of water and applied to a Sep-Pak® C18 cartridge (Waters part. #: 51910) which was equilibrated with 0.1% trifluoroacetic acid. 25 The peptide was eluted from the Sep-Pak® cartridge with 70% acetonitrile in a 0.1% trifluoroacetic acid solution in water. The product was liophilized to give 10.7 mg of the title 30 compound as trifluoroacetate.

HPLC: R_t 35.13 (A1)
R_t 37.08 (B1)


MS: 530.8 ± 0.5 (M+1)

5

Example 3


(2R)-2-((5R)-4-((2E)-5-Amino-5-methylhex-2-enoyl)-5-(2-naphthyl)methyl-2-oxopiperazin-1-yl)-N-methyl-3-phenyl propionamide.

10



((1R)-1-(((1R)-1-Methylcarbamoyl-2-phenylethylamino)methyl)-2-(2-naphthyl)ethyl)carbamic acid tert butyl ester.

15




D-Phenylalanine-N-methyl amide (1.50 g, 8.35 mmol) and (1R)-1-formyl-2-(2-naphthyl)ethylcarbamic acid tert-butyl ester (2.50 g, 8.35 mmol) were dissolved in methanol (40 ml). Molsieves (3Å, 30 g) and acetic acid (3 ml) were added and the mixture was cooled with ice and sodium cyanoborohydride (0.80 g, 12.5 mmol) was added. The mixture was stirred overnight at room temperature. Water (30 ml) and saturated aqueous sodium hydrogen carbonate (30 ml) were added and the mixture was extracted with methylene chloride (3 x 40 ml). The combined organic phases were dried (magnesium sulfate) and the solvent was removed in vacuo. The residue was chromatographed on silica (3 x 30 cm) using ethyl acetate/heptane (1:1) as eluent to afford 1.19 g of ((1R)-1-(((1R)-1-methylcarbamoyl-2-phenylethylamino)methyl)-2-(2-naphthyl)ethyl)carbamic acid tert butyl ester

15

¹H-NMR : (CDCl₃) d 1.37 (s, 9H); 2.32 (dd, 1H); 2.49-2.71 (m, 4H); 2.75 (d, 3H); 3.21 (m, 2H); 3.94 (m, 1H); 4.32 (d, 1H); 7.12-7.81 (12 arom. H)

((1R)-1-((N-Chloroacetyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)amino)methyl)-2-(2-naphthyl)ethyl)carbamic acid tert butyl ester.




25 ((1R)-1-(((1R)-1-Methylcarbamoyl-2-phenylethylamino)methyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester (1.00 g, 2.18 mmol) was dissolved in methylene chloride (20 ml).

Diisopropylethylamine (0.37 ml, 2.13 mmol) was added and the mixture was cooled with ice. Chloroacetic anhydride (0.37 g, 2.18 mmol) was dissolved in methylene chloride (20 ml) and added dropwise. The mixture was stirred overnight. Chloroacetic anhydride (0.18 g, 1.09 mmole was added) and the mixture was stirred 1 h. Water (20 ml) and methylene chloride (20 ml) were added and the organic phase was washed with an aqueous solution of sodium hydrogen sulphate (10%, 25 ml), a saturated aqueous solution of sodium hydrogen carbonate (25 ml), and dried (magnesium sulfate) and the solvent was removed in vacuo. The residue was chromatographed on silica (3 x 30 cm) using ethyl acetate/heptane (1:1) as eluent to afford 0.57 g of ((1R)-1-((N-chloroacetyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)amino)methyl)-2-(2-naphthyl)ethyl)carbamic acid tert butyl ester

10 ¹H-NMR : (CDCl₃) (selected peaks for major rotamer) d 1.38 (s, 9H); 2.80 (d, 3H); 3.95 (m, 2H); 6.90-7.78 (12 arom. H)

15 ESMS: m/z 538

(2R)-2-(N-((2R)-2-Amino-3-(2-naphthyl)propyl)-N-chloroacetylamino)-N-methyl-3-phenylpropionamide.



20

25 ((1R)-1-((N-Chloroacetyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)amino)methyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester (0.56 g, 1.04 mmol) was dissolved in a mixture of trifluoroacetic acid (4 ml) and methylene chloride (4 ml) and stirred for 40 min. The solvent was removed in vacuo and methylene chloride was added and removed in vacuo (3 x 10 ml)


to afford 0.69 g of (2R)-2-(N-((2R)-2-amino-3-(2-naphthyl)propyl)-N-chloroacetyl-amino)-N-methyl-3-phenylpropionamide as a trifluoroacetate.

1 ¹H-NMR : (CDCl₃)(selected peaks for major rotamer) d 2.67 (d, 3H); 3.85, 3.95 (two d (AB-

5 syst.), 2H); 4.55 (t, 1H).

ESMS: m/z: 438 (M+H)⁺

(2R)-N-Methyl-2-((5R)-5-((2-naphthyl)methyl)-2-oxopiperazin-1-yl)-3-phenylpropionamide.



10

(2R)-2-(N-((2R)-2-Amino-3-(2-naphthyl)propyl)-N-chloroacetyl-amino)-N-methyl-3-phenylpropionamide (0.69 g, 1.58 mmol) was dissolved in methanol (14 ml) and sodium hydrogen carbonate (0.40 g, 4.73 mmol) and water (7 ml) were added. The mixture was stirred overnight at room temperature. The solvent was removed in vacuo and the residue was dissolved in a mixture of ethyl acetate (30 ml) and saturated aqueous sodium hydrogen carbonate (20 ml). The mixture was extracted with ethyl acetate (4 x 20 ml). The combined organic phases were dried (magnesium sulfate) and the solvent was removed in vacuo. The residue was chromatographed on silica (2 x 20 cm) using methylene chloride/methanol/25% aqueous ammonia (100:10:1) to afford 0.19 g of (2R)-N-methyl-2-((5R)-5-((2-naphthyl)methyl)-2-oxopiperazin-1-yl)-3-phenylpropionamide

15

residue was dissolved in a mixture of ethyl acetate (30 ml) and saturated aqueous sodium hydrogen carbonate (20 ml). The mixture was extracted with ethyl acetate (4 x 20 ml). The combined organic phases were dried (magnesium sulfate) and the solvent was removed in vacuo. The residue was chromatographed on silica (2 x 20 cm) using methylene chloride/methanol/25% aqueous ammonia (100:10:1) to afford 0.19 g of (2R)-N-methyl-2-((5R)-5-((2-naphthyl)methyl)-2-oxopiperazin-1-yl)-3-phenylpropionamide


20

¹H-NMR : (CDCl₃) d 2.74 (d, 3H); 2.78-3.05 (m, 5H); 3.22 (dd, 1H); 3.30 (m, 1H); 3.32, 3.55 (two d (AB-syst), 2H); 5.27 (dd, 1H); 6.34 (s(br), 1H); 7.05-7.78 (12 arom. H).

25

ESMS: m/z 403 (M+H)⁺

((3E)-1,1-Dimethyl-5-((2R)-4-((1R)-1-(methylcarbamoyl)-2-phenylethyl)-2-((2-naphthyl)methyl)-5-oxopiperazin-1-yl)-5-oxopent-3-enyl)carbamic acid tert-butyl ester.



5

(2E)-5-Methyl-5-(tert-butyloxycarbonylamino)hex-2-enoic acid was dissolved in methylene chloride (10 ml). 1-Hydroxy-7-azabenzotriazol (60 mg, 0.46 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (100 mg, 0.51 mmol) were added and the mixture was stirred for 15 min. (2R)-N-Methyl-2-((5R)-5-((2-naphthyl)methyl)-2-oxopiperazin-1-yl)-3-phenylpropionamide (185 mg, 0.46 mmol) and diisopropylethylamine (0.08 ml) were added and the mixture was stirred overnight. Water (10 ml) and methylene chloride (10 ml) were added and the mixture was washed with an aqueous solution of sodium hydrogen sulphate (10%, 20 ml), a saturated aqueous solution of sodium hydrogen carbonate (20 ml), dried (magnesium sulfate) and the solvent was removed in vacuo. The residue was chromatographed on silica (3 x 30 cm) using ethyl acetate/heptane (1:1) as eluent to afford 0.20 g of ((3E)-1,1-dimethyl-5-((2R)-4-((1R)-1-(methylcarbamoyl)-2-phenylethyl)-2-((2-naphthyl)methyl)-5-oxopiperazin-1-yl)-5-oxopent-3-enyl)carbamic acid tert-butyl ester.

20 ¹H-NMR : (CDCl₃)(selected peaks for major rotamer) δ 1.21 (s, 6H); 1.38 (s, 9H); 2.91 (d, 3H); 5.35 (dd, 1H); 5.42 (t, 1H);

((3E)-1,1-Dimethyl-5-((2R)-4-((1R)-1-(methylcarbamoyl)-2-phenylethyl)-2-((2-naphthyl)methyl)-5-oxopiperazin-1-yl)-5-oxopent-3-enyl)carbamic acid tert-butyl ester (0.20 g, 0.32 mmol) was dissolved in methylene chloride (2 ml) and trifluoracetic acid (2 ml) and stirred for 7 min. Water (1 ml) and methylene chloride (10 ml) was added and pH was

adjusted to neutral with solid sodium hydrogen carbonate. The aqueous phase was extracted with methylene chloride (3 x 8 ml). The combined organic phases were dried (magnesium sulfate) and the solvent was removed in vacuo to afford 0.160 g of the title compound.

5

¹H-NMR : (CDCl₃)(selected peaks for major rotamer) d 1.28 (s, 3H); 1.35 (s, 3H); 2.75 (d, 3H); 4.05, 4.30 (AB, 2H); 5.05 (dd, 1H); 5.27 (dd, 1H); 6.15 (d, 1H).


HPLC: *r*_t = 28.8 min (A1)

10

Example 4


(2E)-5-Amino-5-methyl-N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide

15



20

25 3-Hydroxy-1,1-dimethylpropylcarbamic acid tert-butyl ester:




At 0 °C, ethyl chloroformate (1.10 ½, 11.5 mmol) was given dropwise to a solution of 3-tert-butoxycarbonylamino-3-methylbutanoic acid (2.50 g, 11.5 mmol) and triethylamine (1.92 mL, 13.8 mmol) in tetrahydrofuran (10 mL). The solution was stirred for 40 min at 0 °C. The formed precipitate was filtered off and washed with tetrahydrofuran (20 mL). The liquid was immediately cooled to 0 °C. A 2M solution of lithium boronhydride in tetrahydrofuran (14.4 mL, 28.8 mmol) was added dropwise. The solution was stirred at 0 °C for 2 h, and then warmed to room temperature over a period of 4 h. It was cooled to 0 °C. Methanol (5 mL) was added carefully. 1N Hydrochloric acid (100 mL) was added. The solution was extracted with ethyl acetate (2 x 100 mL, 3 x 50 mL). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (100 mL) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was chromatographed on silica (110 g) with ethyl acetate/heptane 1:2 to give 1.84 g of 3-hydroxy-1,1-dimethylpropylcarbamic acid tert-butyl ester.

¹H-NMR (CDCl₃): _d 1.33 (s, 6 H); 1.44 (s, 9 H); 1.88 (t, 2 H); 1.94 (br, 1 H); 3.75 (q, 2 H); 4.98 (br, 1 H).

20

3-(tert-Butoxycarbonylamino)-3-methylbutanal:




25 Dimethylsulfoxide (1.22 mL, 17.2 mmol) was added to a solution of oxalyl chloride (1.1 mL, 12.9 mmol) at -78 °C in dichloromethane (15 mL). The mixture was stirred for 15 min at -78 °C. A solution of 3-hydroxy-1,1-dimethylpropylcarbamic acid tert-butyl ester (1.75 g, 8.6 mmol) in dichloromethane (10 mL) was added dropwise over a period of 15 min. The solution was stirred at -78 °C for another 15 min. Triethylamine (6.0 mL, 43 mmol) was added. The solution was stirred at -78 °C for 5 min and then warmed to room temperature. The solution was diluted with

dichloromethane (100 ml) and extracted with 1N hydrochloric acid (100 ml). The aqueous phase was extracted with dichloromethane (50 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by column chromatography on silica (140 g) with ethyl acetate/heptane (1:3) to give 1.10 g of 3-(tert-butoxycarbonylamino)-3-methylbutanal.

¹H-NMR (CDCl₃): d 1.39 (s, 6 H); 1.45 (s, 9 H); 2.85 (d, 2 H); 4.73 (br, 1 H); 9.80 (t, 1 H).


10 Ethyl (2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoate:



15 Triethylphosphonoacetate (1.96 ml, 9.8 mmol) was dissolved in tetrahydrofuran (30 ml). Potassium tert-butoxide (1.10 g, 9.8 mmol) was added. The solution was stirred for 40 min at room temperature. A solution of 3-(tert-butoxycarbonylamino)-3-methylbutanal (1.10 g, 5.5 mmol) in Tetrahydrofuran (6 ml) was added. The solution was stirred at room temperature, for 75 min. It was diluted with ethyl acetate (100 ml) and 1N hydrochloric acid (100 ml). The 20 phases were separated. The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic phases were washed with saturated sodium hydrogen carbonate solution (60 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by column chromatography on silica (90 g) with ethyl acetate/heptane (1:4) to give 1.27 g of ethyl (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoate.

25 ¹H-NMR (CDCl₃): d 1.30 (s, 6 H); 1.30 (t, 3 H); 1.46 (s, 9 H); 2.62 (d, 2 H); 4.27 (q, 2 H); 4.42 (br, 1 H); 5.88 (d, 1 H); 6.94 (td, 1 H).

30 (2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoic acid:



Ethyl (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoate (1.233 g, 4.54 mmol) was dissolved in dioxane (20 ml). Lithium hydroxide (0.120 g, 5.00 mmol) was added as a solid.


5 Water (10 ml) was added, until a clear solution was reached. The solution was stirred 16 h at room temperature. The solution was diluted with water (70 ml) and was extracted with tert-butyl methyl ether (2 x 100 ml). The aqueous phase was acidified with 1N sodium hydrogensulfate solution (pH = 1) and was extracted with tert-butylmethylether (3 x 70 ml). The organic phases were combined and dried over magnesium sulfate. The solvent was removed in vacuo to give

10 1.05 g of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid. The crude product was used for further syntheses.

¹H-NMR (DMSO d₆): *d* 1.15 (s, 6 H); 1.35 (s, 9 H); 2.53 (d, 2 H); 5.75 (d, 1 H); 6.57 (br, 1 H); 6.75 (td, 1 H); 12.15 (s, 1 H).

15

N-(2-(2-Thienyl)ethyl)formamide:




20

2-(2-thienyl)ethylamine (15.0 g, 118 mmol) was dissolved in formic acid (120 ml) while cooling with an water bath. The solution was cooled to 0 °C. Acetic acid anhydride (45 ml) was added dropwise. The reaction mixture was stirred at room temperature for 3 h. It was cooled to 0 °C, and water (45 ml) was added dropwise. The mixture was stirred for 16 h, while it was warming up to room temperature. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (300 ml). The solution was washed with water (2 x 150 ml) and saturated sodium hydrogen carbonate solution (200 ml). It was dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (180 g), using ethyl acetate/heptane (2:1) as eluent to give 14.30 g of N-(2-(2-thienyl)ethyl)formamide.

¹H-NMR (CDCl₃): *d* 3.07 (t, 2 H); 3.59 (q, 2 H); 5.90 (br, 1 H); 6.85 (d, 1 H); 6.95 (dd, 1 H); 7.17 (d, 1 H); 8.12 (s, 1 H).

5

N-Methyl-N-(2-(2-thienyl)ethyl)amine:




10

At 7 °C, a solution of N-(2-(2-thienyl)ethyl)formamide (9.98 g, 63.8 mmol) in tetrahydrofuran (200 ml) was added to a suspension of sodium borohydride (2.89 g, 76.5 mmol) in tetrahydrofuran (200 ml). The mixture was stirred for 10 min. A solution of iodine (8.09 g, 31.9 mmol) in tetrahydrofuran (200 ml) was added dropwise. The reaction mixture was stirred for 30 min at 7 °C and 30 min at room temperature. It was heated to reflux for 16 h. The reaction mixture was cooled to 7 °C. Methanol (500 ml) was added dropwise. The solvent was removed in vacuo. The residue was dissolved in 20% aqueous sodium hydroxide solution (500 ml) and tert-butyl methyl ether (200 ml). The phases were separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 200 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (220 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 2.82 g of N-methyl-N-(2-(2-thienyl)ethyl)amine.

¹H-NMR (CDCl₃): *d* 2.05 (s, 1 H); 2.46 (s, 3 H); 2.90 (t, 2 H); 3.04 (t, 2 H); 6.84 (d, 1 H); 6.94 (dd, 1 H); 7.15 (d, 1 H).

N-Methyl-N-((1*R*)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester:




5

(2R)-2-(N-(tert-Butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (4.52 g, 13.7 mmol) was dissolved in N,N-dimethylformamide (6 ml) and dichloromethane (6 ml). 1-Hydroxy-7-azabenzotriazole (1.86 g, 13.7 mmol) was added as a solid. The solution was cooled to 0 °C. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (2.63 g, 13.7 mmol) was added. The solution was stirred for 15 min at 0 °C. A solution of N-methyl-N-(2-(2-thienyl)ethyl)amine in dichloromethane (6 ml) was added. Ethyldiisopropylamine (2.37 ml, 13.7 mmol) was added. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (200 ml). The mixture was washed with 1 N hydrochloric acid (150 ml) and saturated sodium hydrogen carbonate solution (150 ml). It was dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silcia (100 g), using ethyl acetate/heptane (1:2) as eluent to give 5.57 g of N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester.

20 ¹H-NMR (CDCl₃, selected values): δ 4.84, 5.05, and 5.86 (dd, dd, and m, together 1 H); 6.60 - 7.90 (m, 10 H).

(2R)-N-Methyl-2-(methylamino)-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide:




N-Methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester (5.17 g, 11.4 mmol) was dissolved in dichloromethane (12 ml). The solution 5 was cooled to 0 °C. Trifluoroacetic acid (12 ml) was added. The reaction mixture was stirred for 15 min at 0 °C. The solvent was removed in vacuo at 20 °C. The residue was codistilled with dichloromethane (3 x 60 ml). The crude product was purified by flash chromatography on silica (80 g), using dichloromethane/methanol/25% aqueous (100:10:1) ammonia as eluent, to give 1.91 g of (2R)-N-methyl-2-(methylamino)-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide.

10

¹H-NMR (CDCl₃): *d* 2.18, 2.32, 2.46, and 2.89 (all s, together 6 H); 2.50 - 3.60 (m, together 6 H); 3.65 and 3.75 (both dd, together 1 H); 6.58 and 6.69 (both d, together 1 H); 6.87, 7.10, 7.35, 7.45, 7.76 (all m, together 8 H); 7.62 and 7.65 (both s, together 1 H).

15

(3E)-1,1-Dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enylcarbamic acid tert-butyl ester:



20

(2E)-5-tert-Butoxycarbonylamino-5-methylhex-2-enoic acid (380 mg, 1.56 mmol) was dissolved in N,N-dimethylformamide (2 ml) and dichloromethane (2 ml). 1-Hydroxy-7-azabenzotriazole (299 mg, 1.56 mmol) was added as a solid. The solution was cooled to 0 °C. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (380 mg, 1.56 mmol) was added.

5 The solution was stirred for 15 min. at 0 °C. A solution of (2R)-N-methyl-2-(methylamino)-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide (500 mg, 1.42 mmol) in dichloromethane (2 ml) was added. Ethyldiisopropylamine (0.25 ml, 1.42 mmol) was added. The solution was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (70 ml) and washed with 1 N hydrochloric acid (100 ml). The organic layer was washed with saturated 10 sodium hydrogen carbonate solution (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (150 g), using ethyl acetate/heptane (1:1) as eluent, to give 679 mg of (3E)-1,1-dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enylcarbamic acid tert-butyl ester.

15 ¹H-NMR (CDCl₃, selected values): *d* 1.14, 1.17, 1.21, and 1.24 (all s, together 6 H); 1.39 and 1.41 (both s, together 9 H); 2.82, 2.91, 3.03, and 3.06 (all s, together 6 H); 5.84 and 5.88 (both dd, together 1 H); 6.15 and 6.26 (both d, together 1 H).

20 (3E)-1,1-Dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enylcarbamic acid tert-butyl ester (640 mg, 1.11 mmol) was dissolved in dichloromethane (3 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (3 ml) was added. The solution was stirred for 15 min at 0 °C. The solvent was removed in vacuo without warming. The residue was codistilled with dichloromethane (3 x 50 ml). The crude 25 product was purified by flash chromatography on silica (60 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 416 mg of the title compound.

HPLC: *R*_t = 33.48 min (A1).

30 *B*_t = 35.13 min (B1).

MS: 478.2, [M+H]⁺.


¹H-NMR (CDCl₃, selected values): δ 1.04, 1.05, 1.11, and 1.11 (all s, together 6 H); 2.80, 2.90, 3.04 and 3.07 (all s, together 6 H); 5.83 and 5.88 (both dd, together 1 H); 6.14 and 6.25 (both d, together 1 H).

5 For biological testing, the title compound was dissolved in 0.5 M acetic acid and lyophilized.

Example 5


(2E)-5-Methyl-5-(methylamino)-N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-

10 2-(2-naphthyl)ethyl)hex-2-enamide



15

(2E)-5-(N-(tert Butoxycarbonyl)-N-methylamino)-5-methylhex-2-enoic acid.



20


(2E)-5-(tert-Butoxycarbonyl)-N-methylhex-2-enoic acid (5.00 g ; 20.6 mmol) was dissolved in tetrahydrofuran (70 ml). Methyl iodide (10.3 ml; 164 mmol) was added and the solution was cooled to 0° C. Sodium hydride (60% in oil) (2.07 g; 61.6 mmol) was added in portions and the solution was stirred at room temperature for four days. Ethyl acetate (70 ml) and water (60 ml) was added dropwise and the solvent was removed in vacuo. The crude

product was dissolved in water (40 ml) and ether (40 ml). The organic phase was washed with a saturated aqueous solution of sodium hydrogencarbonate (30 ml). The aqueous phases were mixed and 5% aqueous citric acid was added to pH 3. The aqueous phase was extracted with ethyl acetate (4 x 50 ml). The organic phase was washed with water (2 x 40 ml), an aqueous solution of sodium thiosulfate (5%; 40 ml), water (40 ml), dried over MgSO_4 , and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate (45 ml) and washed with an aqueous solution of sodium hydrogensulfate (10%; 3 x 30 ml), dried over MgSO_4 and concentrated in vacuo to give 4.00 g of (2E)-5-(N-(tert-butoxycarbonyl)-N-methylamino)-5-methylhex-2-enoic acid.

10

$^1\text{H-NMR}$ (CDCl_3): d 1.38 (s, 6H), 1.45 (s, 9H); 2.80 (d, 2H); 2.85 (s, 3H); 5.88 (d, 1H); 7.01 (q, 1H).

15 N-Methyl-N-((3E)-1,1-dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester:



20

(2E)-5-(N-(tert-Butoxycarbonyl)-N-methylamino)-5-methylhex-2-enoic acid (146 mg, 0.57 mmol) was dissolved in dichloromethane (2 ml) and N,N-dimethylformamide (2 ml). 1-Hydroxy-7-azabenzotriazole (72 mg, 0.57 mmol) was added as a solid. The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (109 mg, 0.57 mmol) was added. The solution was stirred for 15 min at 0 °C. A solution of (2R)-N-Methyl-2-(methylamino)-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide (200 mg, 0.57 mmol) in dichloromethane (2 ml) was added. Ethyldiisopropylamine (0.1 ml, 0.57 mmol) was added. The

reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (50 ml) and washed with 1 N hydrochloric acid. The aqueous phase was extracted with ethyl acetate (2 x 20 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (40 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane as eluent, to give 270 mg of N-methyl-N-((3E)-1,1-dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester.

¹⁰ ¹H-NMR (CDCl₃, selected values): d 2.67, 2.76, 2.82, 2.90, 3.03, and 3.05 (all s, together 9 H); 5.85 (m, 1 H); 6.10 and 6.22 (both d, together 1 H).

¹⁵ N-Methyl-N-((3E)-1,1-dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester (221 mg, 0.37 mmol) was dissolved in dichloromethane (2 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (2 ml) was added. The solution was stirred for 20 min at 0 °C. ²⁰ Saturated sodium hydrogen carbonate solution (10 ml) was added. The mixture was adjusted to pH = 9, with solid potassium carbonate. The mixture was diluted with water 820 ml). It was extracted with tert-butyl methyl ether (3 x 30 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (30 g), using dichloromethane/methanol/25% aqueous ²⁵ ammonia as eluent, to give 125 mg of the title compound.

¹H-NMR (CDCl₃, selected values): d 1.00 and 1.08 (both s, together 6 H); 2.23 and 2.30 (both s, together 3 H); 2.80, 2.89, 3.04, and 3.07 (all s, together 6 H); 5.85 (m, 1 H); 6.13 and 6.25 (both d, together 1 H).

³⁰ HPLC: 33.27 min (A1)
35.28 min (B1).


MS: 492.0 [M+H].

For biological testing, it was transformed into the acetate by lyophilization from 0.5 N acetic acid (25 ml).

Example 6

5


(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)amide



10

N-(3-Phenylpropyl)formamide

15




3-Phenylproylamine (10 ml, 70.0 mmol) was added at 0 °C dropwise to formic acid (80 ml).

20 Acetic acid anhydride (30 ml) was added dropwise to the reaction mixture. After the addition the reaction mixture was warmed to room temperature. It was stirred for 2.5 h. It was cooled to 0 °C. Water (30 ml) was added dropwise. The reaction mixture was warmed to room temperature. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (300 ml). The organic phase was washed with saturated sodium chloride solution (2 x 150 ml) and with saturated sodium hydrogen carbonate solution (200 ml). It was dried over mag-

nesium sulfate. The solvent was removed in vacuo to furnish 5.82 g of N-(3-phenylpropyl)formamide, which was used without further purification.

5 ¹H-NMR (CDCl₃): d 1.85 (m, 2 H); 2.65 (t, 2 H); 3.21 and 3.30 (both q, together 2 H); 5.85
 (broad, 1 H); 7.10 - 7.50 (m, 5 H); 8.12 (s, 1 H).


N-Methyl-N-(3-phenylpropyl)amine



15 N-(3-Phenylpropyl)formamide (5.70 g, 34.9 mmol) was dissolved in tetrahydrofuran (50 ml) and added dropwise to a suspension of sodium borohydride (1.58 g, 41.91 mmol) in tetrahydrofuran (100 ml), which was cooled to 7 °C. A solution of iodine (4.42 g, 17.46 mmol) in tetrahydrofuran was added dropwise, while the temperature was kept at 7 °C. After the addition was finished, the reaction mixture was warmed to reflux for 16 h. The reaction mixture was cooled to 7 °C, and methanol (250 ml) was added dropwise. The solvent was removed in vacuo. The residue was dissolved in 20% aqueous sodium hydroxide solution (250 ml) and tert-butyl methyl ether (100 ml). The phases were separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 100 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (400 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 2.76 g of N-methyl-N-(3-phenylpropyl)amine.

20 ¹H-NMR (CDCl₃): d 1.85 (m, 2 H); 2.43 (s, 1 H); 2.50 (s, 3 H); 2.65 (m, 4 H); 7.10 - 7.40 (m, 5 H).

25 N-Methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester




(2R)-2-(N-(tert-Butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (2.21 g, 6.70 mmol) was dissolved in N,N-dimethylformamide (3 ml) and dichloromethane (6 ml). 1-5 Hydroxy-7-azabenzotriazole (0.91 g, 6.70 mmol) was added. The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.28 g, 6.70 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C. A solution of N-methyl-N-(3-phenylpropyl)amine (1.0 g, 6.7 mmol) in dichloromethane (3 ml) was added. Ethyldiisopropylamine (1.2 ml, 6.7 mmol) was added. The reaction mixture was stirred for 16 h, while it 10 was slowly warming up to room temperature. The solution was diluted with ethyl acetate (100 ml). It was washed with 1 N hydrochloric acid (100 ml). The aqueous phase was extracted with ethyl acetate (100 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on 15 silica (400 g), using ethyl acetate/heptane (1:3) as eluent to give 1.43 g of N-methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values): δ 1.25 (broad, 9 H); 1.79 (m, 2 H); 2.88 (broad, 3 H); 5.05 and 5.45 (both m, together 1 H).

20

(2R)-N-Methyl-2-methylamino-3-(2-naphthyl)-N-(3-phenylpropyl)propionamide




N-Methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester (1.43 g, 3.10 mmol) was dissolved in dichloromethane (5 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (5 ml) was added. The solution was stirred at 0 °C for 90 min. Dichloromethane (35 ml) and saturated sodium hydrogen carbonate solution were added. Solid sodium hydrogen carbonate was added until pH 7. The phases were separated. The aqueous phase was extracted with dichloromethane (2 x 100 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo to give 0.91 g of crude (2R)-N-methyl-2-methylamino-3-(2-naphthyl)-N-(3-phenylpropyl)propionamide, which was used without further purification.

¹H-NMR (CDCl₃, selected values): δ 0.91 - 1.35 (m, 2 H); 2.35, 2.42, 2.43, and 2.84 (all s, together 6 H); 3.64 and 3.92 (both dd, together 1 H).

MS: 361.2 [M+1]⁺.

((3E)-1,1-Dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester

20



(2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoic acid (405 mg, 1.66 mmol) was dissolved in N,N-dimethylformamide (4 ml) and dichloromethane (4 ml). 1-Hydroxy-7-azabenzotriazole (227 mg, 1.66 mmol) was added. The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (319 mg, 1.66 mmol) was added. The solution was stirred at 0 °C for 40 min. A solution of (2R)-N-methyl-2-methylamino-3-(2-naphthyl)-N-(3-phenylpropyl)propionamide (600 mg, 1.66 mmol) in dichloromethane (4 ml) was added. Ethyldiisopropylamine (0.29 ml, 1.66 mmol) was added. The solution was stirred

for 2 days, while it was slowly warming up to room temperature. The reaction mixture was diluted with ethyl acetate (100 ml) and washed with 1N hydrochloric acid (100 ml). The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (180 g), using ethyl acetate/heptane (1:1) as eluent to give 706 mg of ((3E)-1,1-dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester.

10

¹H-NMR (CDCl₃, selected values): d 1.21, 1.24, 1.25, and 1.26 (all s, together 6 H); 1.41 (s, 9 H); 2.83, 2.83, 3.10, and 3.12 (all s, together 6 H); 5.88 and 5.97 (both dd, together 1 H); 6.25 (m, 1 H); 6.80 (m, 1 H).

15

((3E)-1,1-Dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester was dissolved in dichloromethane (2 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (2 ml) was added. The solution was stirred at 0 °C for 55 min. Dichloromethane (13 ml) was added. A saturated aqueous solution of sodium hydrogen carbonate (16 ml) was added. Solid sodium hydrogen carbonate was added until pH 7. The phases were separated. The aqueous phase was extracted with dichloromethane (2 x 50 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 436 mg of the title compound.

¹H-NMR (CDCl₃, selected values): d 1.10 and 1.11 (both s, together 6 H); 2.85, 3.13, 3.15, and 3.50 (all s, together 6 H); 5.89 and 5.97 (both dd, together 1 H); 6.23 and 6.24 (both d, together 1 H).

30

MS: 486.4; [M+1]⁺


HPLC: 36.62 min (A1)
38.93 min (B1).

For biological testing, the title compound was transferred into its acetate salt by lyophilization from 0.5 M aqueous acetic acid (50 ml).

5 Example 7


(2R)-2-(N-(3-(1-Aminoethyl)benzoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide

10



15

3-(1-(N-tert-Butoxycarbonyl)aminoethyl)benzoic acid




20

Ammonium acetate (10.6 g, 138 mmol) was evaporated from dry ethanol (100 ml), and redissolved in dry methanol (100 ml) over molecular sieves (3 Å, 3 g). 3-Acetylbenzonitrile (2.0 g, 13.8 mmol) was added. After 30 min at room temperature sodium cyanoborohydride (0.87 g, 138 mmol) was added and the reaction mixture was stirred for 18 h. The reaction mixture was concentrated in vacuo and redissolved in water (100 ml). Concentrated hydrochloric acid was added until pH 2, and the aqueous solution was extracted with ethyl acetate (2 x 100 ml). The aqueous phase was adjusted to pH 11 with solid potassium hydroxide, and extracted with dichloromethane (2 x 100 ml). The combined organic phases were dried (magnesium sulfide) and concentrated in vacuo. A concentrated solution of hydrogen chloride in ethyl

25

acetate (100 ml) was added, and the solution was concentrated in vacuo. The residue was dissolved in ethanol (25 ml) and sulfuric acid (9 N, 25 ml) was added. After 16 h at room temperature and 2 h at reflux temperature, the ethanol was removed by evaporation in vacuo and the residual aqueous mixture was adjusted to pH >8, using solid potassium hydroxide. Di-tert.-butyldicarbonate (2.0 g), dissolved in tetrahydrofuran (100 ml) was added at 0 °C. After 18 h at room temperature, the reaction mixture was concentrated in vacuo and redissolved in water (100 ml). Solid citric acid was added until pH 5. The reaction mixture was extracted with dichloromethane (2 x 100 ml), and the combined organic phases were dried (magnesium sulfat) and concentrated in vacuo. The residue was purified by column chromatography on silica gel (3 x 40 cm), using ethanol and dichloromethane (1:9) as eluent to give 1.1 g of 3-(1-(N-tert.-butoxycarbonyl)aminoethyl)benzoic acid.

(1-(3-(N-Methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)phenyl)ethyl)carbamic acid tert-butyl ester



3-(1-(t-Butyloxycarbonylamino)ethyl)benzoic acid (217 mg, 0.82 mmol) was dissolved in dichloromethane (5 ml) and N,N-dimethylformamide (3 ml). 1-Hydroxy-7-azabenzotriazole (111 mg, 0.82 mmol) was added. The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (157 mg, 0.82 mmol) was added. A solution of (2R)-N-Methyl-2-(methylamino)-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide (288 mg, 0.82 mmol) in dichloromethane (3 ml) was added. Ethyldiisopropylamine (0.14 ml, 0.82 mmol) was added. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (80 ml) and washed with 10% sodium hydrogen sulfate solution (50 ml). The aqueous phase was extracted with ethyl acetate (2 x 40 ml). The combined organic layers were washed with sa-

turated sodium hydrogen carbonate solution (50 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (110 g), using ethyl acetate/heptane 1:1 as eluent, to give 479 mg of (1-(3-(N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)phenyl)ethyl)carbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected peaks): δ 1.43 (br, 9 H); 5.91 and 6.02 (both dd, together 1 H).

MS: 600.0 [M+H]⁺.

10

(1-(3-(N-Methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)phenyl)ethyl)carbamic acid tert-butyl ester (479 mg, 0.80 mmol) was dissolved in dichloromethane (2 ml) and cooled to 0 °C. Trifluoroacetic acid (2 ml) was added. The reaction mixture was stirred for 35 min at 0 °C. It was diluted with dichloromethane (8 ml). Saturated sodium hydrogen carbonate solution (10 ml) was added carefully. Solid sodium hydrogen carbonate was added until pH 7. Water was added, until a clear solution was obtained. The phases were separated, and the aqueous phase was extracted with dichloromethane (2 x 50 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (70 g), using dichloromethane/methanol/25% aqueous ammonia as eluent, to give 293 mg of the title compound.

1H-NMR (CDCl₃, selected peaks): δ 1.15 and 1.27 (both d, together 3 H); 2.87 (s, 3 H); 3.00 and 3.03 (both s, together 3 H); 5.90 and 6.00 (both dd, together 1 H).

MS: 500.0 [M+H]⁺.


HPLC: 34.30 (A1).
30 36.85 (B1).

For biological testing, the title compound was transferred into its acetate salt, by lyophilization from 0.5 N acetic acid (50 ml).

Example 8

5


(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-methylamide



10

N-((1R)-2-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-methylcarbamic acid tert-butyl ester

15



(2R)-2-(N-(tert-Butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (7.41 g, 22.5 mmol) was dissolved in N,N-dimethylformamide (90 ml) and dichloromethane (110 ml). 1-Hydroxy-7-azabenzotriazole (3.06 g, 22.5 mmol) was added. The mixture was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (4.32 g, 22.5 mmol) was added. The solution was stirred for 15 min at 0 °C. 1,2,3,4-Tetrahydroquinoline (3.00 g, 22.5 mmol) and ethyldiisopropylamine (3.90 ml, 22.5 mmol) were added. The reaction mixture

was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (80 ml) and extracted with 10% aqueous sodium hydrogen sulfate solution (250 ml). The aqueous phase was extracted with ethyl acetate (3 x 60 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (200 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (130 g), using ethyl acetate/heptane 1:2 as eluent to give 6.12 g of N-((1R)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-methylcarbamic acid tert-butyl ester.

10 ¹H-NMR (CDCl₃, selected values): δ 1.07, 1.22, and 1.28 (all s, together 9 H); 5.14 and 5.50 (m and q, together 1 H); 6.90 - 7.85 (m, together 11 H).

MS: 445.0 ([M+1]⁺).

15 mp: 121 - 126 °C (ethyl acetate/heptane).


C₂₈H₃₂N₂O₃ (444.57)

calc. C 75.65 H 7.26 N 6.03

found C 75.92 H 7.53 N 6.07

20

(2R)-1-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-2-(methylamino)-3-(2-naphthyl)-1-propanone




25

N-((1R)-2-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-methylcarbamic acid tert-butyl ester (6.12 g, 13.8 mmol) was dissolved in dichloromethane (40 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (40 ml) was added. The reaction mixture was stirred for 90 min at 0 °C. Dichloromethane (110 ml) and a saturated aque-

ous solution of sodium hydrogen carbonate (150 ml) were added successively. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 60 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (130 g), using dichloromethane/methanol/25% aqueous ammonia 100:10:1 as eluent, to give 2.20 g of (2R)-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-(methylamino)-3-(2-naphthyl)-1-propanone.

5 ¹H-NMR (CDCl₃, selected values): δ 2.34 and 2.35 (both s, together 3 H); 4.36 and 4.85 (both d, together 1 H); 6.55 - 7.80 (m, together 11 H).

10 MS: 345.2 ([M+1]⁺).
 15 ((3E)-4-(N-((1R)-2-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester



20 (2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoic acid (283 mg, 1.16 mmol) was dissolved in N,N-dimethylformamide (5.5 ml) and dichloromethane (6.5 ml). 1-Hydroxy-7-azabenzotriazole (158 mg, 1.16 mmol) was added. The mixture was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (223 mg, 1.16 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C. A solution of (2R)-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-(methylamino)-3-(2-naphthyl)-1-propanone (400 mg, 1.16 mmol) in dichloromethane (4 ml) and ethyldiisopropylamine (0.2 ml, 1.16 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (60 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (60 ml). The aqueous phase was extracted with ethyl acetate (3 x

50 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane 1:1 as eluent to give 647 mg of ((3E)-4-(N-((1R)-2-(1,2,3,4-
5 tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-methylcarbamoyl)-1,1-
dimethylbut-3-enyl)carbamic acid tert-butyl ester.

10 ¹H-NMR (CDCl₃, selected values): d 1.25 and 1.40 (m and s, together 15 H); 2.97 and 3.09
(both s, together 3 H); 6.00 (t, 1 H); 6.07 and 6.23 (both d, together 1 H); 6.65 - 7.85 (m, to-
gether 13 H).

15 ((3E)-4-(N-((1R)-2-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-
methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester (647 mg, 1.14 mmol)
was dissolved in dichloromethane (3 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (3 ml) was added. The reaction mixture was stirred for 35 min at 0 °C. Dichloromethane (12 ml) and a saturated aqueous solution of sodium hydrogen carbonate (14 ml) were added. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 50 ml). The
20 combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using dichloromethane/methanol/25% aqueous ammonia 100:10:1 as eluent, to give 234 mg of the title compound.

25 ¹H-NMR (CDCl₃, selected values): d 1.08 and 1.10 (both s, together 6 H); 2.20 and 2.25
(both d, together 2 H); 2.96 and 3.08 (both s, together 3 H); 5.98 (m, 1 H); 6.06 and 6.23
(both d, together 1 H); 6.70 - 7.80 (m, 12 H).

30 MS: 470 ([M+1]⁺).


HPLC 33.48 min (A1).
35.43 min (B1).

For biological testing, the title compound was transferred into its acetate salt by lyophilization with 0.5 M acetic acid (50 ml).

Example 9

5


(2E)-5-Methyl-N-methyl-5-(methylamino)-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide



10

N-Methyl-N-((3E)-4-(N-methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester

15



(2E)-5-(N-(tert-Butoxycarbonyl)-N-methylamino)-5-methylhex-2-enoic acid (122 mg, 0.48 mmol) was dissolved in N,N-dimethylformamide (2 ml) and dichloromethane (2 ml). 1-Hydroxy-7-azabenzotriazole (65 mg, 0.48 mmol) was added. The solution was cooled to 0°C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (92 mg, 0.48 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C. A solution of (2R)-2-(methylamino)-

3-(2-naphthyl)propionic acid N-methyl-N-phenethylamide (165 mg, 0.48 mmol) in dichloromethane (2 ml) and ethyldiisopropylamine (0.083 ml, 0.48 mmol) were added successively. The solution was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (50 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (50 ml). The aqueous phase was extracted with ethyl acetate (2 x 10 ml). The combined 5 organic layers were washed with saturated aqueous sodium hydrogen carbonate solution (50 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane 1:1 as eluent to give 204 mg of N-methyl-N-((3E)-4-(N-methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid 10 tert-butyl ester.

¹H-NMR (CDCl₃, selected values): d 0.90 and 0.92 (both s, together 6 H); 5.80 and 5.86 (t and dd, together 1 H); 6.12 and 6.21 (both d, together 1 H); 6.80 (m, 1 H); 7.00 - 7.85 (m, 12 H).

N-Methyl-N-((3E)-4-(N-methyl-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester (182 mg, 0.31 mmol) was dissolved in dichloromethane (2 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (2 ml) was added. The reaction mixture was stirred at 0 °C for 20 min. It was diluted with dichloromethane (50 ml). A saturated aqueous solution of sodium hydrogen carbonate (10 ml) was added. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (2 x 15 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (45 g), using dichloromethane/methanol/25% aqueous ammonia 100:10:1 as eluent to 25 give 80 mg of the title compound.

¹H-NMR (CDCl₃, selected values): d 1.00 and 1.06 (both s, together 6 H); 2.25 and 2.31 (both s, together 3 H); 2.76, 2.87, and 3.05 (all s, together 6 H); 5.77 and 5.85 (t and dd, together 1 H); 6.14 and 6.23 (both d, together 1 H); 6.78 (m, 1 H); 7.00 - 7.90 (m, 12 H).

HPLC 34.30 min (A1).
 36.28 min (B1).

MS: 486.0 ([M+1]⁺).


5

For biological testing, the title compound was transferred into its acetate salt by lyophilization with 0.5 M acetic acid (50 ml).

Example 10


10

(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methyl-3-(2-naphthyl)propionamide



15

2-(2-Hydroxyphenyl)-N-methylacetamide



20

(2-Hydroxyphenyl)acetic acid (9.89 g, 63.7 mmol) and 1-hydroxybenzotriazole hydrate (8.61 g, 63.7 mmol) were dissolved in N,N-dimethylformamide (50 ml) and dichloromethane (200 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (8.67 g, 63.7 mmol) was added. The reaction mixture was stirred for 30 min at 0 °C. A 8.0 M solution of methyl amine (39 ml, 318 mmol) was added. The reaction mixture

25


was stirred for 16 h, while it was slowly warming up to room temperature. It was diluted with ethyl acetate (600 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate (2 x 300 ml). The combined aqueous phases were extracted with ethyl acetate. The combined organic layers were washed with saturated sodium hydrogen carbonate solution (300 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (180 g), using ethyl acetate/heptane (1:1) as eluent to give 4.90 g of 2-(2-hydroxyphenyl)-N-methylacetamide.

mp: 105 - 106 °C (ethyl acetate/heptane).

10

¹H-NMR (CDCl₃): d 2.82 (d, 3 H); 3.56 (s, 2 H); 6.20 (br, 1 H); 6.83 (m, 1 H); 7.00 (m, 2 H); 7.18 (m, 1 H); 9.85 (s, 1 H).

15 Ethyl 2-(2-((N-methylcarbamoyl)methyl)phenoxy)acetate




Potassium carbonate (2.81 g, 20.34 mmol) was given to a solution of 2-(2-hydroxyphenyl)-N-methylacetamide (3.36 g, 20.34 mmol) in acetone (150 ml). Ethyl bromoacetate (2.13 ml, 19.32 mmol) and potassium iodide (166 mg, 1.02 mmol) were added successively. The reaction mixture was heated to reflux for 6 h. It was left at room temperature for 16 h. The solid was filtered off. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/dichloromethane (1:1) as eluent, to give 25 5.00 g of ethyl 2-(2-((N-methylcarbamoyl)methyl)phenoxy)acetate.

¹H-NMR (CDCl₃): d 1.33 (t, 3 H); 2.74 (d, 3 H); 3.61 (s, 2 H); 4.30 (q, 2 H); 4.70 (s, 2 H); 6.68 (br, 1 H); 6.76 (d, 1 H); 6.98 (t, 1 H); 7.24 (t, 1 H); 7.32 (d, 1 H).

30

2-(2-(2-(Methylamino)ethyl)phenoxy)ethanol



5 At 0 °C, a solution of ethyl 2-((N-methylcarbamoyl)methyl)phenoxy)acetate (5.00 g, 19.9 mmol) in tetrahydrofuran (75 ml) was added dropwise to a suspension of sodium borohydride (2.26 g, 59.7 mmol) in tetrahydrofuran (75 ml). A solution of iodine (5.05 g, 19.9 mmol) in tetrahydrofuran (150 ml) was added dropwise. The solution was warmed to room temperature and heated to reflux for 16 h. It was cooled to 0 °C. Methanol (150 ml) was added dropwise. The solvent was removed in vacuo. The solid residue was dissolved in 20% aqueous sodium hydroxide solution/tert-butyl methyl ether (150 ml/150 ml). The phases were separated. The aqueous phase was extracted with tert-butyl methyl ether (3 x 150 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using dichloromethane/methanol/10% aqueous ammonia (first: 100:10:1, then 70:30:3) as eluent, to give 1.124 g of 2-(2-(2-(Methylamino)ethyl)phenoxy)ethanol.


10

15

¹H-NMR (CDCl₃): δ 2.40 (s, 3 H); 2.82 (m, 2 H); 2.92 (m, 2 H); 3.05 (br, 2 H); 3.94 (m, 2 H); 4.10 (m, 2 H); 6.87 (d, 1 H); 6.92 (t, 1 H); 7.17 (m, 2 H).

20

N-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester




At 0 °C N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (558 mg, 2.91 mmol) was given to a solution of (2R)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (959 g, 2.91 mmol) and 1-Hydroxy-7-azabenzotriazole (396 mg, 2.91 mmol) in N,N-dimethylformamide (5 ml) and dichloromethane (5 ml). The solution was stirred for 20 min at 0 °C. A solution of 2-(2-(Methylamino)ethyl)phenoxy)ethanol (608 mg, 2.91 mmol) in dichloromethane (5 ml) and ethyldiisopropylamine (0.50 ml, 2.91 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (150 ml) and washed with a 10% aqueous sodium hydrogen sulfate solution (70 ml). The aqueous phase was extracted with ethyl acetate (2 x 30 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (150 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (110 g), using ethyl acetate/heptane (1:1) as eluent, to give 1.02 g of N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values): δ 1.00, 1.22, and 1.29 (all s, together 9 H); 4.88, 5.02, 5.20, and 5.39 (t, m, q, and t, together 2 H).

20

MS: 507.2 ([M+H]⁺).

25 (2R)-N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide




At 0 °C, trifluoroacetic acid (4 ml) was added to a solution of N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester (986 mg, 1.95 mmol) in dichloromethane (4 ml). The solution was stirred for 3 h at 0 °C. Dichloromethane (50 ml) was added. A saturated solution of sodium hydrogen carbonate (30 ml) was added. Solid sodium hydrogen carbonate was added until pH 7 was obtained. Water was added until a clear solution was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (2 x 20 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 730 mg of (2R)-N-(2-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide.

¹H-NMR (CDCl₃, selected values): δ 2.25 and 2.30 (both s, together 3 H); 2.50 and 2.89 (both s, together 3 H).

(3E)-4-(N-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester

20



At 0 °C N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (125 mg, 0.65 mmol) was added to a solution of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (158 mg, 0.65 mmol) and 1-hydroxy-7-azabenzotriazole (88 mg, 0.65 mmol) in N,N-dimethylformamide (3 ml) and dichloromethane (3 ml). The solution was stirred for 20 min at 0 °C. A solution of (2R)-N-(2-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide (265 mg, 0.65 mmol) in dichloromethane (3 ml) and ethyldiisopro-

pylamine (0.11 ml, 0.65 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (200 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (100 ml). The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic layers were 5 washed with saturated aqueous sodium hydrogen carbonate solution (200 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using ethyl acetate/heptane (first: 2:1 (500 ml), then: 3:1) as elutent, to give 378 mg of (3E)-4-(N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester.

10

¹H-NMR (CDCl₃, selected values): δ 1.32 and 1.40 (both s, together 9 H); 2.91 and 2.97 (both s, together 3 H); 3.02 and 3.05 (both s, together 3 H); 4.80 and 4.90 (both t, together 1 H); 5.69 and 5.87 (both dd, together 1 H); 6.05 and 6.22 (both d, together 1 H).

15

(3E)-4-(N-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester (347 mg, 0.55 mmol) was dissolved in dichloromethane (3 ml). The solution was cooled to 0 20 °C. Trifluoroacetic acid (3 ml) was added. The reaction mixture was stirred at 0 °C for 30 min. A saturated aqueous solution of sodium hydrogen carbonate (6 ml) was added dropwise. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (2 x 30 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The 25 crude product was purified by flash chromatography on silica (15 g), using dichloromethane/methanol/25% aqueous ammonia (first: 100:10:1, then: 50:10:1) as eluent, to give 218 mg of the title compound.

¹H-NMR (CDCl₃, selected values): δ 1.04 and 1.12 (both s, together 6 H); 2.93, 2.99, 3.02, 30 and 3.07 (all s, together 6 H); 5.68 and 5.87 (both dd, together 1 H); 6.05 and 6.25 (both d, together 1 H).


MS: 532.2 ([M+H]⁺).

HPLC: 32.75 min (A1).
33.82 min (B1).

For biological testing, the title compound was transferred into its acetate salt by lyophilization
5 with 0.5 M acetic acid (50 ml).


Example 11

(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-
10 (2-(2-methylsulfonylaminophenyl)ethyl)propionamide



15

N-Methyl-2-(2-nitrophenyl)acetamide



20 (2-Nitrophenyl)acetic acid (10.0 g, 55.21 mmol) was dissolved in N,N-dimethylformamide (15 ml) and dichloromethane (50 ml). 1-Hydroxybenzotriazole hydrate (7.46 g, 55.21 mmol) was added. The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (10.58 g, 55.21 mmol) was added. The solution was stirred for 15 min at 0 °C. A 8.0 M solution of methylamine in ethanol (10.3 ml, 82.81 mmol) and ethyldiisopropylamine

100

(9.55 ml, 55.21 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (180 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (100 ml). The aqueous phase was extracted with ethyl acetate (2 x 40 ml). The combined organic layers were washed with 5 saturated aqueous sodium hydrogen carbonate solution (200 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (200 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 8.01 g of N-methyl-2-(2-nitrophenyl)acetamide.

10 mp: 147 °C (dichloromethane/methanol/25% aqueous ammonia).

¹H-NMR (CDCl₃) δ 2.80 (d, 3 H); 3.82 (s, 2 H); 5.85 (br, 1 H); 7.40 - 7.65 (m, 3 H); 8.04 (d, 1 H).

15 MS: 388.8 ([2M+H]⁺), 195.2 ([M+H]⁺).


C₉H₁₀N₂O₃ (194.2)

calc.: C 55.62 H 5.19 N 14.43

found: C 55.86 H 5.30 N 14.39

20

N-Methyl-N-(2-(2-nitrophenyl)ethyl)amine



25

At 0 °C, a solution of N-methyl-2-(2-nitrophenyl)acetamide (7.00 g, 36.05 mmol) in tetrahydrofuran (410 ml) was added dropwise to a suspension of sodium borohydride (1.63 g, 43.25 mmol) in tetrahydrofuran (110 ml). A solution of iodine (4.57 g, 18.02 mmol) in tetrahydrofuran (150 ml) was added dropwise. The reaction mixture was warmed to reflux for 16 h. It was 30 cooled to 0 °C. Methanol (310 ml) was added dropwise. The solvent was removed in vacuo.

The residue was dissolved in 20% aqueous sodium hydroxide solution (300 ml) and tert-butyl methyl ether (200 ml). The phases were separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 100 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (160 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 1.28 g of N-methyl-N-(2-(2-nitrophenyl)ethyl)amine.


¹H-NMR (CDCl₃) δ 2.49 (s, 3 H); 2.50 (br, 1 H); 2.93 (t, 2 H); 3.12 (t, 2 H); 7.39 (m, 2 H); 7.55 (m, 1 H); 7.91 (d, 1 H).

10

MS: 181.2 ([M+H]⁺).

N-Methyl-N-(2-(2-nitrophenyl)ethyl)carbamic acid tert-butyl ester


15



To a solution of N-methyl-N-(2-(2-nitrophenyl)ethyl)amine (529 mg, 2.9 mmol) in a 1 N aqueous sodium hydroxide solution (2.9 ml, 2.9 mmol) and tetrahydrofuran (3.0 ml), a solution of di-tert-butyl dicarbonate (769 mg, 3.5 mmol) was added dropwise. The reaction mixture was stirred for 16 h at room temperature. It was diluted with water (50 ml) and ethyl acetate (50 ml). The phases were separated. The aqueous phase was extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with saturated aqueous sodium hydrogen carbonate solution (50 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (50 g), using ethyl acetate/heptane (1:1) as eluent, to give 924 mg of N-methyl-N-(2-(2-nitrophenyl)ethyl)carbamic acid tert-butyl ester.

¹H-NMR (CDCl₃) δ 1.35 and 1.44 (both br, together 9 H); 2.85 (br, 3 H); 3.10 (br, 2 H); 3.56 (m, 2 H); 7.20 - 7.50 (br, 2 H); 7.55 (t, 1 H); 7.97 (br, 1 H).

5 N-(2-(2-Aminophenyl)ethyl)-N-methylcarbamic acid tert-butyl ester




10 N-Methyl-N-(2-(2-nitrophenyl)ethyl)carbamic acid tert-butyl ester (924 mg, 3.3 mmol) was dissolved in ethanol (60 ml). 10% palladium on carbon (200 mg) was added. The mixture was hydrogenated at room temperature at 1 atmosphere for 16 h. The catalyst was filtered off through a plug of celite. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using ethyl acetate/heptane (1:2) as eluent, to give 723 mg of N-(2-(2-aminophenyl)ethyl)-N-methylcarbamic acid tert-butyl ester.

15 ¹H-NMR (CDCl₃) δ 1.47 (s, 9 H); 2.75 (t, 2 H); 2.90 (s, 3 H); 3.35 (br, 2 H); 3.71 (br, 1 H); 4.23 (br, 1 H); 6.68 (m, 2 H); 7.00 (d, 1 H); 7.05 (t, 1 H).

20 MS: 151.2 ([M+H]⁺).

N-(2-(2-(Methylsulfonylamino)phenyl)ethyl)-N-methylcarbamic acid tert-butyl ester




A solution of N-(2-(2-aminophenyl)ethyl)-N-methylcarbamic acid tert-butyl ester (723 mg, 2.9 mmol) and triethylamine (0.48 ml, 3.5 mmol) in dichloromethane (10 ml) was cooled to -78

5 °C. A solution of methanesulfonyl chloride (0.22 ml, 2.9 mmol) in dichloromethane (2 ml) was added dropwise. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (50 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (150 ml). The aqueous phase was extracted with ethyl acetate (3 x 80 ml). The combined organic layers were washed with saturated aqueous sodium hydrogen

10 carbonate solution (150 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using ethyl acetate/heptane (1:1) as eluent, to give 870 mg of N-(2-(2-(methylsulfonylamino)phenyl)ethyl)-N-methylcarbamic acid tert-butyl ester.

15 ¹H-NMR (CDCl₃) δ 1.50 (s, 9 H); 2.87 (m, 2 H); 2.91 (s, 3 H); 3.02 (s, 3 H); 3.30 (br, 2 H); 7.05 - 7.30 (m, 3 H); 7.57 (br, 1 H); 8.65 (br, 1 H).

20 N-(2-(Methylamino)ethyl)phenylmethanesulfonamide




At 0 °C, trifluoroacetic acid (6 ml) was added to a solution of N-(2-(2-(methylsulfonylamino)phenyl)ethyl)-N-methylcarbamic acid tert-butyl ester (870 mg, 2.6 mmol) in dichloromethane (6 ml). The reaction mixture was stirred for 50 min. Dichloromethane (24 ml) was added. A saturated aqueous solution of sodium hydrogen carbonate (34 ml) was added. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 50 ml). The combined organic layers were dried over magnesium sulfate. The solvent was

removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 308 mg of N-(2-(methylamino)ethyl)phenyl)methanesulfonamide.

5 $^1\text{H-NMR}$ (CDCl_3) δ 2.51 (s, 3 H); 2.84 (m, 2 H); 2.94 (m, 2 H); 3.00 (s, 3 H); 5.70 - 6.70 (br, 1 H); 7.03 (m, 1 H); 7.12 (d, 1 H); 7.22 (t, 1 H); 7.53 (d, 1 H).

10 N-((1R)-1-(N-(2-(Methylsulfonylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl-ester




15 (2R)-2-(N-(tert-Butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (444 mg, 1.35 mmol) and successively 1-hydroxy-7-azabenzotriazole (184 mg, 1.35 mmol) were dissolved in N,N-dimethylformamide (5 ml) and dichloromethane (7 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (259 mg, 1.35 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C. A solution of N-(2-(2-(methylamino)ethyl)phenyl)methanesulfonamide (308 mg, 1.35 mmol) was added. Ethyldiisopropylamine (0.23 ml, 1.35 mmol) was added. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate and washed with 10% aqueous sodium hydrogen sulfate solution (70 ml). The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate (150 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using ethyl acetate/heptane (1:1) as eluent, to give 245 mg of

N-((1R)-1-(N-(2-(methylsulfonylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl-ester.

¹H-NMR (CDCl₃, selected values) δ 1.15, 1.20, and 1.35 (all s, together 9 H); 4.83, 5.06, and 5.42 (all t, together 1H); 8.07, 8.70, and 8.89 (all br, together 1 H).

MS: 540.0 ([M+H]⁺).

10 (2R)-N-(2-(2-(Methylsulfonylamino)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide




15 At 0 °C, trifluoroacetic acid (1.5 ml) was added to a solution of N-((1R)-1-(N-(2-(2-(methylsulfonylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl-ester (245 mg, 0.45 mmol) in dichloromethane (1.5 ml). The reaction mixture was stirred for 1.75 h at 0 °C. Dichloromethane (5 ml) and a saturated aqueous solution of sodium hydrogen carbonate (6 ml) were added successively. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 50 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (30 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 155 mg of (2R)-N-(2-(2-(methylsulfonylamino)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide.

¹H-NMR (CDCl₃, selected values) δ 2.35 and 2.51 (both s, together 3 H); 2.59 and 2.79 (both s, together 3 H); 2.94 and 3.07 (both s, together 3 H); 3.80 and 3.95 (dd and t, together 1 H).

5

((3E)-4-(N-((1R)-1-(N-(2-(Methylsulfonylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester



10

10 A solution of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (86 mg, 0.35 mmol) and 1-hydroxy-7-azabenzotriazole (48 mg, 0.35 mmol) in N,N-dimethylformamide (1.5 ml) and dichloromethane (1.8 ml) was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (68 mg, 0.35 mmol) was added. The reaction mixture was 15 stirred for 15 min at 0 °C. A solution of (2R)-N-(2-(2-(methylsulfonylamino)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide (155 mg, 0.35 mmol) in dichloromethane (2 ml) and ethyldiisopropylamine (0.06 ml, 0.35 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (50 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (50 ml). The aqueous phase was extracted with ethyl acetate (3 x 20 ml). The combined organic layers were washed with saturated aqueous sodium hydrogen carbonate solution (50 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (40 g), using ethyl acetate/heptane (2:1), as eluent, to give 174 mg of ((3E)-4-(N-((1R)-1-(N-(2-(2-(methylsulfonylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values) δ 5.58 and 5.88 (t and dd, together 1 H); 6.16 and 6.28 (both d, together 1 H); 6.87 (m, 1 H).

5

At 0 °C trifluoroacetic acid (2 ml) was given to a solution of ((3E)-4-((1R)-1-(N-(2-(2-(methylsulfonylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester (168 mg, 0.25 mmol) in dichloromethane (2 ml). The reaction mixture was stirred at 0 °C for 40 min. A saturated aqueous solution of sodium hydrogen carbonate (6 ml) was added. Solid sodium hydrogne carbonate was added until pH 7 was obtained. Water was added, until a clear solution was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (15 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 82 mg of the title compound.

¹H-NMR (CDCl₃, selected values) δ 1.08 and 1.15 (both s, together 1 H); 2.93 and 2.95 (both s, together 3 H); 2.99 and 3.05 (both s, together 3 H); 3.12 and 3.13 (both s, together 3 H); 5.57 and 5.88 (t and dd, together 1 H); 6.18 and 6.30 (both d, together 1 H).

MS: 565.0 ([M+H]⁺).

HPLC 32.08 min (A1).


25 32.53 min (B1).

For biological testing, the title compound was transferred into its acetate salt by lyophilization with 0.5 M acetic acid (40 ml).

30


Example 12

(2E)-5-Amino-N-((1R)-2-(biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-5-methyl-N-methylhex-2-enamide



5

(2R)-3-(Biphenyl-4-yl)-2-(tert-butoxycarbonyl)-N-methylamino)-propionic acid



10

(2R)-3-(Biphenyl-4-yl)-2-(tert-butoxycarbonyl)amino)propionic acid (5.0 g, 14.7 mmol) was dissolved in tetrahydrofuran (50 ml). Iodomethane (7.3 ml, 117.3 mmol) was added. The solution was cooled to 0 °C. A 60% dispersion of sodium hydride in mineral oil (2.0 g, 44.0 mmol) was added portionwise. The reaction mixture was stirred for 8 days at room temperature.

15

Tetrahydrofuran (100 ml) was added. The reaction mixture was cooled to 0 °C. Methanol (50 ml) and successively water (20 ml) were added dropwise. The solvent was removed in vacuo. The residue was dissolved in tert-butyl methyl ether (30 ml) and a saturated aqueous solution of sodium hydrogen carbonate (50 ml). The phases were separated. The aqueous phase was acidified to pH 3 with 5% aqueous citric acid. It was extracted with


ethyl acetate (2 x 100 ml). These extracts were washed with a 5% aqueous sodium thiosulfate solution (2 x 100 ml) and with brine (100 ml). They were dried over magnesium sulfate. The solvent was removed in vacuo, to give 3.96 g of crude (2R)-3-(biphenyl-4-yl)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-propionic acid, which was used for the further steps without 5 purification.

¹H-NMR (DMSO d₆): δ 1.24 and 1.29 (both s, together 9 H); 2.64 and 2.66 (both s, together 3 H); 2.95 - 3.40 (m, 2 H); 4.67 and 4.85 (both dd, together 1 H); 7.20 - 7.70 (m, 9 H); 12.83 (br, 1 H).

10

HPLC: 44.98 min (A1).

15 N-((1R)-2-(Biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-N-methylcarbamic acid tert-butyl ester




20 (2R)-3-(Biphenyl-4-yl)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-propionic acid (753 mg, 2.12 mmol) and 1-hydroxy-7-azabenzotriazole (289 mg, 2.12 mmol) were dissolved in N,N-dimethylformamide (6 ml) and dichloromethane (6 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (406 mg, 2.12 mmol) was added. The solution was stirred for 15 min at 0 °C. A solution of N-methyl-N-(2-(2-thienyl)ethyl)amine (300 mg, 2.12 mmol) in dichloromethane (6 ml) was added. Ethyldiisopropylamine (0.37 ml, 2.12 mmol) was added. The solution was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (300 ml) and washed with 25

10% aqueous sodium hydrogen sulfate solution (50 ml). The aqueous phase was extracted with ethyl acetate (3 x 20 ml). The combined organic layers were washed with a saturated aqueous sodium hydrogen carbonate solution (60 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography 5 on silica (60 g), using ethyl acetate/heptane (1:2) as eluent to give 1.03 g of N-((1R)-2-(biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-N-methylcarbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values): δ 1.13, 1.21, 1.30, 1.36 (all s, together 9 H); 4.79, 4.97, 10 and 5.31 (dd, dd, and m, together 1 H); 6.70 - 7.60 (m, 12 H).

(2R)-3-(Biphenyl-4-yl)-N-methyl-2-(methylamino)-N-(2-(2-thienyl)ethyl)propionamide




At 0 °C, trifluoroacetic acid (4 ml) was added to a solution of N-((1R)-2-(biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-N-methylcarbamic acid tert-butyl ester (910 mg, 1.90 mmol) in dichloromethane (4 ml). The reaction mixture was stirred for 3 h at 0 °C. A 20 saturated solution of sodium hydrogen carbonate (8 ml) was added. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. Water was added, until a clear solution was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (2 x 30 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on 25 silica (60 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent,

to give 674 mg of (2R)-3-(biphenyl-4-yl)-N-methyl-2-(methylamino)-N-(2-(2-thienyl)ethyl)propionamide.

5 ¹H-NMR (CDCl₃, selected values): δ 2.20 and 2.30 (both s, together 6 H); 2.59 and 2.90 (both s, together 3 H); 6.69, 6.78, 6.90, 7.12, and 7.20 - 7.60 (all m, together 12 H).

(3E)-4-(N-((1R)-2-(Biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester

10



A solution of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (202 mg, 0.83 mmol) and 1-hydroxy-7-azabenzotriazole (113 mg, 0.83 mmol) in N,N-dimethylformamide (3 ml) and dichloromethane (3 ml) was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (159 mg, 0.83 mmol) was added. The reaction mixture was stirred for 10 min at 0 °C. A solution of (2R)-3-(biphenyl-4-yl)-N-methyl-2-(methylamino)-N-(2-(2-thienyl)ethyl)propionamide (314 mg, 0.83 mmol) in dichloromethane (3 ml) and ethyldiisopropylamine (0.14 ml, 0.83 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (100 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate (100 ml). The aqueous solution was extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with a saturated solution of sodium hydrogen carbonate (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified on silica (80 g), using ethyl acetate/heptane (1:1 (500 ml), then 2:1) as eluent, to give 374 mg of (3E)-4-(N-((1R)-2-(biphenyl-4-yl)-1-(N-methyl-N-(2-(2-

thienyl)ethyl)carbamoyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester.

5 ¹H-NMR (CDCl₃, selected values): d 1.25 and 1.26 (both s, together 6 H); 1.39 and 1.40 (both s, together 9 H); 2.85, 2.89, 3.01, and 3.02 (all s, together 6 H); 5.78 (m, 1 H); 6.20 and 6.26 (both d, together 1 H); 6.67 - 6.90, 7.10, and 7.20 - 7.60 (all m, together 14 H).

10 At 0 °C, trifluoroacetic acid (3 ml) was added to a solution of (3E)-4-(N-((1R)-2-(biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester in dichloromethane (3 ml). The reaction mixture was stirred for 30 min at 0 °C. Dichloromethane (30 ml) was added. A saturated aqueous solution of sodium hydrogen carbonate (10 ml) was added. Solid sodium hydrogen carbonate was added until pH 7. Water (30 ml) was added. The phases were separated. The aqueous phase 15 was extracted with dichloromethane (3 x 15 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (50 g), using dichloromethane/methanol/25% aqueous ammonia as eluent, to give 152 mg of the title compound.

20 ¹H-NMR (CDCl₃, selected values): d 1.09 and 1.22 (both s, together 6 H); 2.21 and 2.27 (both d, together 2 H); 2.85, 2.90, 3.07, and 3.08 (all s, together 6 H); 5.78 (m, 1 H); 6.20 and 6.26 (both d, together 1 H); 6.65 - 6.95, 7.09, and 7.20 - 7.60 (all m, together 13 H).

25 MS: 504.0 ([M+H]⁺).


HPLC 37.87 min (A1).
 38.52 min (B1).

30 For biological testing, the title compound was transferred into its acetate salt, by lyophilization with 0.5M acetic acid (40 ml).


Example 13

(2E)-N-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methyl-5-methyl-5-(methylamino)hex-2-enamide

5



10 N-((3E)-4-(N-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)-N-methylcarbamic acid tert-butyl ester



15

(2E)-5-(N-(tert-Butoxycarbonyl)-N-methylamino)-5-methylhex-2-enoic acid (133 mg, 0.52 mmol) was dissolved in N,N-dimethylformamide (2 ml) and dichloromethane (2 ml). 1-Hydroxy-7-azabenzotriazole (71 mg, 0.52 mmol) was added. The solution was cooled to 0°C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (100 mg, 0.52 mmol) was added. The solution was stirred for 10 min at 0 °C. A solution of (2R)-N-(2-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide (262 mg, 0.52 mmol) in dichloromethane (2 ml) and ethyldiisopropylamine (0.09 ml, 0.52 mmol)

were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (30 ml) and washed with 10% sodium hydrogen sulfate solution (20 ml). The aqueous phase was extracted with ethyl acetate (2 x 20 ml). The combined organic layers were washed with saturated sodium hydrogen carbonate solution (30 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (100 g), using ethyl acetate/heptane (2:1) as eluent, to give 261 mg of N-((3E)-4-(N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)-N-methylcarbamic acid tert-butyl ester.

10

¹H-NMR (CDCl₃, selected values): d 1.25, 1.26, 1.32, 1.33, 1.36, and 1.43 (all s, together 15 H); 2.61, 2.75, 2.90, 2.91, 3.02, and 3.04 (all s, together 9 H); 4.85 and 5.02 (both t, together 1 H); 5.69 and 5.88 (both dd, together 1 H); 6.02 and 6.22 (both d, together 1 H); 6.60 - 7.85 (m, 12).

15

At 0 °C, trifluoroacetic acid (2 ml) was added to a solution of N-((3E)-4-(N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)-N-methylcarbamic acid tert-butyl ester (236 mg, 0.37 mmol) in dichloromethane (2 ml). The reaction mixture was stirred for 40 min at 0 °C. A saturated solution of sodium hydrogen carbonate (5 ml) was added. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. Water (30 ml) and dichloromethane (30 ml) were added. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 118 mg of the title compound.

¹H-NMR (CDCl₃, selected values): d 1.02 and 1.10 (both s, together 6 H); 2.27 and 2.32 (both s, together 3 H); 2.91, 2.98, 3.02, and 3.06 (all s, together 6 H); 5.65 and 5.86 (both dd, together 1 H); 6.10 and 6.25 (both d, together 1 H); 6.55 - 7.90 (m, 12 H).


MS: 546.0 ([M+H]⁺).

HPLC 33.47 min (A1).
 34.25 min (B1).


5 For biological testing, the title compound was transferred into its acetate salt, by lyophilization with 0.5 M acetic acid (40 ml).

Example 14

10 3-Aminomethyl-N-[(1R)-1-(N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]benzamide



15 [(1R)-1-(N-{2-[2-(2-Hydroxyethoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]carbamic acid tert-butyl ester




20 (2R)-2-(tert-Butoxycarbonylamino)-3-(2-naphthyl)propionic acid (654 mg, 2.07 mmol) was dissolved in N,N-dimethylformamide (4 ml) and dichloromethane (4 ml). 1-Hydroxy-7-azabenzotriazole (282 mg, 2.07 mmol) was added. The solution was cooled to 0°C. N-(3-

Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (397 mg, 2.07 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C. A solution of 2-(2-(2-(methylamino)ethyl)phenoxy)ethanol (434 mg, 2.07 mmol) in dichloromethane (4 ml) and ethyldiisopropylamine (0.36 ml, 2.07 mmol) were added successively. The reaction mixture 5 was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (50 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate (50 ml). The aqueous phase was extracted with ethyl acetate (2 x 20 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate (50 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (70 g), using ethyl acetate/heptane 1:1 10 as eluent, to give 539 mg of [(1R)-1-(N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]carbamic acid tert-butyl ester.

15 ¹H-NMR (CDCl₃): δ 1.39 and 1.41 (both s, together 9 H); 2.60 and 2.94 (both s, together 3 H); 5.45 and 5.50 (both s, together 1 H).

(2R)-2-Amino-N-[2-(2-hydroxyethoxy)phenyl]ethyl]-N-methyl-3-(2-naphthyl)propionamide

20




25 A solution of [(1R)-1-(N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]carbamic acid tert-butyl ester (519 mg, 1.85 mmol) in dichloromethane (3 ml) was cooled to 0 °C. Trifluoroacetic acid (3 mL) was added. The reaction mixture was stirred at 0 °C for 40 min. Dichloromethane (20 ml) was added. A saturated solution of sodium hydrogen carbonate (10 ml) was added dropwise. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magne-

sium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using dichloromethane/methanol/25% aqueous ammonia, to give 377 mg of (2R)-2-amino-N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl}-N-methyl-3-(2-naphthyl)propionamide.

5

¹H-NMR (CDCl₃): δ 2.73 and 2.85 (both s, together 3 H); 3.50 (t, 1 H); 7.60 and 7.65 (both s, together 1 H).

10 ((3-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)phenyl)methyl)carbamic acid tert-butyl ester



15 3-(tert-Butoxycarbonylaminomethyl)benzoic acid (113 mg, 0.45 mmol) and 7-aza-1-hydroxybenzotriazole (61 mg, 0.45 mmol) were dissolved in N,N-dimethylformamide (1 ml) and dichloromethane (1 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (86 mg, 0.45 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C. A solution of (2R)-2-amino-N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl}-N-methyl-3-(2-naphthyl)propionamide (175 mg, 0.45 mmol) and ethyldiisopropylamine (0.08 ml, 0.45 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (50 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate (50 ml). The aqueous phase was extracted with ethyl acetate (2 x 15 ml). The combined organic layers were washed with a 20

20 saturated aqueous solution of sodium hydrogen carbonate (50 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (40 g), using ethyl acetate/heptane 3:1 as eluent, to give 211 mg of

25

((3-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)phenyl)methyl)carbamic acid tert-butyl ester.

5 ¹H-NMR (CDCl₃): d 1.45 (s, 9 H); 2.68 and 2.95 (both s, together 3 H); 4.88 and 4.95 (both br, together 1 H); 5.46 (m, 1 H).

10 A solution of ((3-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)phenyl)methyl)carbamic acid tert-butyl ester (193 mg, 0.31 mmol) in dichloromethane (2 ml) was cooled to 0 °C. Trifluoroacetic acid (2 ml) was added. The reaction mixture was stirred for 20 min at 0 °C. It was diluted with dichloromethane (10 ml). A saturated aqueous solution of sodium hydrogen carbonate (10 ml) was added. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 10 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (15 g), using dichloromethane/methanol/25% aqueous ammonia as eluent, to give 130 mg of the title compound.

15 ¹H-NMR (CDCl₃): d 2.75 and 3.04 (both s, together 3 H); 3.86 and 3.90 (both s, together 2 H); 5.51 (m, 1 H).


HPLC: 32.63 min (A1);
20 39.5 min (B1).

25 MS: 525.8 ([M+H]⁺).


30 For biological testing, the title compound was transferred into its acetate salt by lyophilization with 0.5 M acetic acid (40 ml).

Example 15

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)amide



5 {(3E)-4-[(1R)-1-(N-{2-[2-(2-Hydroxyethoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl]-1,1-dimethylbut-3-enyl}carbamic acid tert-butyl ester



10 (2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoic acid (95 mg, 0.39 mmol) was dissolved in dichloromethane (1 ml) and N,N-dimethylformamide (1 ml). 1-Hydroxy-7-azabenzotriazole (55 mg, 0.39 mmol) was added. The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (75 mg, 0.39 mmol) was added. The reaction mixture was stirred for 20 min at 0 °C. A solution of (2R)-2-amino-N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl}-N-methyl-3-(2-naphthyl)propionamide (155 mg, 0.39 mmol) in dichloromethane (1 ml) and ethyldiisopropylamine (0.07 ml, 0.39 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (30 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (30 ml). The aqueous phase was extracted with ethyl acetate (2 x 20 ml).

15 The combined organic layers were washed with a saturated aqueous solution of sodium hy-

20

drogen carbonate solution (30 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (12 g), using ethyl acetate/heptane (2:1) as eluent to give 147 mg of $\{(3E)-4-[(1R)-1-(N-\{2-[2-(2-hydroxyethoxy)phenyl]ethyl\}-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl]-1,1-dimethylbut-3-enyl\}carbamic acid tert-butyl ester$.

5 $^1\text{H-NMR}$ (CDCl_3): d 1.42 (s, 9 H); 2.58 and 2.92 (both s, together 3 H); 5.31 and 5.37 (both q, together 1 H); 5.80 and 5.87 (both d, together 1 H).

10 $\{(3E)-4-[(1R)-1-(N-\{2-[2-(2-Hydroxyethoxy)phenyl]ethyl\}-N-4methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl]-1,1-dimethylbut-3-enyl\}carbamic acid tert-butyl ester$ (129 mg, 0.21 mmol) was dissolved in dichloromethane (2 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (2 ml) was added. The solution was stirred for 15 min at 0 °C. It was diluted with dichloromethane (10 ml). A saturated aqueous solution of sodium hydrogen carbonate (10 ml) was added. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 10 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (25 g), using dichloromethane/methanol/25% aqueous ammonia as eluent, to give 71 mg of the title 15 compound.

15

20

$^1\text{H-NMR}$ (CDCl_3): d 1.13 and 1.14 (both s, together 6 H); 2.24 ("t", 2 H); 2.62 and 2.92 (both s, together 3 H); 5.32 and 5.39 (both q, together 1 H); 5.86 and 5.91 (both d, together 1 H).

25 HPLC 31.92 min (A1).
36.57 min (B1).


MS: 518.0 ($(\text{M}+\text{H})^+$).

30 For biological testing, the title compound was transferred into its acetate salt, by lyophilization with 0.5 M acetic acid (40 ml).


Example 16

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-[N-[2-(2-benzenesulfonylamino)phenyl]ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-

5 methylamide



10 N-[2-(2-(Phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamic acid tert-butyl ester




15 N-(2-(2-Aminophenyl)ethyl)-N-methylcarbamic acid tert-butyl ester (555 mg, 2.22 mmol) and triethylamine (0.40 ml, 2.66 mmol) were dissolved in dichloromethane (12 ml) and cooled to -78 °C. A solution of benzenesulfonyl chloride (0.28 ml, 2.22 mmol) in dichloromethane (3 ml) was added dropwise. The solution was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (40 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (20 ml). The aqueous phase was extracted with ethyl acetate (2 x 15 ml). The combined organic layers were washed with saturated aqueous sodium hydrogen carbonate solution (30 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (30 g), using ethyl

acetate/heptane 1:3 as eluent, to give 557 mg of N-[2-(2-(phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values): δ 1.55 (br, 9 H); 2.82 (br, 3 H); 8.80 (br., 1 H).

5

N-[2-(2-(Methylamino)ethyl)phenyl]benzenesulfonamide



10


N-[2-(2-(Phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamic acid tert-butyl ester (547 mg, 1.4 mmol) was dissolved in dichloromethane (5 ml). 3.1 N hydrogen chloride in ethyl acetate (3 ml, 9.3 mmol) was added. The solution was stirred at room temperature for 1 h. Another portion of 3.1 N hydrogen chloride in ethyl acetate (5 ml, 15.3 mmol) was added. The solution was stirred for another 3.5 h. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silcia (7 g), using dichloromethane/methanol/25% aqueous ammonia 50:10:1 as eluent, to give 521 mg of N-[2-(2-(methylamino)ethyl)phenyl]benzenesulfonamide.

15

20 ¹H-NMR (CDCl₃, selected values): δ 2.42 (m, 2 H), 2.50 (s, 3 H); 2.82 (m, 2 H).

N-((1R)-1-{N-[2-(2-(Phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester

25



(2R)-2-(N-(tert-Butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (517 mg, 1.57 mmol)

and 1-hydroxy-7-azabenzotriazole (214 mg, 1.57 mmol) were dissolved in dichloro-

5 methane (6 ml) and N,N-dimethylformamide (6 ml). The mixture was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (301 mg, 1.57 mmol) was added.

The reaction mixture was stirred for 15 min at 0 °C. A solution of N-[2-(2-(methylamino)ethyl)phenyl]benzenesulfonamide (457 mg, 1.57 mmol) in dichloromethane (6 ml) and ethyldiisopropylamine (0.27 ml, 1.57 mmol) were added successively. The reaction


10 mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (100 ml) and washed with a 10% aqueous sodium hydrogen sulfate solution (100 ml). The aqueous phase was extracted with ethyl acetate (2 x 30 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (25 g), using ethyl acetate/heptane 1:1

15 as eluent, to give 785 mg of N-((1R)-1-{N-[2-(2-(phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values): δ 4.80, 5.05, and 5.43 (dd, t, and t, together 1 H).

20


(2R)-N-[2-(2-(Phenylsulfonylamino)phenyl)ethyl]-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide



At 0 °C, trifluoroacetic acid (4 ml) was given to a solution of N-((1R)-1-{N-[2-(2-(phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester (647 mg, 1.08 mmol) in dichloromethane (4 ml). The reaction mixture was stirred for 2.5 h at 0 °C. It was diluted with dichloromethane (15 ml). A saturated aqueous solution of sodium hydrogen carbonate (15 ml) was added. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (2 x 15 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (20 g), using dichloromethane/methanol/25% aqueous ammonia 200:10:1 as eluent to give 434 mg of (2R)-N-[2-(2-(phenylsulfonylamino)phenyl)ethyl]-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide.

15 ¹H-NMR (CDCl₃, selected values): δ 2.37, 2.43, 2.52, and 2.75 (all s, together 6 H); 3.72 and 3.89 (dd and t, together 1 H).

20 {(3E)-4-[N-((1R)-1-{N-[2-(2-(Phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamoyl]-1,1-dimethylbut-3-enyl}carbamic acid tert-butyl ester



At 0 °C, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (138 mg, 0.72 mmol) was added to a solution of (2E)-5-(tert.-butoxycarbonylamino)-5-methylhex-2-enoic acid (175 mg, 0.72 mmol) and 1-hydroxy-7-azabenzotriazole (98 mg, 0.72 mmol) in dichloromethane (3 ml) and N,N-dimethylformamide (3 ml). The reaction mixture was stirred for 20 min at 0 °C. A solution of (2R)-N-[2-(2-(phenylsulfonylamino)phenyl)ethyl]-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide (363 mg, 0.72 mmol) in dichloromethane (3 ml) and ethyldiisopropylamine (0.13 ml) were added successively. The reaction mixture was stirred for 3 d, while it was warming up to room temperature. It was diluted with ethyl acetate (60 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate (60 ml). The aqueous phase was extracted with ethyl acetate (2 x 30 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate (60 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (50 g), using ethyl acetate/heptane 1:1 as eluent, to give 363 mg of ((3E)-4-[N-((1R)-1-{N-[2-(2-(phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamoyl]-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values): δ 1.25 and 1.40 (both m, together 15 H); 2.85 and 2.86 (both s, together 3 H); 3.12 and 3.18 (both s, together 3 H); 5.62 and 5.87 (t and dd, together 1 H); 6.20 and 6.31 (both d, together 1 H).

20

A solution of ((3E)-4-[N-((1R)-1-{N-[2-(2-(phenylsulfonylamino)phenyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamoyl]-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester (330 mg, 0.45 mmol) in dichloromethane (3 ml) was cooled to 0 °C. Trifluoroacetic acid (3 ml) was added. The reaction mixture was stirred for 40 min at 0 °C. It was diluted with dichloromethane (20 ml). A saturated aqueous solution of sodium hydrogen carbonate (6 ml) was added. Solid sodium hydrogen carbonate was added until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (20 g), using dichloromethane/methanol/25% aqueous ammonia 100:10:1 as eluent, to give 252 mg of the title compound.

¹H-NMR (CDCl₃, selected values): δ 1.09 and 1.12 (both s, together 6 H); 2.84 and 2.86 (both s, together 3 H); 3.15 and 3.20 (both s, together 3 H); 5.65 and 5.87 (t and dd, together 1 H); 6.22 and 6.32 (both d, together 1 H).


5 HPLC 37.87 min (A1).
40.23 min (B1).

MS: 627.2 ([M+H]⁺).


10 For biological testing, the title compound was transferred into its acetate salt, by lyophilization with 0.5 M acetic acid (40 ml).

Example 17

15 2-Amino-N-(2-(2-(N-((2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-N-methylamino)ethyl)phenyl)acetamide




20 ((2-[2-(N-(tert-Butoxycarbonyl)-N-methylamino)ethyl]phenylcarbamoyl)methyl)carbamic acid ((9-fluorenyl)methyl) ester



2-((9-Fluorenyl)methoxycarbonyl)amino)acetic acid (2.49 g, 2.79 mmol) was suspended in dichloromethane (40 ml). The suspension was cooled to 0 °C. N-(3-Dimethylaminopropyl)-5-N'-ethylicarbodiimide hydrochloride (802 mg, 4.19 mmol) was added. The reaction mixture was stirred for 30 min at 0 °C. A solution of N-(2-(2-aminophenyl)ethyl)-N-methylcarbamic acid tert-butyl ester (698 mg, 2.79 mmol) in dichloromethane (15 ml) was added. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with dichloromethane (100 ml) and washed with brine (100 ml). The aqueous solution was extracted with dichloromethane (2 x 30 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane (1:1) as eluent, to give 1.412 g of (2-[2-(N-(tert-butoxycarbonyl)-N-methylamino)ethyl]phenylcarbamoyl)methyl)carbamic acid ((9-fluorenyl)methyl) ester.

15 ¹H-NMR (CDCl₃, selected values): d 1.50 (br, 9 H); 2.80 (m, 2 H); 2.98 (br, 3 H); 3.22 (m, 2 H); 4.25 (m, 3 H); 4.40 (m, 2 H); 6.32 (br, 1 H); 9.20 (br, 1 H).


20 {[2-(Methylamino)ethyl]phenylcarbamoyl)methyl}carbamic acid 9H-((fluoren-9-yl)methyl)ester



5 ((2-[2-(N-(tert-butoxycarbonyl)-N-methylamino)ethyl]phenylcarbamoyl)methyl)carbamic acid ((9-fluorenyl)methyl) ester (1.342 g, 2.53 mmol) was dissolved in 3.0 M hydrogen chloride in ethyl acetate (10 ml). The reaction mixture was stirred for 2 h at room temperature. Diethyl ether (40 ml) was added. The precipitation was filtered off and dried in *vacuo* to give 857 mg of crude ((2-(methylamino)ethyl)phenylcarbamoyl)methyl carbamic acid 9H-((fluoren-9-yl)methyl) ester as hydrochloride, which was used for the next step without purification.

10 ¹H-NMR (DMSO-d₆, selected values): δ 2.99 (br, 4 H); 9.05 (br, 2 H); 9.68 (br, 1 H).

15 N-((1R)-1-[N-(2-[2-((Fluoren-9-yl)methoxycarbonyl)amino)acetyl]amino]phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester




20 (2R)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (590 mg, 1.79 mmol) and 1-hydroxy-7-azabenzotriazole (243 mg, 1.79 mmol) were dissolved in dichloromethane (12 ml) and N,N-dimethylformamide (6 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (343 mg, 1.79 mmol) was added.

The solution was stirred for 25 min at 0 °C. The hydrochloride of {[2-(2-(methylamino)ethyl)phenylcarbamoyl]methyl}carbamic acid 9H-((fluoren-9-yl)methyl) ester (834 mg, 1.79 mmol) and ethyldiisopropylamine (0.62 ml, 3.58 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature.

5 It was diluted with ethyl acetate (30 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (30 ml). The aqueous phase was extracted with ethyl acetate (3 x 30 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate (30 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using ethyl 10 acetate/heptane (1:1) as eluent, to give 1.293 g of N-((1R)-1-[N-(2-[2-((fluoren-9-ylmethoxycarbonyl)amino)acetyl]amino]phenyl)ethyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl-N-methylcarbamic acid tert-butyl ester.

15 ¹H-NMR (CDCl₃, selected values): d (1.25 and 1.30, both br, together 9 H); 2.85, 3.03 and 3.04 (all s, together 6 H); 5.08 and 5.45 (both t, together 1 H); 9.31 and 9.45 (both s, together 1 H).

20 [(2-{2-[N-Methyl-N-((2R)-2-methylamino-3-(2-naphthyl)propionyl)amino]ethyl}phenylcarbamoyl)methyl]carbamic acid (fluoren-9-yl)methyl ester




25 N-((1R)-1-[N-(2-[2-((Fluoren-9-ylmethoxycarbonyl)amino)acetyl]amino]phenyl)ethyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl-N-methylcarbamic acid tert-butyl ester (1.18 g, 1.59 mmol) was dissolved in 3.0 M hydrogen chloride in ethyl acetate (8 ml). The reaction mixture

was stirred for 2.25 h at room temperature. The solvent was removed in vacuo. The residue was washed with diethyl ether (3 x 20 ml) and dried in vacuo to give 1.198 g of crude [(2-{2-[N-methyl-N-((2R)-2-methylamino-3-(2-naphthyl)propionyl)amino]ethyl}phenylcarbamoyl)methyl]carbamic acid (fluoren-9-yl)methyl ester as hydrochloride, which was used for the next step without purification.

¹H-NMR (DMSO-d₆, selected values): δ 4.41 and 4.67 (both m, together 1 H).

10 (3E)-4-(N-((1R)-1-(N-(2-(2-((9-Fluorenyl)methoxycarbonyl)amino)acetyl)amino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester



15 (2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoic acid (200 mg, 0.82 mmol) and 1-hydroxy-7-azabenzotriazole (112 mg, 0.82 mmol) were dissolved in dichloromethane (4 ml) and N,N-dimethylformamide (2 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (157 mg, 0.82 mmol) was added.


20 The reaction mixture was stirred for 20 min at 0 °C. The hydrochloride of crude [(2-{2-[N-methyl-N-((2R)-2-methylamino-3-(2-naphthyl)propionyl)amino]ethyl}phenylcarbamoyl)methyl]carbamic acid (fluoren-9-yl)methyl ester (553 mg, 0.82 mmol) and ethyldiisopropylamine (0.28 ml, 1.64 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (50 ml) and washed with 10% aqueous sodium hydrogen sulfate solution (50 ml). The aqueous phase was extracted with ethyl acetate (2 x 20 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate (50 ml) and dried over magnesium sulfate. The solvent was removed in

vacuo. The crude product was purified by flash chromatography on silica (40 g), using ethyl acetate/heptane (2:1) as eluent, to give 265 mg of (3E)-4-(N-((1R)-1-(N-(2-(2-((9H-9-fluorenyl)methoxycarbonyl)amino)acetylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester.

5

¹H-NMR (CDCl₃, selected values): δ 5.51 and 5.94 (t and dd, together 1 H); 6.13 and 6.25 (both d, together 1 H); 6.25 (br, 1 H); 6.75 and 6.83 (both m, together 1 H).

10 (3E)-4-(N-((1R)-1-(N-(2-(2-Aminoacetylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester



15 At room temperature tris(2-aminoethyl)amine (2.99 ml, 19.8 mmol) was added to a solution of (3E)-4-(N-((1R)-1-(N-(2-(2-((9-fluorenyl)methoxycarbonyl)amino)acetylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester (346 mg, 0.40 mmol) in dichloromethane (2.8 ml). The reaction mixture was stirred for 1.2 h
20 at room temperature. It was diluted with dichloromethane (40 ml) and washed with brine (50 ml). The aqueous phase was extracted with dichloromethane (3 x 20 ml). The combined organic layers were washed with buffer of sodium dihydrogen phosphate and dipotassium hydrogen phosphate (pH 6.4, 3 x 30 ml) and successively with brine (20 ml). They were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified
25 by flash chromatography on silica (40 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 185 mg of (3E)-4-(N-((1R)-1-(N-(2-(2-aminoacetylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester.

¹H-NMR (CDCl₃, selected values): δ 1.14, 1.15, 1.23, and 1.24 (all s, together 6 H); 1.39 and 1.40 (both s, together 9 H); 2.90, 2.94, 3.02, and 3.10 (all s, together 6 H); 5.64 and 5.90 (t and dd, together 1 H); 6.12 and 6.26 (both d, together 1 H); 6.63 and 6.82 (both m, together 1 H); 9.42 and 9.53 (both br, together 1 H).

(3E)-4-((1R)-1-(N-(2-(2-Aminoacetylamino)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester (175 mg, 0.27 mmol) was dissolved in dichloromethane (2 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (2 ml) was added. The reaction mixture was stirred for 25 min at 0 °C. Dichloromethane (20 ml) and ethanol (20 ml) were added successively. The solvent was removed in vacuo without warming. The residue was dissolved in dichloromethane (40 ml) and the solvent was removed in vacuo. The last procedure was repeated. The crude product was purified by flash chromatography on silica (15 g), using dichloromethane/methanol/25% aqueous ammonia (first: 100:10:1, then: 100:20:2) as eluent, to give 128 mg of the title compound.

¹H-NMR (CDCl₃, selected values): δ 1.03 and 1.12 (both s, together 6 H); 2.92, 2.94, 3.01, and 3.12 (all s, together 6 H); 5.62 and 5.90 (t and dd, together 1 H); 6.10 and 6.25 (both d, together 1 H); 6.70 and 6.89 (both m, together 1 H); 9.48 and 9.52 both br, together 1 H).

HPLC: 7.15 min (H8).
25 For biological testing, the title compound was transferred into its acetate salt by lyophilization with 0.5 M acetic acid (40 ml).


HPLC-method H8:
30 The RP-analysis was performed using UV detections at 214, 254, 276, and 301 nm on a 218TP54 4.6 mm x 150 mm C-18 silica column, which was eluted at 1 mL/min at 42°C. The column was equilibrated with 5% acetonitrile, 85% water and 10% of a solution of 0.5% trifluoroacetic acid in water and eluted by a linear gradient from 5% acetonitrile, 85% water and

10% of a solution of 0.5% trifluoroacetic acid to 90% acetonitrile and 10% of a solution of 0.5% trifluoroacetic acid over 15 min.

Example 18


5

(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-N-(2-(3-hydroxypropanoxy)phenyl)ethyl)-N-methyl-3-(2-naphthyl)propionamide



10

2-(2-Benzoyloxyphenyl)-N-methylacetamide



15

2-(2-Benzoyloxyphenyl)acetic acid (15.0 g, 62 mmol) was dissolved in dichloromethane (270 ml) and N,N-dimethylformamide (70 ml). 1-Hydroxybenzotriazole (8.37 g, 62 mmol) was added. The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (11.89 g, 62 mmol) was added. The reaction mixture was stirred for 20 min. A 8.0 M solution of methylamine in ethanol (38.8 ml, 310 mmol) was added. The solution was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl ace-


tate (500 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate solution (500 ml). The aqueous phase was extracted with ethyl acetate (2 x 300 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate (400 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The 5 remaining crystals were washed with a mixture of ethyl acetate/heptane 1:4 (100 ml). They were dried in vacuo. They were dissolved in ethyl acetate. The solution was washed with a saturated aqueous solution of sodium hydrogen carbonate (2 x 500 ml) and dried over magnesium sulfate. The solvent was removed in vacuo to give 10.24 g of 2-(2-benzyloxyphenyl)-N-methylacetamide.

10

¹H-NMR (DMSO-d₆): d 2.57 and 2.58 (both s, together 3 H); 3.44 (s, 2 H); 5.60 and 5.61 (both s, together 2 H); 6.89 (t, 1 H); 7.03 (d, 1 H); 7.19 (m, 2 H); 7.30 (m, 1 H); 7.38 (m, 2 H); 7.45 (m, 2 H); 7.69 (br, 1 H).

15

N-(2-(2-BenzylOxyphenyl)ethyl)-N-methylamine




20 At 0 °C, a solution of 2-(2-benzyloxyphenyl)-N-methylacetamide (9.39 g, 36.8 mmol) in tetrahydrofuran (150 ml) was added dropwise to a suspension of sodium borohydride (1.67 g, 44.12 mmol) in tetrahydrofuran (100 ml). After the addition was finished, a solution of iodine (4.67 g, 18.39 mmol) in tetrahydrofuran (200 ml) was added dropwise. The solution was warmed to reflux for 16 h. It was cooled to 0 °C. Methanol (200 ml) was added dropwise. The 25 solvent was removed in vacuo. The residue was dissolved in an aqueous 20% sodium hydroxide solution (200 ml) and tert-butyl methyl ether (200 ml). The phases were separated. The aqueous phase was extracted with tert-butyl methyl ether (3 x 75 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (400 g), using dichlorometha-

ne/methanol/25% aqueous ammonia as eluent (100:10:1), to give 4.38 g of N-(2-(2-benzyloxyphenyl)ethyl)-N-methylamine.

¹H-NMR (CDCl₃): δ 2.40 (s, 3 H); 2.70 (br, 1 H); 2.87 (m, 4 H); 5.07 (s, 2 H); 6.89 (m, 2 H);

5 7.18 (m, 2 H); 7.35 (m, 5 H).

N-(2-(2-BenzylOxyphenyl)ethyl)-N-methylcarbamic acid tert-butyl ester



10


A solution of di-tert-butyl dicarbonate (3.80 g, 17.4 mmol) in tetrahydrofuran (8.7 ml) was added dropwise to a solution of N-(2-(2-benzyloxyphenyl)ethyl)-N-methylamine (3.82 g, 15.8 mmol) in tetrahydrofuran (8.7 ml) and an 1 N aqueous sodium hydroxide solution (17.4 ml,

15 17.4 mmol). The reaction mixture was stirred for 16 h at room temperature. It was diluted with ethyl acetate (200 ml) and water (200 ml). The phases were separated. The aqueous phase was extracted with ethyl acetate (200 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate (400 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by 20 flash chromatography on silica (225 g), using ethyl acetate/heptane 1:4 as eluent, to give 4.73 g of N-(2-(2-benzyloxyphenyl)ethyl)-N-methylcarbamic acid tert-butyl ester.

¹H-NMR (CDCl₃): δ 1.32 and 1.42 (both br, together 9 H); 2.74 and 2.86 (both br, together 5 H); 3.43 (t, 2 H); 5.08 (s, 2 H); 6.89 (m, 2 H); 7.17 (br, 2 H); 7.40 (m, 5 H).

25

N-(2-(2-Hydroxyphenyl)ethyl)-N-methylcarbamic acid tert-butyl ester




N-(2-(2-BenzylOxyphenyl)ethyl)-N-methylcarbamic acid tert-butyl ester (4.66 g, 13.65 mmol) was dissolved in ethanol (35.6 ml) and was hydrogenated at room pressure in the presence 5 of 10% palladium on activated carbon for 16 h. The reaction mixture was filtered through a plug of celite. The celite was washed with ethyl acetate (50 ml). The liquid phases were collected. The solvents were removed in vacuo. The crude product was purified by flash chromatography on silica (300 g), using ethyl acetate/heptane (1:2) as eluent, to give 2.84 g of N-(2-(2-hydroxyphenyl)ethyl)-N-methylcarbamic acid tert-butyl ester.

10

¹H-NMR (CDCl₃): δ 1.45 (s, 9 H); 2.86 (t, 2 H); 2.90 (s, 3 H); 3.34 (br, 2 H); 6.81 (t, 1 H); 6.87 (br, 1 H), 7.03 (d, 1 H), 7.12 (t, 1 H).

15 {2-[2-(3-Hydroxypropoxy)phenyl]ethyl}-N-methylcarbamic acid tert-butyl ester




N-(2-(2-Hydroxyphenyl)ethyl)-N-methylcarbamic acid tert-butyl ester (702 mg, 2.79 mmol) 20 was dissolved in N,N-dimethylformamide (6 ml). Potassium carbonate (1.93 g, 13.97 mmol) and cesium chloride (24 mg, 0.14 mmol) were added. 3-bromo-1-propanol (0.28 ml, 3.07 mmol) was added. The reaction mixture was stirred at 80 °C for 16 h. It was cooled to room

temperature and diluted with ethyl acetate (75 ml) and water (75 ml). The phases were separated. The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with a 10% aqueous solution of sodium hydrogen sulfate solution (70 ml) and a saturated aqueous solution of sodium hydrogen carbonate (70 ml). They were 5 dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane (1:1) as eluent, to give 606 mg of {2-[2-(3-hydroxypropoxy)phenyl]ethyl}-N-methylcarbamic acid tert-butyl ester.

10 ¹H-NMR (CDCl₃): δ 1.39 (br, 9 H); 2.06 (m, 2 H); 2.82 (br, 5 H); 3.45 (br, 2 H); 3.90 (br, 2 H); 4.14 (t, 2 H); 6.85 (m, 2 H); 7.09 (br, 1 H); 7.17 (t, 1 H).

3-[2-(2-Methylaminoethyl)phenoxy]propan-1-ol


15



{2-[2-(3-Hydroxypropoxy)phenyl]ethyl}-N-methylcarbamic acid tert-butyl ester (0.587 g, 1.90 mmol) was dissolved in dichloromethane (5 ml). The solution was cooled to 0 °C. Trifluoroacetic acid (5 ml) was added. The reaction mixture was stirred for 30 min at 0 °C. Dichloromethane (50 ml) was added. A saturated aqueous solution of sodium hydrogen carbonate (50 ml) was added dropwise. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. The phases were separated. The aqueous solution was extracted with dichloromethane (3 x 70 ml). The aqueous phase was made basic to pH 14 with a 20% aqueous sodium hydroxide solution. It was extracted with tert-butyl methyl ether (3 x 100 ml). The tert-butyl methyl ether extracts were combined and dried over magnesium sulfate. The solvent was removed in vacuo to give 227 mg of crude 3-[2-(2-methylaminoethyl)phenoxy]propan-1-ol. The crude product was used in the next step without further purification.

¹H-NMR (CDCl₃): δ 1.19 (s, 1 H); 2.03 (m, 2 H); 2.25 (br, 1 H); 2.39 (s, 3 H); 2.83 (m, 4 H); 3.87 (m, 2 H); 4.10 (m, 2 H); 5.90 (m, 2 H); 7.15 (m, 2 H).

5 N-[(1R)-1-(N-{2-[2-(3-Hydroxypropoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]-N-methylcarbamic acid tert-butyl ester



10 (2R)-2-(N-(tert-Butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionic acid (357 mg, 1.08 mmol) and 1-hydroxy-7-azabenzotriazole (148 mg, 1.08 mmol) were dissolved in N,N-dimethylformamide (2 ml) and dichloromethane (2 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (208 mg, 1.08 mmol) was added. The reaction mixture was stirred for 20 min at 0 °C. A solution of 3-[2-(2-methylaminoethyl)phenoxy]propan-1-ol (227 mg, 1.08 mmol) in dichloromethane (2 ml) and ethyldiisopropylamine (0.2 ml, 1.08 mmol) were added. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (100 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate (100 ml). The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic layers were 15 washed with a saturated aqueous solution of sodium hydrogen carbonate (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (30 g), using ethyl acetate/heptane (2:1) as eluent, to give 383 mg of N-[(1R)-1-(N-{2-[2-(3-hydroxypropoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]-N-methylcarbamic acid tert-butyl ester.


20

25

¹H-NMR (CDCl₃, selected values): δ 0.98, 1.05, 1.18, and 1.26 (all s, together 9 H); 4.28, 4.98, 5.18, and 5.32 (m, m, dd, and t, together 1 H).

(2R)-N-(2-(2-(3-Hydroxypropoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide


5



A solution of N-[(1R)-1-(N-{2-[2-(3-hydroxypropoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]-N-methylcarbamic acid tert-butyl ester (383 mg, 0.74 mmol) in dichloromethane (4 ml) was cooled to 0 °C. Trifluoroacetic acid (4 ml) was added. The reaction mixture was stirred for 105 min at 0 °C. Dichloromethane (40 ml) was added. A saturated aqueous solution of sodium hydrogen carbonate (40 ml) was added dropwise. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 60 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (30 g), using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 216 mg of (2R)-N-(2-(3-hydroxypropoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide.

20 ¹H-NMR (CDCl₃, selected values): δ 2.00 (m, 2 H); 2.12 and 2.19 (both s, together 3 H); 2.47 and 2.91 (both s, together 3 H).

25 ((3E)-4-N-[(1R)-1-(N-{2-[2-(3-Hydroxypropoxy)phenyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester



(2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (125 mg, 0.514 mmol) and 1-hydroxy-7-azabenzotriazole (70 mg, 0.514 mmol) were dissolved in dichloromethane (2 ml)

5 and N,N-dimethylformamide (2 ml). The solution was cooled to 0 °C. N-(3-Dimethylaminopropyl)-N'-ethylicarbodiimide hydrochloride (99 mg, 0.514 mmol) was added. The reaction mixture was stirred for 20 min at 0 °C. A solution of (2R)-N-(2-(2-(3-hydroxypropoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide (216 mg, 0.514 mmol) in dichloromethane (2 ml) and ethyldiisopropylamine (0.09 ml, 0.514 mmol) 10 were added. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (70 ml) and washed with a 10% aqueous solution of sodium hydrogen sulfate solution (70 ml). The aqueous phase was extracted with ethyl acetate (2 x 40 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogen carbonate and dried over magnesium sulfate. The solvent was 15 removed in vacuo. The crude product was purified by flash chromatography on silica (15 g), using ethyl acetate/heptane (3:1) as eluent, to give 270 mg of ((3E)-4-N-((1R)-1-(N-((2-(3-hydroxypropoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester.

20 ¹H-NMR (CDCl₃, selected values): δ 1.05, 1.11, 1.34, and 1.41 (all s, together 15 H); 2.82, 2.90, and 3.02 (all s, together 6 H); 5.46 and 5.83 (dd and t, together 1 H); 5.95 and 6.20 (both d, together 1 H); 6.45 (m, 1 H).

25 A solution of ((3E)-4-N-((1R)-1-(N-((2-(3-hydroxypropoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)carbamic acid tert-butyl ester (176 mg, 0.27 mmol) in dichloromethane (2 ml) was cooled to 0 °C.

Trifluoroacetic acid (2 ml) was added. The reaction mixture was stirred at 0 °C for 35 min. Dichloromethane (20 ml) was added. A saturated solution of sodium hydrogen carbonate (30 ml) was added dropwise. Solid sodium hydrogen carbonate was added, until pH 7 was obtained. The phases were separated. The aqueous phase was extracted with dichloromethane (3 x 30 ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica, using dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent to give 64 mg of the title compound.

10 $^1\text{H-NMR}$ (CDCl₃, selected values): δ 0.98, 0.99, 1.10, and 1.11 (all s, together 6 H); 2.82, 2.85, 2.91, and 3.03 (all s, together 6 H); 5.47 and 5.84 (both dd, together 1 H); 5.95 and 6.19 (both d, together 1 H); 6.55 (m, 1 H).


15 HPLC: 32.57 min (A1).
 34.60 min (B1).

MS: 546.0 ([M+H]⁺).


20 For biological testing, the title compound was transferred into its acetate salt by lyophilization with 0.5 M acetic acid (40 ml).

Example 19

25 1-((2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methyl amino)-3-(2-naphthyl)propionyl-2-benzyl-4-ethylsemi-carbazide



N'-Benzylidenehydrazinecarboxylic acid tert-butyl ester:




5

To a solution of t-butyl carbazate (2.0 g, 15.1 mmol) in 99% ethanol (20 ml) was added benzaldehyde (1.6 g, 15.1 mmol) and the mixture was stirred for 30 min. Then the mixture was cooled to 0 °C and the precipitate was separated and washed with cold ethanol and dried in vacuo to give 2.7 g (81%) of N'-benzylidenehydrazinecarboxylic acid tert-butyl ester.

10

¹H-NMR (CDCl₃): δ 1.5 (s, 9H) 7.35 (m, 3H) 7.65 (m, 2H) 7.85 (s, 1H) 8.0 (s, 1H)

15 **N'-Benzylhydrazinecarboxylic acid tert-butyl ester:**




To a solution of N'-benzylidenehydrazinecarboxylic acid tert-butyl ester (2.7 g, 12.3 mmol) in tetrahydrofuran (100 ml) was added 10% palladium on carbon (0.3 g) and the

mixture was hydrogenated with 280 ml of hydrogen for 40 min at atmospheric pressure. The mixture was filtered through a plug of celite and the filtrate was concentrated in vacuo to give 2.63 g of N'-benzylhydrazinecarboxylic acid tert-butyl ester.

5 ¹H-NMR (CDCl₃): d 1.5 (s, 9H) 4.0 (s, 2H) 4.2 (b, 1H) 6.1 (b, 1H) 7.2-7.4 (m, 5H).

2-Benzyl-1-tert-butoxycarbonyl-4-ethylsemicarbazide:



10


To a solution of N'-benzylhydrazinecarboxylic acid tert-butyl ester (2.5 g, 11.8 mmol) in 99% ethanol (40 ml) was added ethyl isocyanate (1.1 g, 15.2 mmol) and the mixture was stirred for 2 h. Then the mixture was concentrated in vacuo and chromatographed 15 on silica (20 g) with petrol ether/ethyl acetate 3:2 to give 3.0 g of 2-benzyl-1-tert-butoxycarbonyl-4-ethylsemicarbazide.

1H-NMR (CDCl₃): d 1.1 (t, 3H) 1.45 (s, 9H) 3.3 (m, 2H) 3.9-5.0 (b, 2H) 5.35 (t, 1H) 5.9 (s, 1H) 7.2-7.4 (m, 5H).

20

¹³C-NMR (CDCl₃): 15.0 (-CH₂CH₃) 27.6 (-C(CH₃)₃) 34.9 (-CH₂CH₃) 50.0 (-C(CH₃)₃) 81.7 (-CH₂-C₆H₅) 127.3-128.6 (-CH₂-C₆H₅) 135.9 (-CH₂-C₆H₅) 154.0 (-OCON) 157.1 (-NCON).

25 2-Benzyl-4-ethylsemicarbazide:




A solution of of 2-benzyl-1-tert-butoxycarbonyl-4-ethylsemicarbazide (2.8 g, 9.6 mmol) in 50% trifluoroacetic acid in dichloromethane (10 ml) was stirred for 10 min at room temperature. Then saturated sodium bicarbonate was added until pH > 7 and the aqueous layer was extracted with dichloromethane (2 x 10ml) and the combined organic layers were dried (magnesium sulfate) and concentrated in vacuo. The obtained oil was chromatographed on silica (100 g) with ethyl acetate as eluent to give 1.7 g of 2-benzyl-4-ethylsemicarbazide.

¹H-NMR (CDCl₃): d 1.15 (t, 3H) 3.3 (m, 2H) 4.7 (s, 2H) 7.2-7.4 (m, 5H).

10

2-Benzyl-1-[(2R)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide:




15 To a solution of (2R)-2-(N-tert-butoxycarbonyl-N-methylamino)-3-(2-naphthyl)propionic acid (2.6 g, 7.9 mmol) in dichloromethane (20 ml) was added 1-hydroxy-7-azabenzotriazole (1.1 g, 8.0 mmol) and 1-ethyl-3-dimethylaminopropyl carbodiimide hydrochloride (1.6 g, 8.6 mmol) and the mixture was stirred at 30 min at room temperature. Then 2-benzyl-4-ethylsemicarbazide (1.3 g, 6.6 mmol) and diisopropylethylamine (1.5 ml, 8.6 mmol) in dichloromethane (20 ml) were added and the mixture was stirred overnight. The mixture was washed with saturated sodium bicarbonate (2 x 50 ml), dried (magnesium sulfate) and concentrated in vacuo. The obtained product was chromatographed on silica (100 g) with petrol ether/ethyl acetate 1:1 to give 3.0 g (90%) of 2-benzyl-1-[(2R)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide.

20

25

¹H-NMR (CDCl₃): d 0.9 (t, 3H) 1.45 (s, 9H) 2.65 (s, 3H) 3.1 (m, 2H) 3.2 (m, 1H) 3.3 (dd, 2H) 4.4 (b, 2H) 4.9 (b, 1H) 5.2 (b, 1H) 6.9-7.8 (m, 12H).

2-Benzyl-1-[(2R)-2-N-methylamino-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide:




To a solution of 2-benzyl-1-[(2R)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide (2.9 g, 5.7 mmol) in dichloromethane (15 ml) at 0 °C was added trifluoroacetic acid (5 ml) and the mixture was allowed to stir for 3 h at 0 °C. Then sodium bicarbonate was added until pH > 7 and the aqueous layer was extracted with dichloromethane (3 x 25 ml) and the combined organic layers were dried (magnesium sulfate) and concentrated to 2.0 g of 2-benzyl-1-[(2R)-2-N-methylamino-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide.

¹H-NMR (CDCl₃): δ 0.9 (t, 3H) 2.1 (s, 3H) 3.0 (m, 2H) 3.3 (dd, 2H) 4.6 (t, 1H) 4.7 (dd, 2H) 7.1-7.8 (m, 12H) 8.3 (s, 1H).

15

2-Benzyl-1-((2R)-2-(N-((2E)-5-(N-tert-butoxycarbonyl)amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-4-ethylsemicarbazide:



To a solution of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (0.5 g, 2.1 mmol) in dichloromethane (20 ml) were added 1-hydroxy-7-azabenzotriazole (336 mg, 2.5 mmol) and 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (5.5 g, 2.9 mmol) and the mixture was stirred at 30 min at room temperature. Then 2-benzyl-1-

[(2R)-2-N-methylamino-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide (0.5 g, 1.2 mmol) and diisopropylethylamine (0.4 ml, 2.3 mmol) in dichloromethane (20 ml) were added and the mixture was stirred overnight. The mixture was washed with saturated sodium bicarbonate (2 x 20 ml), dried (magnesium sulfate) and concentrated in vacuo.

5 The obtained product was chromatographed on silica (20 g) with petrol ether/ethyl acetate 1:1 to give 0.68 g of 2-benzyl-1-((2R)-2-(N-((2E)-5-(N-tert-butoxycarbonyl)amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-4-ethylsemicarbazide.

10 $^1\text{H-NMR}$ (CDCl₃): d 0.9 (t, 3H) 1.25 (s, 6H) 1.4 (s, 9H) 2.65 (d, 2H) 2.9 (s, 3H) 3.0 (m, 2H) 3.1 (m, 1H) 3.5 (m, 1H) 4.4 (s, 1H) 4.7 (b, 1H) 5.4 (b, 1H) 5.1 (b, 1H) 6.1 (d, 1H) 6.8 (m, 1H) 6.9-7.8 (m, 12H).

15 To a solution of 2-benzyl-1-((2R)-2-(N-((2E)-5-(N-tert-butoxycarbonyl)amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-4-ethylsemicarbazide (0.66 g, 1.0 mmol) in dichloromethane (5 ml) was added trifluoroacetic acid (2.5 ml) at 0 °C and stirred for 2 h. Then sodium bicarbonate was added until pH > 7 and the aqueous layer was extracted with dichloromethane (2 x 10 ml) and the combined organic layers were dried (magnesium sulfate) and concentrated in vacuo. The obtained 20 product was dissolved in water (20 ml) and 1 N acetic acid (2 ml) and the mixture was lyophilized to 0.5 g of the acetate salt of the title compound.

HPLC (A1): R_t = 31.3 min

(B1): R_t = 33.0 min

25


LC-MS: 530.2 (M+H)⁺

$^1\text{H-NMR}$ (DMSO) (selected peaks): d 0.9 (t, 3H) 1.1 (s, 6H) 2.7 (s, 3H) 6.25 (d, 1H) 6.6 (m, 1H) 7.2-7.9 (m, 12H).


30

Example 20

1-((2S)-2-(N-(2-((2R)-pyrrolidin-2-yl)methoxy)acetyl)-N-methylamino)-3-(2-naphthyl)propionyl-2-benzyl-4-ethyl semicarbazide



(2S)-2-(((Carboxy)methoxy)methyl)pyrrolidin-1-carboxylic acid tert-butylester:



5 To a solution of N-t-butyloxycarbonyl-(S)-prolinol (5.0 g, 25 mmol) in 1,2-dichloroethane (500 ml) rhodium(II)acetate (180 mg) was added and the mixture was heated to 80 °C. Ethyldiazoacetate (3.9 ml, 37 mmol) in 1,2-dichloroethane (180 ml) was added over a period of 90 min and the mixture was heated at 80 °C for 3 hours. Then another portion of ethyl diazoacetate (1.3 ml, 12 mmol) in 1,2-dichloroethane (40 ml) was added and the mixture was refluxed for 6 hours. The mixture was cooled to room temperature and washed with saturated sodium bicarbonate (2 x 100 ml) and brine (100 ml), dried (magnesium sulfate) and concentrated in vacuo. The crude product was chromatographed on silica (300 g) with petrol ether/ethyl acetate 4:1 as eluent to give 4.7 g of (2S)-2-(((ethoxycarbonyl)methoxy)methyl)pyrrolidin-1-carboxylic acid tert-butylester. The obtained product was dissolved in 1 M lithium hydroxide in water/methanol 1:3 (50 ml) and stirred at room temperature overnight. The mixture was concentrated in vacuo, water (20 mL) was added and washed with ether (20 mL). The aqueous phase was acidified to pH 4 with 1 M aqueous hydrogen chloride, extracted with ethyl acetate (2 x 100 ml) and the combined organic layers were dried

(magnesium sulfate) and concentrated in vacuo to give 3.6 g of (2S)-2-((carboxy)methoxy)methyl)-pyrrolidin-1-carboxylic acid tert-butyl ester.

1H-NMR (CDCl₃): δ 1.45 (2, 9H) 1.90 (m, 4H) 3.55 (t, 2H) 3.60 (m, 3H) 4.10 (s, 2H)

5 10.6 (s, 1H).

To a solution of (2S)-2-((carboxy)methoxy)methyl)-pyrrolidin-1-carboxylic acid tert-butylester (0.97 g, 3.7 mmol) in dichloromethane (15 ml) were added 1-hydroxy-7-azabenzotriazole (0.51 g, 3.7 mmol) and 1-ethyl-3-dimethylaminopropylcarbodiimide 10 hydrochloride (0.79 g, 4.1 mmol) and the mixture was stirred at 30 min at room temperature. Then 2-benzyl-1-[(2R)-2-methylamino-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide (0.75 g, 1.9 mmol) and diisopropylethylamine (0.42 ml, 2.4 mmol) in dichloromethane (15 ml) were added and the mixture was stirred overnight. The mixture was washed with saturated sodium bicarbonate (2 x 20 ml), dried (magnesium 15 sulfate) and concentrated in vacuo. The obtained product was chromatographed on silica (20 g) with petrol ether/ethyl acetate 1:1. The chromatographed product was dissolved in dichloromethane (10 ml) and trifluoroacetic acid (2.5 ml) was added at 0 °C and stirred for 2 h. Then sodium bicarbonate was added until pH > 7 and the aqueous layer was extracted with dichloromethane (2 x 10 ml) and the combined organic layers 20 were dried (magnesium sulfate) and concentrated in vacuo. The obtained product was dissolved in water (20 ml) and 1 N acetic acid (2 ml) and the mixture was lyophilized to 0.88 g of the acetate salt of the title compound.

HPLC (A1): R_t = 31.1


25 (B1): R_t = 32.6

LC-MS: 546.0 (M+H)⁺


Example 21

30

1-((2R)-2-(N-((2-Amino-2-methylpropoxy)acetyl)-N-methylamino)-3-(2-naphthyl)propionyl)-2-benzyl-4-ethylsemicarbazide



(2-t-Butoxycarbonylamino-2-methylpropoxy)acetic acid:



5 A solution of 2-t-butoxycarbonylamino-2-methylpropanol (5.0 g, 26.46 mmol) and rhodium(II)acetate (90 mg) in dichloroethane (500 ml) was heated to 80 °C. Then ethyl diazoacetate (4.0 g, 34.78 mmol) was added over a period of 1 h and the mixture was stirred at reflux for 3 h. Another portion of rhodium(II)acetate (90 mg) was added and the mixture was refluxed for another 5 h. The mixture was cooled overnight and saturated sodium bicarbonate (500 ml) was added, the layers were separated and the organic layer was washed twice with saturated sodium bicarbonate (2 x 200 ml) and dried (magnesium sulfate) and concentrated in vacuo. The obtained product was dissolved in 1 M lithium hydroxide in methanol/water 3:1 (200 ml) and stirred overnight. The solvent was removed in vacuo to a minimum, water (50 ml) was added (pH>9) and the mixture 10 was washed with ether (100 ml). Then 1 M hydrochloric acid was added until pH<4 and the mixture was extracted with ethyl acetate (100 ml) and the combined organic layers were dried (magnesium sulfate) and concentrated in vacuo to give 2.5 g of (2-t-butoxycarbonylamino-2-methylpropoxy) acetic acid.

15

H₁-NMR (CDCl₃): d 1.3 (s, 6H) 1.45 (s, 9H) 3.5 (s, 2H) 4.15 (s, 2H) 9.9 (b, 1H).

20

To a solution of (2-t-butoxycarbonylamino-2-methylpropoxy) acetic acid (0.93 g, 3.7 mmol) in dichloromethane (15 ml) were added 1-hydroxy-7-azabenzotriazole (0.51 g,

150

3.7 mmol) and 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (0.79 g, 4.1 mmol) and the mixture was stirred at 30 min at room temperature. Then 2-benzyl-1-[(2R)-2-N-methylamino-3-(2-naphthyl)propionyl]-4-ethylsemicarbazide (0.75 g, 1.9 mmol) and diisopropylethylamine (0.42 ml, 2.4 mmol) in dichloromethane (15 ml) were 5 added and the mixture was stirred overnight. The mixture was washed with saturated sodium bicarbonate (2 x 20 ml), dried (magnesium sulfate) and concentrated in vacuo. The obtained product was chromatographed on silica (20 g) with petrol ether/ethyl acetate 1:1. The chromatographed product was dissolved in dichloromethane (10 ml) and trifluoroacetic acid (2.5 ml) was added at 0 °C and stirred for 2 h. Then sodium bicarbonate was added until pH > 7 and the aqueous layer was extracted with dichloromethane (2 x 10 ml) and the combined organic layers were dried (magnesium sulfate) 10 and concentrated in vacuo. The obtained product was dissolved in water (20 ml) and 1 N acetic acid (2 ml) and the mixture was lyophilized to 0.98 g of the acetate salt of the title compound.

15

HPLC (A1): R_t = 31.0


(B1): R_t = 32.6

LC-MS: 534.2 (M+H)⁺

20


Example 22

(3R)-4-((2E)-5-Amino-5-methylhex-2-enoyl)-3-((2-naphthyl)methyl)-1-phenethylpiperazin-2-one



25

(2R)-2-((2-(tert-Butoxycarbonylamino)ethyl)amino)-3-(2-naphthyl)propionic acid methylester.




5

(2R)-2-Amino-3-(2-naphthyl)propionic acid (5.0 g, 23 mmol) was added to methanol (150 ml) and thionylchloride (2.0 ml; 23 mmol) was added dropwise and the mixture was stirred overnight and then refluxed for 2.5 h. The solvent was removed in vacuo and the residue 10 was dissolved in a mixture of methanol (95 ml) and acetic acid (5 ml). (2-Oxoethyl)carbamic acid tert-butyl ester (3.4 g, 23 mmol, prepared as in Dueholm et al. Org. Prep. Proced. Int. (1993), 457), sodium cyanoborohydride (1.9 g, 31 mmol) and molecular sieves (50 g, Fluka, 3A) were added and the mixture was left overnight. The mixture was filtered and the filtrate 15 was added to water (200 ml) and extracted with methylene chloride (3 x 100 ml). The combined organic phases were dried (magnesium sulphate), and the solvent was removed in vacuo. The residue was chromatographed on silica (3 x 30 cm) to afford 3.55 g of (2R)-2-((2-(tert-butoxycarbonylamino)ethyl)amino)-3-(2-naphthyl)propionic acid methylester.

20 ¹H-NMR: (CDCl₃): d 1.39 (s, 9H); 2.56 (m, 1H); 2.75 (m, 1H); 3.09 (m, 3H); 3.59 (m, 1H); 3.65 (s, 3H); 7.28-7.81 (7 arom. H)

(3R)-3-((2-Naphthyl)methyl)piperazin-2-one.




25

(2R)-2-((2-(tert-butoxycarbonylamino)ethyl)amino)-3-(2-naphthyl)propionic acid methylester (3.4 g, 9.1 mmol) was stirred for 1 h in a mixture of TFA (5 ml) and methylene chloride (5 ml). The volatiles were removed in vacuo and the residue was dissolved in a mixture of water (40 ml) and methanol (100 ml). Sodium hydrogencarbonate (2.3 g) was added and the mixture was stirred overnight. The solvent was removed in vacuo and the residue was dissolved in water (40 ml) and extracted with ethyl acetate (10 x 50 ml). The combined organic phases were dried (magnesium sulphate) and the solvent was removed in vacuo to afford 1.96 g of (3R)-3-((2-naphthyl)methyl)piperazin-2-one.

10 $^1\text{H-NMR}$: (CDCl_3 ; selected peaks for major rotamer): d 2.95 (m, 1H); 3.05 (m, 2H); 3.24 (m, 1H); 3.39 (m, 1H); 3.59 (dd, 1H); 3.72 (dd, 1H)

(2R)-2-(2-Naphthyl)methyl-3-oxo-4-phenethylpiperazine-1-carboxylic acid tert-butyl ester



15

(3R)-3-((2-Naphthyl)methyl)piperazin-2-one (1.9 g; 7.9 mmol) and di-tert-butyl dicarbonate (2.1 g; 9.5 mmol) was suspended in a mixture of THF (20 ml) and aqueous sodium hydroxide (1M, 8 ml) and stirred overnight. The solvent was removed in vacuo and water (30 ml) was added. The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic phases were dried (magnesium sulphate) and the solvent was removed in vacuo. The residue was dissolved in a mixture of DMSO (15 ml) and potassium hydroxide (1.3 g). (2-bromoethyl)benzene (2.2 g, 11 mmol) was added and the mixture was stirred for 1 h. Water (30 ml) and methylene chloride (60 ml) were added. The organic phase was washed with water (5 x 10 ml) and the solvent was removed in vacuo. The residue was chromatographed on silica (3 x 40 cm) using ethyl acetate/heptane (1:2) as eluent to afford 1.25 g of (2R)-2-(2-naphthyl)methyl-3-oxo-4-phenethylpiperazine-1-carboxylic acid tert-butyl ester.

$^1\text{H-NMR}$: (CDCl_3 ; selected peaks for major rotamer): d 1.15 (s, 9H); 2.76 (t, 2H); 3.39 (t, 3H);

(2R)-2-(2-naphthyl)methyl-3-oxo-4-phenethylpiperazine-1-carboxylic acid tert-butyl ester (1.2 g; 2.7 mmol) was dissolved in a mixture of TFA (5 ml) and methylene chloride (5 ml) and stirred for 15 min. Methylene chloride (30 ml) and aqueous sodium hydrogencarbonate (saturated) was added to pH 8. The mixture was extracted with methylene chloride (3 x 10 ml) and the combined aqueous phases were dried (magnesium sulphate) and the solvent was removed in vacuo. Part of the residue (400 mg 1.2 mmol) were added to a mixture of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (282 mg; 1.2 mmol); HOAt (158 mg; 1.2 mmol), EDAC (245 mg; 1.3 mmol) and DIEA (150 mg; 1.2 mmol) and stirred overnight. Methylene chloride (50 ml) was added and the mixture was washed with aqueous sodium hydrogensulphate (10 %; 50 ml); aqueous sodium hydrogencarbonate (saturated; 50 ml) and water (50 ml). The organic phase was dried (magnesium sulphate) and the solvent removed in vacuo. The residue was chromatographed on silica (2 X 20 cm) and the residue was dissolved in a mixture of TFA (2 ml) and methylene chloride (2 ml) and stirred for 5 min. Methylene chloride and an aqueous solution of sodium hydrogencarbonate (sat.) was added to pH 8. The mixture was extracted with methylene chloride (2 x 10 ml). The organic phase was dried (magnesium sulphate) and the solvent was removed in vacuo to afford 310 mg of the title compound.

20

¹H-NMR: (CDCl₃; selected peaks for major rotamer): d 0.99 (s, 6H); 4.51 (dd, 1H); 5.61 (d, 1H); 6.56 (m, 1H)

HPLC: (method A1): R_t = 32.47 min.


PDMS: m/z 470.5 (M+H)⁺.

25

30


CLAIMS

1. A compound of the general formula I



formula I


wherein

10 A is A¹ or A²;G is G¹ or G²;D is hydrogen, -O-(CH₂)_k-R^{5a},15 wherein R⁵, R⁶, R⁷, R⁸, and R⁹ independently are hydrogen, halogen, aryl, C₁₋₆-alkyl or C₁₋₆-alkoxy;R^{5a} is hydrogen, aryl optionally substituted with halogen or C₁₋₆-alkyl, or C₁₋₆-alkyl optionally substituted with halogen or C₁₋₆-alkyl,

k is 0, 1, 2, or 3;


20

E is hydrogen, -O-(CH₂)_l-R^{10a},



wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently are hydrogen, halogen, aryl, C₁₋₆-alkyl, C₁₋₆-alkoxy, -CONR¹⁵R¹⁶, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶, -(CH₂)_v-OR¹⁷, -(CH₂)_v-OCOR¹⁶, -CH(R¹⁵)R¹⁶, -(CH₂)_v-NR¹⁵-CS-NR¹⁶R¹⁸, -(CH₂)_v-NR¹⁵-CO-NR¹⁶R¹⁸.

5 CH(R¹⁵)R¹⁶, -(CH₂)_v-NR¹⁵-CS-NR¹⁶R¹⁸, -(CH₂)_v-NR¹⁵-CO-NR¹⁶R¹⁸,



wherein

X¹ is -N(R¹⁹)-, -O- or -S-,

X² is -C(R²⁰)= or -N=,

10 X³ is -C(R²¹)= or -N=,

X⁴ is -C(R²²)= or -N=;


R² and R¹⁰ may be taken together to form -CH₂- or -CH₂-CH₂-.

15 R¹⁹ is hydrogen or C₁₋₆-alkyl optionally substituted with aryl,

R²⁰, R²¹ and R²² independently are hydrogen, -COOR²³, -CONR²⁴R²⁵, -(CH₂)_wNR²⁴R²⁵, -(CH₂)_wOR²³, -(CH₂)_wR²³ or halogen;

20 R¹⁵, R¹⁶, R²³, R²⁴ and R²⁵ independently are hydrogen or C₁₋₆-alkyl optionally substituted with halogen, -N(R²⁶)R²⁷, hydroxyl, C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkyl- carbonyloxy or aryl,

or R¹⁶ is



wherein

Q^1 is $-CH<$ or $-N<$,

T^1 and J^1 are independently $-CH_2-$, $-CO-$, $-O-$, $-S-$, $-NR^{28}-$ or a valence bond,
where R^{28} is hydrogen or linear or branched C_{1-6} -alkyl;

5 t and u are independently 0, 1, 2, 3 or 4;

R^{17} is C_{1-6} alkyl or phenyl optionally substituted with hydroxyl or aryl;

R^{18} is C_{1-6} alkyl;



R^{26} and R^{27} are independently hydrogen or C_{1-6} -alkyl;

v and w are independently 0, 1, 2 or 3;

10 R^{10a} is hydrogen, aryl optionally substituted with halogen or C_{1-6} -alkyl, or C_{1-6} -alkyl optionally substituted with halogen or C_{1-6} -alkyl,

l is 0, 1, 2, or 3;


15 A^1 is



or $R^{33} - NH - (CR^{34}R^{35})_p - (CH_2)_m - M - (CHR^{36})_q - (CH_2)_n -$


wherein R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} , R^{35} and R^{36} are independently hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxyl or aryl;
 R^{33} and R^{34} , R^{33} and R^{35} , or R^{34} and R^{35} may optionally form $-(CH_2)_i-Z-(CH_2)_j-$, wherein i and j independently are 1 or 2 and Z is $-O-$, $-S-$ or a valence bond;
5 n , m and q are independently 0, 1, 2, or 3;
 o and p are independently 0 or 1;
 M is $-CR^{37}=CR^{38}-$, $-O-$, $-S-$, or a valence bond;
 R^{37} and R^{38} are independently hydrogen, or C_{1-6} -alkyl optionally substituted with aryl;

10 A^2 is



15 R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} , R^{35} and R^{36} are independently hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxyl or aryl;
 R^{33} and R^{34} , R^{33} and R^{35} or R^{34} and R^{35} may optionally form $-(CH_2)_i-Z-(CH_2)_j-$, wherein i and j independently are 1 or 2 and Z is $-O-$, $-S-$ or a valence bond;
 n , m and q are independently 0, 1, 2, or 3;
 o and p are independently 0 or 1;
20 M is $-CR^{37}=CR^{38}-$, $-O-$, or $-S-$;
 R^{37} and R^{38} are independently hydrogen, or C_{1-6} -alkyl optionally substituted with aryl;

G^1 is hydrogen, halogen, aryl, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-CONR^{39}R^{40}$, $-(CH_2)_n-NR^{39}SO_2R^{41}$, $-(CH_2)_n-NR^{39}COR^{40}$, $-(CH_2)_n-OR^{41}$, $-(CH_2)_n-OCOR^{40}$, $-CH(R^{39})R^{40}$, $-CON^{39}-NR^{40}R^{42}$, $-(CH_2)_n-NR^{39}-CS-NR^{40}R^{42}$, $-(CH_2)_n-NR^{39}-CO-NR^{40}R^{42}$,



5

wherein

X^5 is $-N(R^{43})-$, $-O-$ or $-S-$,

X^6 is $-C(R^{44})=$ or $-N=$,

X^7 is $-C(R^{45})=$ or $-N=$,

10 X^8 is $-C(R^{46})=$ or $-N=$,

R^{43} is hydrogen or C_{1-6} -alkyl optionally substituted with aryl,

R^{44} , R^{45} and R^{46} independently are hydrogen, $-COOR^{47}$, $-CONR^{48}R^{49}$, $-(CH_2)_nNR^{48}R^{49}$, $-(CH_2)_nOR^{47}$, $-(CH_2)_nR^{47}$ or halogen;

15


R^{39} , R^{40} , R^{47} , R^{48} and R^{49} independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen,

$-N(R^{50})R^{51}$, hydroxyl, C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonyl,

C_{1-6} -alkylcarbonyloxy or aryl,

20

or R^{40} is



wherein

25 Q^2 is $-CH<$ or $-N<$,

J^2 and T^2 are independently $-CH_2-$, $-CO-$, $-O-$, $-S-$, $-NR^{52}-$ or a valence bond,

where R^{52} is hydrogen or C_{1-6} -alkyl;

x and y are independently 0, 1, 2, 3 or 4;

R^{41} is C_{1-6} alkyl substituted with aryl;

30 R^{42} is C_{1-6} alkyl;


R⁵⁰ and R⁵¹ are independently hydrogen or C₁₋₆-alkyl;
e and f are independently 0, 1, 2 or 3;

G² is hydrogen or C₁₋₆-alkyl;

5

R¹ is hydrogen, or C₁₋₆-alkyl;
R² is hydrogen, -C(=O)-R⁵⁴ or C₁₋₆-alkyl;
R¹ and R² may be taken together to form a bridge of type

10



wherein R⁵⁵ and R⁵⁶ independently of each other are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl, C₁₋₆-alkoxyl or aryl;

15 R⁵⁵ and R⁵⁶ may be taken together to form =O or =S;

c and d are independently 0, 1, or 2;

c + d is 0, 1, or 2;

R⁵⁴ is hydrogen or C₁₋₆-alkyl,

R³ and R⁴ are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl, C₁₋₆-alkoxyl, halogen, or

20 aryl;

R³ and R⁴ may be taken together to form =S, =O;

L¹ is CR⁵⁷ or N;

L² is CR⁵⁸ or N;

R⁵⁷ and R⁵⁸ independently are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl,


25 halogen, C₁₋₆-alkoxy, or aryl;

a and b independently are 0, 1, 2, or 3;

with the proviso that


when G is G² and L¹ is CR⁵⁵ and L² is CR⁵⁶, then A is A²;

30 when G is G¹ and L¹ is CR⁵⁵ and L² is CR⁵⁶, then A is A¹ and R² is -C(=O)-R⁵⁴ or R¹ and R² are taken together to form a bridge of the type



when either of L¹ or L² is N, then G is G¹ and A is A¹;
or a pharmaceutically acceptable salt thereof.

5 2. A compound of the general formula I



formula I

10


wherein

A is A¹ or A²;

G is G¹ or G²;

D is hydrogen, -O-(CH₂)_k-R^{5a},

15




wherein R⁵, R⁶, R⁷, R⁸, and R⁹ independently are hydrogen, halogen, aryl, C₁₋₆-alkyl or C₁₋₆-alkoxy;


R^{5a} is hydrogen, aryl, or C₁₋₆-alkyl

20 k is 0, 1, 2, or 3;

E is hydrogen, -O-(CH₂)₁-R^{10a},



wherein R^{10} , R^{11} , R^{12} , R^{13} and R^{14} independently are hydrogen, halogen, aryl, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-CONR^{15}R^{16}$, $-(CH_2)_v-NR^{15}SO_2R^{17}$, $-(CH_2)_v-NR^{15}COR^{16}$, $-(CH_2)_v-OR^{17}$, $-(CH_2)_v-OCOR^{16}$, $CH(R^{15})R^{16}$, $-(CH_2)_v-NR^{15}-CS-NR^{16}R^{18}$, $-(CH_2)_v-NR^{15}-CO-NR^{16}R^{18}$,



wherein

X^1 is $-N(R^{19})-$, $-O-$ or $-S-$,

X^2 is $-C(R^{20})=$ or $-N=$,

X^3 is $-C(R^{21})=$ or $-N=$,

X^4 is $-C(R^{22})=$ or $-N=$;


R^{19} is hydrogen or C_{1-6} -alkyl optionally substituted with aryl,

R^{20} , R^{21} and R^{22} independently are hydrogen, $-COOR^{23}$, $-CONR^{24}R^{25}$, $-(CH_2)_wNR^{24}R^{25}$, $-(CH_2)_wOR^{23}$, $-(CH_2)_wR^{23}$ or halogen;

R^{15} , R^{16} , R^{23} , R^{24} and R^{25} independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen,

$-N(R^{26})R^{27}$, hydroxyl, C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkylcarbonyloxy or aryl,

or R^{18} is



wherein

Q¹ is -CH< or -N<,

T¹ and J¹ are independently -CH₂-, -CO-, -O-, -S-, -NR²⁸- or a valence bond,

5 where R²⁸ is hydrogen or linear or branched C₁₋₆-alkyl;

t and u are independently 0, 1, 2, 3 or 4;

R¹⁷ is C₁₋₆ alkyl substituted with aryl;

R¹⁸ is C₁₋₆ alkyl;










R²⁶ and R²⁷ are independently hydrogen or C₁₋₆-alkyl;

10 v and w are independently 0, 1, 2 or 3;

R^{10a} is hydrogen, aryl or C₁₋₆-alkyl

l is 0, 1, 2, or 3;

A¹ is



wherein R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} , R^{35} and R^{36} are independently hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxyl or aryl;

R^{33} and R^{34} , R^{33} and R^{35} , or R^{34} and R^{35} may optionally form $-(CH_2)_i-Z-(CH_2)_j-$, wherein i and j independently are 1 or 2 and Z is $-O-$, $-S-$ or a valence bond;


5 n, m and q are independently 0, 1, 2, or 3;

o and p are independently 0 or 1;

M is $-CR^{37}=CR^{38}-$, $-O-$, $-S-$, or a valence bond;

R^{37} and R^{38} are independently hydrogen, or C_{1-6} -alkyl optionally substituted with aryl;

10 A^2 is



wherein R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} , R^{35} and R^{36} are independently hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxyl or aryl;

15 R^{33} and R^{34} , R^{33} and R^{35} or R^{34} and R^{35} may optionally form $-(CH_2)_i-Z-(CH_2)_j-$, wherein i and j independently are 1 or 2 and Z is $-O-$, $-S-$ or a valence bond;


n, m and q are independently 0, 1, 2, or 3;

o and p are independently 0 or 1;

M is $-CR^{37}=CR^{38}-$, $-O-$, or $-S-$;

20 R^{37} and R^{38} are independently hydrogen, or C_{1-6} -alkyl optionally substituted with aryl;

G^1 is hydrogen, halogen, aryl, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-CONR^{39}R^{40}$, $-(CH_2)_e-NR^{39}SO_2R^{41}$, $-(CH_2)_e-NR^{39}COR^{40}$, $-(CH_2)_e-OR^{41}$, $-(CH_2)_e-OCOR^{40}$, $-CH(R^{39})R^{40}$, $-CON^{39}-NR^{40}R^{42}$, $-(CH_2)_e-NR^{39}-CS-NR^{40}R^{42}$, $-(CH_2)_e-NR^{39}-CO-NR^{40}R^{42}$,



wherein

X^5 is $-N(R^{43})-$, $-O-$ or $-S-$,

X^6 is $-C(R^{44})=$ or $-N=$,

5 X^7 is $-C(R^{45})=$ or $-N=$,

X^8 is $-C(R^{46})=$ or $-N=$,

R^{43} is hydrogen or C_{1-6} -alkyl optionally substituted with aryl,

R^{44} , R^{45} and R^{46} independently are hydrogen, $-COOR^{47}$, $-CONR^{48}R^{49}$, $-(CH_2)_tNR^{48}R^{49}$, $-$


10 $(CH_2)_tOR^{47}$, $-(CH_2)_tR^{47}$ or halogen;

R^{39} , R^{40} , R^{47} , R^{48} and R^{49} independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen,

$-N(R^{50})R^{51}$, hydroxyl, C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonyl,

15 C_{1-6} -alkylcarbonyloxy or aryl,

or R^{40} is



20 wherein

Q^2 is $-CH<$ or $-N<$,

J^2 and T^2 are independently $-CH_2-$, $-CO-$, $-O-$, $-S-$, $-NR^{52}-$ or a valence bond,

where R^{52} is hydrogen or C_{1-6} -alkyl;

x and y are independently 0, 1, 2, 3 or 4;

25 R^{41} is C_{1-6} alkyl substituted with aryl;

R^{42} is C_{1-6} alkyl;

R^{50} and R^{51} are independently hydrogen or C_{1-6} -alkyl;

e and f are independently 0, 1, 2 or 3;


30 G^2 is hydrogen or C_{1-6} -alkyl;

R¹ is hydrogen, or C₁₋₆-alkyl;

R² is hydrogen, -C(=O)-R⁵⁴ or C₁₋₆-alkyl;

R¹ and R² may be taken together to form a bridge of the type

5



wherein R⁵⁵ and R⁵⁶ independently of each other are hydrogen, C₁₋₆-alkyl, optionally substituted

10 with hydroxyl, C₁₋₆-alkoxyl or aryl;

R⁵⁵ and R⁵⁶ may be taken together to form =O or =S;

c and d are independently 0, 1, or 2;

c + d is 0, 1, or 2;

R⁵⁴ is hydrogen or C₁₋₆-alkyl,

15 R³ and R⁴ are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl, C₁₋₆-alkoxyl, halogen, or aryl;

R³ and R⁴ may be taken together to form =S, =O;

L¹ is CR⁵⁷ or N;

L² is CR⁵⁸ or N;


20 R⁵⁷ and R⁵⁸ independently are hydrogen, C₁₋₆-alkyl, optionally substituted with hydroxyl, halogen, C₁₋₆-alkoxy, or aryl;

a and b independently are 0, 1, 2, or 3;

with the proviso that

25 when G is G² and L¹ is CR⁵⁵ and L² is CR⁵⁶, then A is A²;


when G is G¹ and L¹ is CR⁵⁵ and L² is CR⁵⁶, then A is A¹ and R² is -C(=O)-R⁵⁴ or R¹ and R² are taken together to form a bridge of the type



when either of L¹ or L² is N, then G is G¹ and A is A¹;

30 or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or 2, wherein A is




wherein R^{33} is hydrogen or C_{1-6} alkyl optionally substituted with hydroxyl,

5 R^{34} and R^{35} are independently of each other C_{1-6} alkyl,

R^{36} is hydrogen,

M is $-CR^{37}=CR^{38}-$ or $-O-$, wherein R^{37} and R^{38} are hydrogen or C_{1-6} alkyl, p is 1, m is 1, o is 0 or 1 and n is 0 or 1.

10 4. The compound according to claim 1 or 2, wherein A is




wherein M is $-O-$ or $-S-$,

o is 0 or 1,

15 q is 0, 1 or 2, and

m + n is 3 or 4.

5. The compound according to claim 1 or 2, wherein A is




20 wherein R^{33} is hydrogen or C_{1-6} alkyl,

R^{34} and R^{35} independently of each other are hydrogen or C_{1-6} alkyl,


m is 0 or 1, n is 0 or 1, and p is 0 or 1.

6. The compound according to any one of claims 1-5, wherein D is




wherein R⁵, R⁶, R⁷, R⁸ and R⁹ independently of each other are hydrogen or aryl.

7. The compound according to any one of claims 1-5, wherein D is




5 wherein R⁵ and R⁶ independently of each other are hydrogen or C₁₋₆ alkyl.

8. The compound according to any one of claims 1-7, wherein E is



10 wherein R¹⁰ and R¹¹ independently of each other are hydrogen or C₁₋₆ alkyl.

9. The compound according to any one of claims 1, 3-7, wherein E is




wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-

15 NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, R¹⁵ is hydrogen or C₁₋₆ alkyl, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl, R¹⁷ is C₁₋₆ alkyl or phenyl optionally substituted with hydroxyl or phenyl; or R² and R¹⁰ may be taken together to form -CH₂- or -CH₂-CH₂.

20

10. The compound according to claim 2, wherein E is




wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently of each other are hydrogen, -(CH₂)_v-NR¹⁵SO₂R¹⁷, -(CH₂)_v-NR¹⁵COR¹⁶ or -(CH₂)_v-OR¹⁷, wherein v is 0 or 1, R¹⁵ is hydrogen or C₁₋₆ alkyl, R¹⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with -N(R²⁶)R²⁷, wherein R²⁶ and R²⁷ independently of each other are hydrogen or C₁₋₆ alkyl, R¹⁷ is C₁₋₆ alkyl substituted with phenyl.

11. The compound according to any one of claims 1-10, wherein G is hydrogen or -CONR³⁹R⁴⁰, wherein R³⁹ and R⁴⁰ independently of each other are hydrogen or C₁₋₆ alkyl.

10 12. The compound according to any one of claims 1-11, wherein R¹ is hydrogen or C₁₋₆ alkyl.

13. The compound according to any one of claims 1-12, wherein R² is hydrogen, -C(=O)-R⁵⁴ or C₁₋₆ alkyl, wherein R⁵⁴ is C₁₋₆ alkyl.

15 14. The compound according to any one of claims 1-11, wherein R¹ and R² are taken together to form a bridge of type



wherein R⁵⁵ and R⁵⁶ are hydrogen, or
 20 R⁵⁵ and R⁵⁶ may be taken together to form =O or =S,
 c and d are independently 0, 1, or 2,
 c + d is 0, 1, or 2.

25 15. The compound according to any one of claims 1, 3-12, wherein R² and R¹⁰ may be taken together to form -(CH₂)_r, wherein r is 1, 2 or 3.

16. The compound according to any one of claims 1-15, wherein R³ is hydrogen or C₁₋₆ alkyl.

17. The compound according to any one of claims 1-16, wherein R⁴ is hydrogen or C₁₋₆ alkyl.

18. The compound according to any one of claims 1-15, wherein R³ and R⁴ are taken together to form =O.

5

19. The compound according to any one of claims 1-18, wherein a is 1.

20. The compound according to any one of claims 1-19, wherein b is 0 or 1.

10 21. The compound according to any one of claims 1-20, wherein L¹ is -CH-.

22. The compound according to any one of claims 1-21, wherein L² is -CH- or >N-.

23. The compound according to claim 1, selected from the group comprising

15 1-((2R)-2-(N-((2E)-5-amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-2-benzyl-4-ethylsemicarbazide,

1-((2R)-2-(N-(2-(((2S)-pyrrolidin-2-yl)methoxy)acetyl)-N-methylamino)-3-(2-naphthyl)propionyl)-2-benzyl-4-ethylsemicarbazide,

20 1-((2R)-2-(N-((2-amino-2-methylpropoxy)acetyl)-N-methylamino)-3-(2-naphthyl)propionyl)-2-benzyl-4-ethylsemicarbazide,

(2R)-2-((5R)-4-((2E)-5-Amino-5-methylhex-2-enoyl)-5-(2-naphthyl)methyl-2-oxopiperazin-1-yl)-N-methyl-3-phenylpropionamide,

(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-phenethylamide, or the trifluoroacetate salt,

25 (2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-(2-(methylsulfonylamino)phenyl)ethyl)amide,

(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionic acid N-methyl-N-(2-(2-thienyl)ethyl)amide,

(2R)-2-(N-((2E)-5-((2R)-2-hydroxypropylamino)-5-methylhex-2-enoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-phenethylpropionamide, or the trifluoroacetate salt,

(3R)-4-((2E)-5-Amino-5-methylhex-2-enoyl)-3-((2-naphthyl)methyl)-1-phenethylpiperazin-2-one,

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(N-acetyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)amino)-1-((2-naphthyl)methyl)ethyl)amide,

(2E)-5-Amino-5-methyl-N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide,

(2E)-5-Methyl-5-(methylamino)-N-methyl-N-((1R)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide,

5 (2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-(3-phenylpropyl)carbamoyl)-2-(2-naphthyl)ethyl)amide,

(2R)-2-(N-(3-(1-Aminoethyl)benzoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-(2-(2-thienyl)ethyl)propionamide,

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-1-((2-naphthyl)methyl)-2-oxoethyl)-N-methylamide,

10 (2E)-5-Methyl-N-methyl-5-(methylamino)-N-((1R)-1-(N-methyl-N-phenethylcarbamoyl)-2-(2-naphthyl)ethyl)hex-2-enamide,

(2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methyl-3-(2-naphthyl)propionamide,

15 (2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-N-methyl-3-(2-naphthyl)-N-(2-(2-methylsulfonylaminophenyl)ethyl)propionamide,

(2E)-5-Amino-N-((1R)-2-(biphenyl-4-yl)-1-(N-methyl-N-(2-(2-thienyl)ethyl)carbamoyl)ethyl)-5-methyl-N-methylhex-2-enamide,

(2E)-N-((1R)-1-(N-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methyl-5-methyl-5-(methylamino)hex-2-enamide,

20 3-Aminomethyl-N-[(1R)-1-(N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl})-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]benzamide,

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide,

25 (2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[2-(2-benzenesulfonylaminophenyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide,

2-Amino-N-(2-(2-(N-((2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-naphthyl)propionyl)-N-methylamino)ethyl)phenyl)acetamide,

30 (2R)-2-(N-((2E)-5-Amino-5-methylhex-2-enoyl)-N-methylamino)-N-(2-(2-hydroxypropoxy)phenyl)ethyl)-N-methyl-3-(2-naphthyl)propionamide,

3-Aminomethyl-N-[(1R)-1-(N-{2-[2-(2-hydroxyethoxy)phenyl]ethyl})-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]benzamide,

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbomoyl)-2-(2-naphthyl)ethyl)amide, and
(3R)-4-((2E)-5-Amino-5-methylhex-2-enoyl)-3-((2-naphthyl)methyl)-1-phenethylpiperazin-2-one; or a pharmaceutically acceptable salt thereof, such as the acetate salt.

5

24. A pharmaceutical composition comprising, as an active ingredient, a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- 10 25. The composition according to claim 24 in unit dosage form, comprising from about 10 to about 200 mg of the compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof.
- 15 26. A pharmaceutical composition for stimulating the release of growth hormone from the pituitary, the composition comprising, as an active ingredient, a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- 20 27. A pharmaceutical composition for administration to animals to increase their rate and extent of growth, to increase their milk and wool production, or for the treatment of ailments, the composition comprising, as an active ingredient, a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- 25 28. A pharmaceutical composition according to any one of the claims 24-27 for oral, nasal, transdermal, pulmonal, or parenteral administration.
- 30 29. A method of stimulating the release of growth hormone from the pituitary, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof or of a composition according to any one of the claims 24-26 or 28.
- 30 30. A method according to claim 29, wherein the effective amount of the compound according to any one of the claims 1-23 or pharmaceutically acceptable salt or ester thereof is in the

range of from about 0.0001 to about 100 mg/kg body weight per day, preferably from about 0.001 to about 50 mg/kg body weight per day.

31. A method for increasing the rate and extent of growth of animals to increase their milk and
5 wool production, or for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof or of a composition according to any one of the claims 24, 25, 27 or 28.
- 10 32. The method according to any one of the claims 29-31, wherein said administration is carried out by the oral, nasal, transdermal, pulmonal, or parenteral route.
- 15 33. Use of a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof for the preparation of a medicament.
- 20 34. Use of a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulating the release of growth hormone from the pituitary.
- 25 35. Use of a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for administration to animals to increase their rate and extent of growth, to increase their milk and wool production, or for the treatment of ailments.
- 30 36. Use of a compound according to any one of the claims 1-23 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of stimulation of growth hormone release in the elderly; prevention of catabolic side effects of glucocorticoids, prevention and treatment of osteoporosis, stimulation of the immune system, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating renal failure or insufficiency resulting from growth retardation, treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic illness, treatment of obesity and growth retardation associated with obesity, treatment of anorexia, treatment of NIDDM, treating growth retardation associated with the Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients;

treatment of intrauterine growth retardation, skeletal dysplasia, hypercortisolism and Cushing's syndrome; induction of pulsatile growth hormone release; replacement of growth hormone in stressed patients, treatment of osteochondrodysplasias, Noonan's syndrome, schizophrenia, depressions, Alzheimer's disease, delayed wound healing and psychosocial deprivation, treatment of pulmonary dysfunction and ventilator dependency, attenuation of protein catabolic responses after major surgery, reducing cachexia and protein loss due to chronic illness such as cancer or AIDS; treatment of hyperinsulinemia including nesidioblastosis, adjuvant treatment for ovulation induction; to stimulate thymic development and prevent the age-related decline of thymic function, treatment of immunosuppressed patients, improvement in muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis, renal homeostasis in the frail elderly, stimulation of osteoblasts, bone remodelling and cartilage growth, stimulation of the immune system in companion animals and treatment of disorder of aging in companion animals, growth promoter in livestock and stimulation of wool growth in sheep.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00314

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07C 237/16, C07C 237/20, C07C 281/06, C07C 311/08, C07C 311/21,
 C07D 207/08, C07D 217/06, C07D 241/08, 333/20, A61K 31/16, 31/33
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07C, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9723508 A1 (NOVO NORDISK A/S), 3 July 1997 (03.07.97) --	1-28,33-36
P,X	WO 9622997 A1 (NOVO NORDISK A/S), 1 August 1996 (01.08.96) --	1-28,33-36
A	WO 9517423 A1 (NOVO NORDISK A/S), 29 June 1995 (29.06.95) -----	1-28,33-36

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 October 1997

Date of mailing of the international search report

24.10.97

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer

Gerd Strandell
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00314

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 29-32
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.: 1-22 in part
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The formulation of claims 1-22 is so complicated because of the long lists of cascading constituents that it does not comply with Article 6 PCT prescribing that claims shall be clear and concise. For this reason the search has mainly been limited to the examples.
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/10/97

International application No.

PCT/DK 97/00314

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9723508 A1	03/07/97	AU	1092997 A	17/07/97
WO 9622997 A1	01/08/96	AU	4431596 A	14/08/96
		IL	116923 D	00/00/00
		NO	973446 D	00/00/00
WO 9517423 A1	29/06/95	AU	1272495 A	10/07/95
		CA	2179597 A	29/06/95
		CN	1138335 A	18/12/96
		CZ	9601834 A	12/02/97
		EP	0736039 A	09/10/96
		FI	962584 A	20/06/96
		HU	73497 A	28/08/96
		HU	9501947 D	00/00/00
		IL	112112 D	00/00/00
		NO	962665 A	23/08/96
		NZ	277486 A	24/03/97
		PL	315113 A	14/10/96
		SK	82096 A	08/01/97
		ZA	9410261 A	23/06/95